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ABSTRACT: 
The cost of healthcare has become generally expensive the world over, of which 
the greater part of the money is spent buying drugs. In order to reduce the cost of 
drugs, drug manufacturers came up with the idea of manufacturing generic drugs, 
which cost less as compared to brand name drugs. The challenge which arose was 
how safe, effective and efficient the generic drugs are compared to the brand 
name drugs, if people were to buy them. As a consequence of this challenge, 
bioequivalence studies evolved, being statistical procedures for comparing 
whether the generic and brand name drugs are similar in treating patients for 
various diseases. This study was undertaken to show the existence of 
bioequivalence in drugs. Bioavailability is considered in generic drugs to ensure 
that it is more or less the same as that of the original drugs by using statistical 
tests. The United States of America’s Food and Agricultural Department took a 
lead in the research on coming up with statistical methods for certifying generic 
drugs as bioequivalent to brand name drugs. Pharmacokinetic parameters are 
obtained from blood samples after dosing study subjects with generic and brand 
name drugs. The design for analysis in this research report will be a 2 2 
crossover design. Average, population and individual bioequivalence is checked 
from pharmacokinetic parameters to ascertain as to whether drugs are 
bioequivalent or not. Statistical procedures used include confidence intervals, 
interval hypothesis tests using parametric as well as nonparametric statistical 
methods. On presenting results to conclude that drugs are bioequivalent or not, in 
addition to hypothesis tests and confidence intervals, which indicates whether 
there is a difference or not, effect sizes will also be reported. If ever there is a 
difference between generic and brand name drugs, effect sizes then quantify the 
magnitude of the difference. 
KEY WORDS: 
bioequivalence, bioavailability, generic (test) drugs, brand name (reference) 
drugs, average bioequivalence, population bioequivalence, individual 
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Chapter 1 
Introduction 
1.1 General Introduction 
The cost of healthcare is high mainly due to expensive drugs. Generic drugs (test 
treatment formulation) are manufactured, with some stages which are carried out 
when manufacturing brand name drugs (reference treatment formulations) 
excluded, for example, expensive clinical trials. As a result, generic drugs cost 
less as compared to the brand name drugs hence reducing healthcare costs. During 
drug development bioequivalence studies are used. This chapter motivates the 
need for carrying out bioequivalence studies. In bioequivalence studies the test 
treatment and reference treatment formulations are compared to check if they are 
bioequivalent. 
Definitions of generic and brand name drugs, bioavailability and bioequivalence 
are discussed in this chapter. Relevant methods for bioequivalence studies, 
pharmacokinetics and pharmacodynamics are mentioned. The source of data and 
data collection method is stated. The outline of the rest of this research report 
completes this chapter. 
1.2 Background Information 
Bioequivalence studies are used in the industries where drugs are manufactured, 
pharmaceutical industries, during the development of new and generic drugs. The 
basis of this bioequivalence study was to compare a drug product to be tested 
(generic drug) with an appropriate reference treatment formulation (brand name or 
original drug or innovator drug). The cost of healthcare is expensive, with the 
main contributing factor to the high cost of healthcare being the cost of drugs 
according to many researchers who include, Chow and Liu (2000), Meredith 
(2003), Midha and Mackay (2009), Kamerow (2011), Mastan, Latha and Ajay 
(2011) and Qayyum (2012). Generic drugs are manufactured to try and reduce the 
cost of drugs in the market. They are cheaper than the brand name drugs but the 
quality should be almost the same as that of the reference drugs, in terms of the 
2 
safety and effectiveness in treating ailments. Maintaining the quality of generic 
drugs is mentioned in many research papers, though, consumers are concerned 
about that generic drugs may be bioequivalent but not necessarily therapeutic 
equivalent. To avoid this fear many guidelines or guidance and regulations on 
bioequivalence covering the licensing of generic products have been published as 
mentioned in Section 2.2 on literature review to ensure that the market dispenses 
quality drugs. 
Therapeutic equivalence refers to the effectiveness and safety of the generic drugs 
in producing similar results as compared to the reference drugs in terms of 
treating diseases. The Medicines Control Council of South Africa (MCC, 2003) 
guideline to bioequivalence defines therapeutic equivalence as two 
pharmaceutical products that are therapeutically equivalent after same quantities 
of a drug have been administered to patients, regarding both their efficacy and 
safety, as determined from an appropriate bioequivalence, pharmacodynamics, 
clinical or in vitro studies. Southern African Development Cooperation (SADC, 
2007) guidelines to bioequivalence defines therapeutic equivalence in a similar 
manner compared to the MCC (2003) since they both talk of that two 
pharmaceutical drugs, the generic and reference should be more or less equally 
safe and effective, after administration of a drug in the same molar dose, as 
determined from an appropriate bioequivalence method. 
1.2.1 Test and Reference Treatment Formulations 
A test treatment formulation is a drug which has more or less the same chemical 
composition and is as safe and effective, after it has been administered to a 
patient, as the reference drug. A reference treatment formulation (brand name 
drug) is the original drug formulation from which the test (generic) is developed. 
Meredith (2003) stated that a test treatment drug must contain similar amounts of 
the same active ingredient in the same formulation and route of administration as 
compared to the reference treatment formulation. Dighe (1999) also looks at 
generic drug formulations as drugs which when prescribed to patients are the 
same as brand name drugs in terms of possessing the identical active drug 
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substance in the same amount or concentration and the same dosage form after 
being administered by the same route of administration as the brand name drug 
products. Mastan et al. (2011) contrasted the terms brand name and generic drug, 
by referring to a brand name drug as a formulation available in the market, sold 
under a known trademark protected name while a generic is the same as a brand 
name in dosage, safety, strength and its intended use. According to Qayyum 
(2012) the reference treatment formulation is the compound that was developed 
first and was approved to be marketed for purposes of treating health conditions 
after it showed satisfactory efficacy and safety. The generic drug is a result of the 
modification which is done on the reference drug though preserving the quality 
such that both drug formulations are pharmaceutically equivalent and the same in 
terms of how they are taken, as well as quality and performance. SADC (2007) 
defines a reference treatment formulation as a pharmaceutical control drug 
product to be compared to a new product being developed. Both drug 
formulations should produce similar effects after being administered, in equal 
quantities and using the same route of administration, in terms of efficacy, safety 
and quality. Based on the above definitions of generic and brand name drugs by 
Meredith (2003), Dighe (1999) and Mastan et al. (2001), it is evident that in 
bioequivalence studies generic drugs are tested to check whether they are safe and 
effective for treating diseases as compared to the brand name drugs. In South 
Africa the Medicines Control Council is a body which is responsible for 
ascertaining drug formulations as bioequivalent or not. MCC (2003), on 
discussing generic and reference drugs, indicated that the reference product must 
be a drug available in South African pharmacies. The generic drug is then 
manufactured modelling the reference product on the South African market so as 
to ensure that both drugs are pharmaceutically equivalent, hence quality, 
effectiveness and safety is maintained. 
1.2.2 Bioavailability 
A bioequivalence study allows researchers to compare bioavailability between the 
generic drug and the reference drug to find out if there is a significant difference 
between the two formulations. Qayyum (2012) define bioavailability as the 
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concentration of a drug that is in the blood after dosing. Bioavailability according 
to the definitions provided by the MCC (2003) and SADC (2007) refers to the rate 
and extent to which the active pharmaceutical ingredient (API) is absorbed from a 
pharmaceutical product and becomes available at the appropriate part of the body. 
This definition of bioavailability correlates with one provided by the Food and 
Drug Administration (FDA, 2003) which states that bioavailability is the rate and 
extent to which the active ingredient of a drug formulation is absorbed from the 
drug product and becomes available at the site of action. In general, 
bioavailability is whereby a drug formulation administered is absorbed in the 
body and become available where it is intended to be used. 
1.2.3 Bioequivalence 
A generic drug is said to be bioequivalent if its difference in terms of 
bioavailability is minimal as compared to a reference drug when evaluated in 
similar conditions. SADC (2007) defines bioequivalence as an insignificant 
difference in terms of bioavailability between two pharmaceutically equivalent 
products or pharmaceutical alternatives under similar conditions in an 
appropriately designed study. FDA (2003) defines bioequivalence as a small 
difference in the rate and extent to which the active ingredient in pharmaceutical 
equivalents or pharmaceutical alternatives becomes available at the site of drug 
action when administered using same quantities of the drug under similar 
conditions in an appropriately designed study. Rani and Pargal (2004) and Lopes 
(2009) also define bioequivalence as an insignificant difference between the brand 
name and generic drug formulations in terms of their bioavailability. The basis of 
bioequivalence is that when two treatment formulations of the same drug, generic 
and reference, are equivalent in the rate and extent of their drug absorption, they 
should have the same therapeutic effect. In practice, we can never have two 
treatment formulations with exactly the same bioavailability, an insignificant 
difference would always exist. 
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1.2.4 Pharmacokinetic and Pharmacodynamics Studies 
Pharmacokinetic and pharmacodynamics studies are used in conjunction to 
establish bioequivalence. Pharmacokinetics is the study of the way in which drugs 
move through the body, that is, what the body does to the drug while 
pharmacodynamics account for the effect that drug(s) have on the body. 
Pharmacokinetics is a science describing drug: 
 Absorption from the administration site; 
 Distribution to, tissues and target sites of desired and /or undesired 
activity; 
 Metabolism; 
 Elimination or excretion (Peer, 2007). 
1.3 Significance of the Research 
Brand name drugs and generic drugs are both available in the market, but the 
brand name drugs are usually expensive compared to the generic. The cost of 
healthcare has been rising in the last two decades and the main aspects causing the 
increase according to Chow and Liu (2000), Borgherini (2003), Meredith (2003), 
Midha and Mckay (2009), Kamerow (2011), Mastan et al. (2011) and Kalpesh, 
Sokindra and Kishore (2013) are the expensive drugs. The cost of drugs, 
especially the original ones, makes medical expenses escalate to a point where the 
majority of people cannot afford it. Hence, high costs of drugs necessitate 
bioequivalence studies, as there is a need to find drugs which cost less as 
compared to the brand name ones. Generic drugs cost less than the original drugs 
though their effect on treating patients is similar to that of the original drugs. 
Generic drugs are developed at a lower cost because some stages or tests which 
were done when manufacturing brand name drugs are skipped now, for example, 
expensive chemical trials are not necessary. Kamerow (2011) states that generic 
drugs which can be procured at a lesser cost as compared to brand name drugs are 
available in the market for a wide range of major diseases including diabetes, 
hypertension, heart failure, lipid disorders and acid reflux. Bioequivalence studies 
are an area of research pursued by many researchers in recent years because there 
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is a need to reduce the financial burden of high medical costs due to expensive 
drugs. In addition to being bioequivalent, the pharmaceutical effectiveness of a 
generic drug should also be of almost the same degree with the reference drug so 
as to preserve the quality of a generic drug. The stages carried out in 
bioequivalence studies involve: designing the study, conducting the study and the 
evaluation of results. 
It has been observed by Kamerow (2011) that in the United States of America 
(USA), healthcare consumes a big part of the country budget, approximately 10% 
of the budget. He goes on to indicate that, it is observed that changing from using 
original drugs to generic drugs seems to be a feasible way of reducing the costs of 
the healthcare budget and quotes figures to substantiate the claim that costs are 
really reduced by switching to generic drugs. The USA government was able to 
save $33bn in 2007 by adopting a programme called Medicare, where generic 
drugs are prescribed to patients. Overall savings from the healthcare budget were 
estimated to be $139 in 2009 from the allocated amount by using the generic 
prescriptions in the United States (US). It is further indicated in the article by 
Kamerow (2011) that the amount saved in 2009 was not much significant 
contrasted with the $2.5 trillion annual healthcare bill, but, it should be noted that 
such reductions will eventually go a long way in saving some funds on healthcare. 
Mastan et al. (2011) had the same observation and opinion as Kamerow (2011) on 
that a good strategy for lowering healthcare costs is to introduce generic drugs 
which are much cheaper compared to the brand name drugs. This strategy has 
been effective in reducing total prescription cost by 11% without sacrificing 
quality. Generic drugs have captured more than 65% of the global market and 
account for 66% of prescriptions filled in the US but for less than 13% of the cost. 
Borgherini (2003) is also of the opinion that healthcare costs can be drastically 
reduced by introducing generic drugs in the market. Many countries including 
those in the industrialized world have a challenge of incurring high healthcare 
costs, hence they realise that there is a need to substitute the brand name drugs by 
generic drugs. He indicates that drug patents in the European Union expire after 
six to ten years after registration, after which generic drugs are then introduced in 
7 
the market at a lesser cost because registration costs of original drugs are not 
carried over to the generic ones. 
Advantages of using generic drugs are: 
 There is more knowledge about the chemical composition as well as the 
therapeutic effects of a generic drug as compared to a brand name drug; 
 A uniform name can be chosen for a test treatment formulation when it 
gets distributed into the market; 
 Pharmacists have the freedom to select the most suitable formulation of 
generic drug in terms of quality and price (Meredith, 2003). 
However, Meredith (2003) just like many researchers on bioequivalence mentions 
that the safety and effectiveness of generic drugs need to be monitored. The 
disadvantage highlighted is that the rate and extent of absorption may differ 
between test and reference treatment drugs and that the physical properties of the 
generic drug such as, colour, shape, size and flavour might not be the same as that 
of the brand name drug. Borgherini (2003) and Mastan et al. (2011) also note that 
the reduction in costs of drugs due to the use of generic ones is undisputed, though 
there are disadvantages of using generic drugs, they discuss three disadvantages. 
The first disadvantage is that the difference in costs of purchasing generic drugs is 
not much between those using medical aid compared to those who are not. There 
is therefore the non-cost benefit felt by those using medical aid. Secondly, the 
clinical equivalence of generic drugs as compared to brand name drugs is not fully 
investigated. FDA (2001) approves the sale of generic drugs which are 
bioequivalent to be within 90% confidence interval, this reduces costs but as 
argued by many researchers, clinical equivalence is not fully assessed. Thirdly, 
confusion arises, especially with elderly patients when packaging changes, for 
example, if a pill which used to be yellow and round is now dispensed as a green 
pill in the form of an oblong shape after a generic drug is introduced or changed. 
According to the observations by Kamerow (2011) and Midha and McKay (2009) 
it is quite evident that the use of generic drugs have pros and cons, but the fact 
that they are lower in costs and their drug safety and effectiveness is similar to the 
original drugs necessitates further research to be done in addressing the 
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disadvantages. In addition to being bioequivalent, the pharmaceutical 
effectiveness of a generic drug should also be of almost the same degree with the 
reference drug so as to preserve the quality of a generic drug. 
1.4 Aims and Objectives 
1.4.1 Aims 
The aims of the research were to: 
 Establish whether the test treatment formulations are safe and efficient as 
compared to the reference drugs when administered to patients; 
 Ensure that the test treatment formulation are a copy of the reference 
treatment drugs with the same dosage, strength, route of administration as 
well as its intended use; 
 Justify why bioequivalence studies are necessary; 
 Provide areas for further research. 
1.4.2 Objectives 
The objectives of this study were to assess bioequivalence between a generic drug 
and a brand name drug (an antibiotic) using statistical tests. Pharmacokinetics, 
pharmacodynamics, clinical studies and in-vitro as well as in-vivo studies are 
suggested by Mastan et al. (2011) for the purpose of assessing bioequivalence. 
1.5 Research Instruments 
Blood samples obtained through a 2 2 crossover design from fourteen sheep were 
used to get the data for the research project. The data set was obtained courtesy of 
the University of Pretoria at Onderstepoort within the Directorate of Veterinary 
Pharmacology. It consists of fourteen sheep, each being dosed by a test and 
reference treatment formulation in phase one (sequence one) then reference and 
test treatments in phase two (sequence two). The drugs were administered intra 
muscular, whereby the original drug was an antibiotic. The antibiotic was used to 
test the effect of heart water (parasite infection) and 10 mg/kg was administered 
per time interval. 
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The drugs were tested on sheep to evaluate bioequivalence hoping that if they are 
bioequivalent chances are likely that if administered on human beings the same 
effect would be noted. When they are tested on human beings results would have 
already been shown that the drugs are bioequivalent, such that the main focus 
would be to check if the same effect of the drugs is achieved. 
The software to be used will be a combination of Microsoft Excel (2010), SAS 
Enterprise Guide 7.1 and SAS 9.4. 
1.6 Outline of the Rest of the Project 
The next section of the research, Chapter 2, looks at the literature review. In this 
chapter, the evolution of bioequivalence studies is traced and then the 
fundamental concepts are defined and discussed, notably: 
Average bioequivalence (ABE) assessed by the confidence interval approach and 
Schuirmann’s interval hypothesis testing using two one-sided tests procedures on 
the pharmacokinetic parameters, area under a curve (AUC) and      for the test 
and the reference treatment drugs. Wilcoxon Mann-Whitney two one-sided test is 
used to analyse the bioequivalence for the parameter     . Population 
bioequivalence (PBE) and individual bioequivalence (IBE) are also discussed. 
The procedure recommended by the Food and Drug Administration (FDA, 2001) 
is used to assess PBE. Chapter 3 describes the methodology, which includes the 
study design to be used in this research report, 2 2 crossover design, 
pharmacokinetic parameters needed for the bioequivalence study. Parametric, 
nonparametric distributions are discussed. Outliers, power of a test, bootstrapping 
and effect sizes are also covered. Chapter 4 deals with the results and analysis of 
results achieved after using statistical models/techniques to establish 
bioequivalence between test and reference drugs. Chapter 5 discusses the 
conclusion and recommendations based on the research. 
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Chapter 2 
Literature Review 
2.1 Introduction 
In this chapter, a review of bioequivalence studies from where they started until 
current time is undertaken. Pharmacokinetic parameters, notably,       , 
      ,     and      are the metrics which are used to compare bioavailability 
between the test and reference treatment formulations.       ,        and 
     should be logarithmically transformed before statistical data analysis is 
carried out, while,      is analysed on the original scale of measurement. The 
justification for transforming the data is discussed in this chapter as well as the 
criteria used to certify drugs as bioequivalent. This chapter also looks at 
bioequivalence models and methods of assessing ABE, PBE and IBE. 
2.2 A Short Account of the Beginnings of Bioequivalence Studies 
The Americans were pioneers of this area of drug development leading to 
marketing the final product. The Food and Drug Administration, the research 
centre responsible for checking and ascertaining that the test treatment and 
reference treatment formulations are bioequivalent took a considerably amount of 
time, dating back from the early 1970s to come up with statistical models of ABE, 
PBE and IBE which are generally accepted worldwide. Other countries also set up 
their drug development centres emulating the Americans (Jones and Kenward, 
2003). Midha and Mckay (2009) also indicated that bioequivalence studies have 
been ongoing for over twenty years and are accepted by pharmaceutical industries 
as a method of approving generic drug products which are sold at a reduced cost 
compared to the brand name drugs. 
Chow and Liu (2000) trace the evolution of bioequivalence studies from its early 
days and state that the research and developments on bioequivalence studies 
commenced from the early 1970s and are in four stages. The first stage was from 
the early 1970s to 1984, when the Drug Price Competition and Patent Restoration 
Act (1984), was passed. The next stage was from 1984 to 1992, when a 
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bioequivalence guideline was published: FDA (1992) Guidance on Statistical 
Procedures for Bioequivalence Using a Standard Two-Treatment Crossover 
Design. The third phase, where population and individual bioequivalence and 
their statistical procedures were discussed kicked off from 1992. The fourth phase 
started from the beginning of the twenty first century, basically reviewing and 
updating the research conducted in the last thirty years of the twentieth century. 
Another guideline on BE studies, FDA (2001) Guidance for industry: Statistical 
Approaches to Bioequivalence, was issued out during this period. 
During the early 1980s focus shifted from bioavailability, to bioequivalence 
though the two studies still complement each other and are assessed through 
statistical methods. The Drug Price Competition and Patent Term Restoration Act 
of 1984 whereby generic drug products could only be approved through 
bioavailability and bioequivalence studies was a noble one because there is need 
to find the balance between producing drugs which cost less compared to the 
original ones while the quality of the drugs need not be compromised to ensure 
safety and effectiveness when administered to patients. In 1986 concerns were 
raised over the safety and efficacy of generic drugs. The challenge was that 
generic drugs could match the required standard for them to be approved as 
bioequivalent but therapeutic equivalence was not fully investigated. There was a 
need, through statistical tests or evidence to assure people that the bioequivalent 
drug products were also therapeutically equivalent. Midha and Mckay (2009) 
pointed out that issues or challenges on whether bioequivalent drug products are 
also therapeutic equivalent were addressed by the FDA (2003) during a meeting 
on bioequivalence of solid oral dosage forms. 
Since certain acceptable standards have to be attained in order to approve a 
generic drug, it happened that when bioequivalence studies started to gain 
momentum, regulatory authorities were also put in place to approve or disapprove 
the generic products. In US, the FDA published guidelines on how industry can 
properly use bioavailability and bioequivalence studies well, which were entitled 
Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally 
Administered Drugs General Considerations. Such guidelines are continuously 
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being improved or updated to meet the current changes in pharmaceutical needs 
and technology. Other FDA guidelines were in 1992, 1999, 2001 and 2003 and 
then elsewhere following the research done in US, regulatory authorities were 
established which published guidelines to be followed if a generic drug is to be 
licensed such that it becomes available on the market at a lower cost as compared 
to the brand name drug. 
In South Africa generic drugs are controlled by the medicines regulatory 
authority, known as the Medicines Control Council (MCC, 2003), which was 
established in the early 1970s. The MCC (2003) is a body that was constituted 
under the Medicines and Related Substances Control Act, 101 of 1965, to monitor 
the regulation of medicines in South Africa. The members of this statutory body 
are chosen by the Minister of Health and its major function is to safeguard and 
protect the public through ensuring that all medicines that are marketed and used 
in South Africa are safe, therapeutically effective and are consistently of the 
required standard of quality. 
Regulatory authorities established in other countries include Japanese guidelines 
(2001), MCC (2003), Central Drugs Standard Control Organization (CDSCO, 
2005) and SADC (2007). These regulatory authorities concur on that generic 
products have to be pharmaceutically equivalent and should be of the same 
bioavailability as compared to the original drugs after administration. There is 
also a criterion, pharmacokinetic parameters, which they use to certify a test 
treatment formulation as bioequivalent to a reference treatment formulation. 
2.3 Pharmacokinetic Parameters 
Wang and Bakhai (2006) recommended that statistical analysis of bioequivalence 
should be based on non-compartmental pharmacokinetic parameters, namely: 
AUC: refers to the area under a curve, it depicts a blood concentration time curve 
which illustrates information on the extent of the absorption of a drug, be it 
generic or brand name. Appendix 1 has figures showing AUC for the sheep used 
in this research report. 
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       : is the area under the plasma/serum/blood concentration time curve from 
time zero to time t, where t is the last time point where the amount of drug 
concentration can be measured. 
      : is the area under the blood concentration time profile from time zero to 
infinity. 
    : is the maximum value of drug concentration. 
    : is the time point corresponding to     . 
  is the elimination constant which describes the loss of drug activity from the 
body per time unit (for example, per hour). Chow and Liu (2000) states that   is 
the constant rate at which the drug is excreted and can be estimated as the slope of 
the terminal part of the logarithmically transformed concentration time curve 
multiplied by –2.303. The justification of multiplying 2.303 by a minus is due to 
the fact that at the stage where the drug is excreted from the body (elimination 
phase), the slope of the line is negative. 
  
 
 : refers to the time taken for the drug concentration to decrease by half when a 
drug is eliminated from the body. 
Regulatory guidelines on bioequivalence studies recommends that all 
concentration dependent pharmacokinetic parameters, for example, AUC from 
time zero to time t, AUC from time zero to infinity and      should be 
logarithmically transformed using either common logarithms to base 10 or natural 
logarithms (base e). The choice of adopting the use of common or natural 
logarithms should be consistent and should be stated in the bioequivalence study 
report (FDA, 1992). The view of transforming the bioequivalence 
pharmacokinetic parameters AUC and      is also expressed by Concordet 
(2004) stating that transforming the parameters prior to the analysis enables the 
researcher to proceed using assumptions of normality. He also indicates that the 
logarithmic transformation of the parameters      and AUC helps to make the 
variance constant so as to obtain a symmetric distribution but the parameter      
rarely follows a symmetric distribution and the variance remains unstable. 
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There are several reasons given motivating why the parameters AUC and      
should be logarithmic transformed: 
2.3.1 Clinical Rationale 
In the USA a committee responsible for giving direction as to what needs to be 
done in bioequivalence studies, known as the Generic Drugs Advisory Committee 
(GDAC) agreed in a meeting which was held in September 1991 that the ratio of 
the means of two treatment formulations, test and reference, need to be considered 
for the evaluation of bioequivalence instead of the difference of the means. The 
ratio of means can only be compared statistically after the data has been 
logarithmic transformed (FDA, 1992). 
2.3.2 Pharmacokinetic Rationale 
The 2 2 crossover design used in bioequivalence studies consists of subjects, 
period, sequence and treatment effects. As a result, it is assumed to be a model 
where all these components are added to each other. However, since GDAC 
(1991) advised that the ratio of two treatment formulations be used to assess 
bioequivalence, the 2   crossover design would then become a model where the 
various components, (subjects, period, treatment effects and sequence) are 
multiplied because of the logarithmic transformation to get the ratio of means 
(Rani and Pargal, 2004). 
2.3.3 Statistical Rationale 
Statistical analysis is done effectively and efficiently if the bioequivalence dataset 
approximately follows a log-normal distribution. In practice, the pharmacokinetic 
parameters AUC and      are usually skewed and there is a correlation between 
the means and the variances, whereby as the means of the treatment formulations 
increase, the variances also increase. Logarithmic transformation is carried out to 
reduce skewness in the parameters so that they become almost symmetrical and 
ensures that the increase of the means does not affect the variance (Concordet, 
2004). 
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     is obtained from a set of discrete values, though not exact, they are 
measured with errors. Parametric statistical methods used in bioequivalence 
studies cannot be applied for the parameter     , as they are considered 
inappropriate (Hauck and Anderson, 1984). Nonparametric tests such as the 
Wilcoxon Signed-Ranks test, Wilcoxon Rank Sum test or Wilcoxon Mann-
Whitney two one-sided tests seem appropriate for the analysis of      (Westlake, 
1976). 
2.4 Bioequivalence Criteria 
The regulatory authorities indicate that generic products and brand name products 
are bioequivalent if the ratio of the means of      and AUC of the two treatment 
formulations should lie in the range 0.80 to 1.25. If the ratio is less than 0.80 we 
say there is sub-availability while greater than 1.25 implies super-availability. 
Schall and Endrenyi (2010) point out that the bioequivalence range need to be 
tightened from 0.90 to 1.111 especially for cases of formulations with narrow 
therapeutic index (window).      (time to reach maximum blood concentration) 
should also be similar between the generic product and the original product. 
Regulatory authorities FDA (2001) strive to ensure that the scientific or statistical 
approaches used for assessing bioequivalence are of an acceptable standard, as 
mentioned earlier, so that the quality of generic drugs, though at reduced costs, is 
high. 
All stakeholders, at all possible levels, both nationally and internationally, have 
been convened in meetings, conferences and workshops to discuss as well as to 
reach agreements on approaches to standardise bioequivalence of pharmaceutical 
products in order to satisfy pharmaceutical equivalence. According to SADC 
(2007) the key issue is to ensure safety and efficacy of generic or new drugs in 
line with the FDA (2001) guidelines and regulatory bodies in other countries. 
Regulatory bodies concur that generic drugs could be bioequivalent but they 
should be also pharmaceutically equivalent at the site of action for a desired 
period of time. 
16 
2.5 Pharmacokinetic and Pharmacodynamics Models 
Pharmacokinetics and pharmacodynamics techniques are used in the development 
of drugs to ascertain bioequivalence of new or generic drugs. Greenblatt, Moltke, 
Harmatz and Shade (1998) discuss pharmacokinetics and pharmacodynamics 
procedures noting that they have been applied during the process of the 
development of new drug entities as well as for the improved understanding of the 
clinical actions of drugs that are already marketed. Pharmacokinetics is based on 
mathematical equations that allow the prediction of a drug’s behaviour and more 
emphasis is put on the relationships between drug concentrations and the time 
elapsed after administering the treatment formulation. According to the FDA 
(1999), population pharmacokinetics is the study which looks at the amount by 
which treatment formulation effects measured in a study subject differ after 
dosing with the test and reference treatment formulations., whereas 
pharmacodynamics measures the effect of drug concentration in individuals. In 
general, pharmacokinetics is the study of the way in which drugs move through 
the body during absorption, distribution metabolism and excretion and 
pharmacodynamics refers to the relationship between drug concentration at the 
site of action and the resulting effect including the time course and intensity of 
therapeutic and adverse effects. In short, pharmacokinetics refers to the effect the 
body has on the drugs whereas pharmacodynamics accounts for the effect that 
drugs have on the body. Models for pharmacokinetic and pharmacodynamics are 
used in the development of drugs and they complement each other in the sense 
that, pharmacokinetic models project the time period by which the treatment drug 
would be still available in the body after a treatment drug has been administered 
but the pharmacodynamics models accounts for the intensity of drug effects on 
subjects used for research, whether human or animals (Greenblatt et al, 1998). 
The combination of pharmacokinetics and pharmacodynamics give rise to kinetic-
dynamic modelling which investigates the drug concentration-effect relationship. 
This relationship is important in bioequivalence studies because clinical 
therapeutic of a drug is determined by a concentration-effect relationship.  
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 KINETIC-DYNAMIC MODELING 
Figure 2.1 Concentration-Effect Model 
The diagram above is adapted from Greenblatt et al. (1998) 
Greenblatt et al. (1998) point out that some models have been developed which 
incorporates the concentration-effect relationship. The models are: 
Sigmoid     : E 
         
  
          
        (2.5.1) 
Exponential: E m CA       (2.5.2) 
Linear: E m C       (2.5.3) 
where; 
E: Effect, 
C: Concentration, 
    : is the maximum pharmacodynamics effect, 
EC50: is the 50% effective concentration, 
C
A
: the exponent A represents the steepness of the concentration-response 
relationship in ascending order, though the biological importance of A is not 
established. 
(t, C) (t, E) 
(C, E) 
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The sigmoid      is an important model since conclusions can be drawn from it 
about the potency and efficacy of drugs producing the same clinical effect, 
individual differences in drug sensitivity, the mechanism of action of 
pharmacologic potentiators or antagonists, and the possible clinical role of new 
medications, these realisations were made by Greenblatt et al. (1998). The model 
has limitations, it does not apply to all concentration-effect data and an example 
of where the sigmoid      cannot be used is when the experimental data is not 
consistent with the model. Many researchers use both techniques, 
pharmacokinetic and pharmacodynamics in the development of generic drugs, of 
which nowadays the emphasis is more on the accuracy and sensitivity of the 
results when measuring drug concentration and drug effects respectively. 
2.6 Compartmental and Non-Compartmental Models 
Models have been developed that explain the interaction between an organism and 
drugs. There are two classes of models, namely: the non-compartmental and the 
compartmental models. According to Schutz (2009), compartmental models use 
kinetic models to describe and predict the amount of treatment drug in the body. 
Compartmental models are subdivided into non-compartmental, two compartment 
models and multi-compartment models. The non-compartment model (single 
compartment) considers a study subject (organism) as one homogeneous 
compartment whereby if a dose is administered, the blood concentration of a drug 
is distributed uniformly to other body fluids or tissues resulting in the excretion of 
the drug being directly proportional to the drug concentration in a subject under 
study. Peer (2007) describes the human body as a single compartment through 
which the drugs circulates through various organs of the body. A drug taken orally 
in tablet form is absorbed into this compartment as the tablet dissolves in the 
stomach and drug elimination from this compartment is due to the actions of the 
liver as well as kidneys. While the tablet is being dissolved in the stomach, the 
rate of absorption of the drug into the circulating blood is greater than the rate it is 
eliminated and the concentration of drug in the blood increases. After the tablet 
has been dissolved the rate of elimination is greater and the concentration 
declines. 
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A non-compartmental (single compartment) model measures the concentration of 
a drug administered by estimating the AUC. A numerical integration method, the 
trapezoidal rule is used to estimate the area under a curve of a concentration. The 
equation encompassing method of residuals is used to estimate the constant rate of 
absorption of a treatment formulation (Chow and Liu, 2000). 
   
       
 (     )
(           )      (2.6.1) 
where; 
   and    are the absorption and the constant rate of elimination, respectively, 
   is the amount of drug administered, 
V is the volume of distribution, 
F is the fraction of the drug that penetrates the body up to where circulation takes 
place, 
t is the time period for drug concentration in the body. 
In equation 2.6.1      and      can be similarly obtained as follows: 
     
     
     
 log(
  
  
) and       (2.6.2) 
      
       
 (     )
(               ).     (2.6.3) 
In practice,      and      are not found by applying the formulae in equation 
2.6.2 and 2.6.3 but are read from the blood concentration profiles. 
  
 
 is the amount of time taken for the drug concentration to decrease by a half is 
considered when a drug is eliminated from the body, computed as: 
logD log   
    
     
         (2.6.4) 
where D is the quantity of drug in the body. Thus, at D=
  
 
, that is, t=  
 
 we have 
log(
 
 
) 
     
 
     
         (2.6.5) 
Hence 
  
 
 
     
  
         (2.6.6) 
where    is given by 
   ( 2.303)(
     
  
)        (2.6.7) 
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The concentration-time graph of a one-compartment model is a linear graph or 
approximately linear. However, in reality, this model seems inadequate in 
pharmacokinetics since an organism’s supply of blood is not the same for all 
parts, there are areas or parts of an organism which receive more blood supply as 
compared to others. A two compartment model comprises the central 
compartment, there is more blood supply, for example, liver and kidneys and in 
the peripheral compartment organs of the body have a lower blood flow, for 
example, the brain tissues. The elimination of a drug tends to be rapid for a two 
compartment model in the central compartment though in rare occasions it occurs 
in the peripheral compartment or even in both. The two compartment model, 
according to many researchers performs better than the non-compartmental model 
though in real life each body tissue has its own distribution characteristics, hence 
a multi-compartment model is suggested, which is represented by fitting a curve. 
Pharmacokinetics parameters, such as the area under the curve are then calculated. 
The compartmental models are able to predict the concentration of a treatment 
formulation at any time as compared to non-compartmental models but are 
difficult to develop and validate. Non-compartmental models do not have the 
limitation of having different compartments within an organism. Both are used in 
finding pharmacokinetics parameters (Peer, 2007). 
2.7 Methods of Assessing Bioequivalence 
2.7.1 Average Bioequivalence 
Patterson (2010) points out that the FDA (1999) initially used average 
bioequivalence to assess the bioequivalence between brand name and generic 
drugs, though later on, there were debates as to whether certifying drugs using the 
average bioequivalence criterion was enough or not. It has been noted that average 
bioequivalence has limitations since it only compares the population means 
between test and reference treatment formulations. The intra subject variance of 
the formulations or the subject by formulation interaction is not taken into 
account. Hence, there is a major concern to know whether approved test treatment 
products can be used safely and interchangeably, if certified bioequivalent using 
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average bioequivalence. As a result of the limitations of average bioequivalence, 
the FDA (2001) recommended a statistical test procedure for PBE and IBE. 
Currently, researchers on bioequivalence of generic and original drugs combine 
population bioequivalence and individual bioequivalence for certifying 
formulations as bioequivalent or not.  
The Average Bioequivalence criterion (ABE) is given as: 
(µT µR)
2≤  
         (2.7.1.1) 
also given as: 
                   (2.7.1.2) 
where; 
   The average bioequivalence limit which is   =ln(1.25), 
   Mean of the test treatment formulation, 
   Mean of the reference treatment formulation, 
(     )  Mean difference of the two treatment formulations. 
2.7.2 Confidence Interval Approach 
Bioequivalence study data is best evaluated using 90% confidence intervals of the 
individual parameters of interest, usually,      and AUC, after transforming 
original data using logarithmic transformation based on common logarithms (base 
10) or natural logarithms (base e). According to Chow and Liu (2000) the 
confidence interval approach is one of the many methods which can be used for 
certifying drugs as bioequivalent or not. 
To calculate confidence intervals for untransformed data, we let; 
 ̅   Mean of the test treatment formulation in period 1, 
 ̅   Mean of the test treatment formulation in period 2, 
similarly; 
 ̅   and  ̅   Mean of the reference treatment formulation in periods 1 and 2 
respectively, 
 ̅   
 
 
 ( ̅     ̅  ): is the estimate for the test treatment drug averaged over 
both periods, 
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 ̅   
 
 
 ( ̅     ̅  ): is the estimate for the reference treatment drug averaged 
over both periods. 
Bioequivalence studies usually start with the same number of study subjects,    
and   , in sequence 1 and sequence 2, but the number that completes the study 
may not be equal. According to Chow and Liu (2000) it should be noted that  ̅  
and  ̅  are the equivalent to  ̅  and  ̅ , least square means for the test and 
reference formulations respectively. 
According to Rani and Pargal (2004) an ANOVA gives the mean square error 
(MSE), which is needed to obtain an unbiased estimate of   
  (the pooled sample 
variance of period differences from both sequences). MSE, in ANOVA Table 2.1 
is used when calculating the confidence intervals. 
Table 2.1 ANOVA Table 
Sources of 
variation 
Degree of 
freedom 
(DF) 
Sum of 
squares (SS) 
Mean sum 
of squares 
(MS) 
F Statistic 
Treatment t
a
-1 SST MST MST/MSE 
Subject n
b
-1 SSS MSS MSS/MSE 
Period t-1 SSP MSP MSP/MSE 
Error (t-1)(n-2) SSE MSE  
Total tn-1    
The 90% confidence interval approach discussed on untransformed data also 
applies when data is transformed. For example, using the pharmacokinetic 
parameter, AUC, if transformed it becomes lnAUC. 
The mean after the logarithmic transformation becomes: 
 n̅ AUC ∑  
         
 
 
         (2.7.2.1) 
where the subscript t represents the test treatment formulation of the AUC for the 
    study subject and n is the sample size. 
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The geometric mean is obtained by transforming the mean back to original data. 
Geometric mean  (       )      (2.7.2.2) 
The confidence interval approach, first suggested by Westlake (1976), states that 
bioequivalence may be concluded if a (1 2α) 100% confidence interval for the 
difference        or ratio 
  
  
 is within an acceptance range (  is usually set at 
0.05). If the ±20 rule (for original data) is used, this means that the confidence 
interval for the difference of the means of the two treatment formulations must be 
between  0.2 and 0.2. Likewise, the confidence interval for the ratio of means 
must be totally included in the interval 0.8 to 1.2 or 80% to 120%. The lower 
bound (LB) for the confidence interval is 0.8 and 1.2 is the upper bound (UB) for 
the confidence interval. Average bioequivalence is achieved if the confidence 
interval is totally included in the equivalence interval 0.80 to 1.25 or 80% to 
125% for the logarithmic transformed data, where 0.8 is the LB and 1.25 is the 
UB. There are several methods which can be used for calculating confidence 
intervals. Researchers on bioequivalence studies suggest that among the several 
available methods, the most appropriate one for a particular research project 
should be selected. 
2.7.2.1 Classic Confidence Interval of the Difference of the Means 
Let  ̅  and  ̅  be the respective least squares means for the test and reference 
formulations. The classic or shortest (1 2 )  100% confidence interval can be 
obtained based on the following t statistic: 
T 
(  ̅    ̅  ) (      )
 ̂ √
 
  
  
 
  
 
where    and    are the number of subjects in sequences 1 and 2, respectively 
and  ̂  the mean square error is obtained from  ̂
 
 , the pooled sample variance of 
period differences from sequences.    and    are the lower and upper confidence 
interval bounds for the interval of the difference of the means. 
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   ( ̅   ̅ )   (            ) ̂ √
 
  
  
 
  
 
and         (2.7.2.1.1) 
   ( ̅   ̅ )  (            ) ̂ √
 
  
  
 
  
. 
2.7.2.2 Classic Confidence Interval of the Ratio of the Means 
A confidence interval for the ratio: 
  
  
 may be computed from the confidence 
interval on the difference of the means of two treatments by dividing by  ̅  to 
obtain the formula: 
   (      ̅    )       
and         (2.7.2.2.1) 
   (      ̅    )      . 
   and    are the lower and upper confidence interval bounds for the ratio of the 
means for the test and reference treatment formulation. 
2.7.2.3 Westlake’s Symmetric Confidence Interval of the Difference of the 
Means 
Compute values of    and    so that, according to Chow and Liu (2000) the 
classic confidence interval derived from an unpaired two sample t statistic in 
equation 2.7.2.1.1 is:         where k is the upper  
   percentile of a central 
t distribution with (      2) degrees of freedom. In general, a (1 2 ) 100% 
confidence interval for the difference       can be expressed as: 
       , where    and    are chosen so that the probability from    to    
based on a central t distribution with (      2) degrees of freedom is (1 2 ), 
that is, 
      ∫     
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 ( ̅   ̅ ) 
and         (2.7.2.3.1) 
      ̂ √
 
  
  
 
  
 ( ̅   ̅ ). 
Finally, conclude bioequivalence if 
|                (2.7.2.3.2) 
2.7.2.4 Westlake’s Symmetric Confidence Interval of the Ratio of the 
Means 
A confidence interval for the ratio may be computed from the confidence interval 
on the difference of means using the formula  
   (       ̅    )       
and         (2.7.2.4.1) 
   (      ̅    )      . 
2.7.2.5 Confidence Interval of the Ratio of Means Based on Fieller’s 
Theorem 
The (1 2α) 100% confidence limits for    
  
  
 are the roots of the quadratic 
equation  
( ̅    ̅ )
   (              )
   (           
     )    (2.7.2.5.1) 
where; 
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         (2.7.2.5.5) 
Additionally, in order for the roots of the quadratic equation to be real, rational 
and positive, the above values must satisfy the conditions 
 ̅ 
√    
               
and         (2.7.2.5.6) 
 ̅ 
√    
              . 
In this research report the classic or shortest confidence interval (C.I.) approach 
will be used to assess ABE. The choice of using this C.I. approach instead of 
others, discussed above, is based on the fact that this approach is globally applied 
and accepted on evaluating ABE. Classic C.I. has a weakness of that the required 
level of equivalence to conclude ABE, 0.8 to 1.25, may not be achieved if the 
within subject variability is large. To overcome this weakness, bootstrapping, as 
described in Sections 3.12 and 4.7 can be used. Limitations of other C.I. 
approaches seem to be more than the weakness of the classic C.I. method. 
Westlake’ symmetric confidence interval approach is a modification of the classic 
C.I. Many researchers criticize Westlake’s C.I. because they are symmetric about 
   instead of  ̅   ̅  and the tail probabilities for the hypotheses are not 
symmetric, they divert from being two sided, becoming a one sided hypothesis as 
      or the standard error increases. Westlake can be used for decision making 
not necessarily for estimation and hypothesis testing. Confidence interval based 
on Fieller’s theorem is very attractive since variability of the treatment 
formulations is accounted for. However, Fieller’s method’s limitations are that it 
is derived using very mild assumptions of normality and is an approximation, not 
an exact procedure since the method is developed by substituting an estimate of 
the intra subject correlation (Chow and Liu, 2000). 
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2.7.3 Interval Hypothesis Testing Approach 
In order to investigate average bioequivalence the student t-test or Fisher test are 
not recommended since the hypothesis tested is not the same. For the classical 
student t-test as well as the Fisher test (ANOVA), the hypothesis tested is: 
H0:         bioequivalence 
H1:         bioinequivalence  (2.7.3.1) 
Where,    represent the population mean for the test treatment and    stands for 
the reference treatment formulation. While, the hypothesis for a bioequivalence 
study is: 
Additive bioequivalence test of hypotheses 
H0:          or           bioinequivalence 
H1:              bioequivalence (2.7.3.2) 
 (    ;   ) represents absolute equivalence interval. 
Multiplicative bioequivalence test of hypotheses 
    
  
  
            
  
  
         bioinequivalence 
           
  
  
         bioequivalence (2.7.3.3) 
 (    ;    ) is the relative equivalence interval where, 0<   1<    for example, 
0.8 to 1.25. 
Multiplicative hypotheses for the bioequivalence test become additive after a log 
transformation 
H0:ln   ln  <ln    or ln   ln  ˃ln    
H1:ln   ln   ln    ln         (2.7.3.4) 
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2.7.3.1 Schuirmann’s Two One-Sided Tests Procedure  
Schuirmann (1987) introduced the idea of using an interval hypothesis to evaluate 
ABE, applying the following null and alternative hypotheses: 
                                    
         (2.7.3.1.1) 
               
where    and    are limits selected to satisfy bioequivalence. The hypotheses 
2.7.3.1.1 can be separated to form two one-sided tests below: 
               versus               
               versus                 (2.7.3.1.2) 
The first hypothesis test whether the treatment effect is too low and the second 
tests whether the treatment effect is too high. If both null hypotheses are rejected, 
it can be concluded that the test treatment is average bioequivalent compared to 
the reference treatment formulation by using the Schuirmann’s two one-sided tests 
procedures. Jones and Kenward (2003) states that the method gets its name, 
TOST, because the process of deciding if the 90% confidence interval lies within 
the acceptance limits is the same as rejecting both of the following one-sided 
hypotheses in equation 2.7.3.1.3 at 5% level of significance. 
   :       ln1.25 versus    :      ln1.25  (2.7.3.1.3) 
If both tests are rejected, the conclusion of bioequivalence is made at α 
significance level. That is, conclude that    and    are average bioequivalent at 
the α significance level if  
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( ̅    ̅  )    
 ̂ √
 
  
  
 
  
                
and        (2.7.3.1.4) 
    
( ̅    ̅  )    
 ̂ √
 
  
  
 
  
                
If the hypothesis being tested leads to the same conclusion, parametric tests will 
be preferred, but if the conclusion is not the same, nonparametric tests are then 
used. 
2.7.3.2 Anderson and Hauck’s Test  
Unlike Schuirmann’s tests procedures, Anderson and Hauck (1984) suggested a 
one sided hypothesis interval approach for concluding ABE between two 
treatment formulations. The significance level of the Anderson and Hauck test is 
given by: 
    (       ̂)     (        ̂)    (2.7.3.2.1) 
where; 
  ( )  ∫            
 
  
      (2.7.3.2.2) 
 ̂  
     
 ̂ √
 
  
  
 
  
        (2.7.3.2.3) 
    
( ̅    ̅  ) (      )  
 ̂ √
 
  
  
 
  
      (2.7.3.2.4) 
Anderson and Hauck’s test (1984) has a higher probability of concluding ABE as 
compared to the C.I. approaches discussed in Sections 2.7.2.2, 2.7.2.3, 2.7.2.4 and 
2.7.2.5 and is also powerful contrasted to Schuirmann’s TOST procedures. 
However, Anderson and Hauck’s weaknesses are mainly on that the actual 
significance level ( ) may be bigger than the nominal significance level and this 
test may also conclude ABE even when variability is very large due to the fact 
that its rejection region is open ended. As a result of the serious limitations of 
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Anderson and Hauck’s test, Schuirmann’s TOST procedures are widely used 
(Chow and Liu, 2000). 
Bayesian methods can also be used to assess average bioequivalence. The main 
Bayesian methods according to Chow and Liu (2000), Jones and Kenward (2003) 
include the Rodda and Davis method as well as the Mandallaz and Mau’s method. 
2.7.4 Wilcoxon Mann-Whitney Two One-Sided Test Statistics 
Chow and Liu (2000) indicated that because the 2 2 crossover design consists of 
two sequences, that is, RT and TR, a distribution free sum of the ranks test can be 
applied directly to the two one-sided tests procedure. The Wilcoxon Mann-
Whitney two one-sided test statistics is applied when assessing average 
bioequivalence for the pharmacokinetic parameter      because this parameter 
does not exhibit normality hence a distribution free test is applied. The Wilcoxon 
Mann-Whitney two one-sided test statistics is as follows: 
Let:                 (2.7.4.1) 
The following hypotheses are tested: 
      
                     
    
and         (2.7.4.2) 
      
                    
   . 
where 
  
              (2.7.4.3) 
  
              (2.7.4.4) 
Let       {
                                                   
                                                                     
 (2.7.4.5) 
Where      
 
 
 (          )                         (2.7.4.6) 
When carryover effects are absent, the expected value and variance of      is 
given by: 
 (    )   {
 
 
 ,(      )   (     )-          
 
 
 ,(      )    -                          
   (2.7.4.7) 
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where                             and  (    )   (   ) 
    
  
  
  
 
 
 (2.7.4.8) 
Therefore,  (    )   (    )   (    ) 
   
      (2.7.4.9) 
Define    to be the value obtained by adding ranks of the responses for study 
subjects in sequence 1, given as: 
    ∑   
  
   (    )       (2.7.4.10) 
Therefore, the Wilcoxon Mann-Whitney test statistic for     is: 
        
  (    )
 
       (2.7.4.11) 
                       (   ),     (2.7.4.12) 
where  (     ) is the (     )   quantile of the distribution of  . 
Similarly, for the second set of hypotheses: 
       
     versus        
    we reject     if  
        
  (    )
 
   ( )     (2.7.4.13) 
Where    is the sum of the ranks of *    + for subjects in sequence 1. Hence, 
average bioequivalence can be concluded if     and     are both rejected, that 
is:  
     (    ) and    ( )     (2.7.4.14) 
The expected values and variances for    and   under the null hypotheses     
and      when there are no ties, are given by: 
 (  )    (  )   
    
 
      (2.7.4.15) 
 (  )    (  )   
 
  
       (        )   (2.7.4.16) 
If some ranks are equal, assign the mean of the ranks to compute    and   . In 
this case, however, the expected values and variances of   and   become: 
 (  )    (  )   
    
 
      (2.7.4.17) 
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 (  )    (  )   
 
  
       (          )   (2.7.4.18) 
where 
   
 
(       )(         )
 ∑  (  
    )
 
       (2.7.4.19) 
Where q is the number of groups with the same rank values and    is the 
magnitude of ranks with the same value in group V. Suppose all observations are 
different,                  for V 1,2,…, n and Q 0, equation 2.7.4.19 
reduces to equations 2.7.4.17 and 2.7.4.18. 
Since    and    are symmetric about their mean, 
     
 
, we have   (    )  
       ( )  
When        , is a large sample size (say,           ) and the ratio     and 
   is close to 
 
 
 , the distribution becomes approximately normal (symmetric): 
     (    ) and    ( )     (2.7.4.20) 
for average bioequivalence testing, that is, we may conclude bioequivalence if 
    ( ) and       ( )      (2.7.4.21) 
where  ( ) is the     quantile of a symmetric distribution, and 
    
    (  )
√ (  )
 
   ,
  (       )
 
-
√  
  
        (        )
    (2.7.4.22) 
    
    (  )
√ (  )
 
   ,
  (       )
 
-
√  
  
        (        )
    (2.7.4.23) 
Note that the expected values and variances in    and    should be replaced with 
that given in equations 2.7.4.17 and 2.7.4.18 if ties exist. 
2.7.5 Population Bioequivalence 
According to Chen and Lesko (2001), population bioequivalence puts emphasis 
mainly on prescribability (pre-approval), that is, can a patient be safely and 
effectively started on some other drug formulation. 
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The population bioequivalence (PBE) criterion is: 
Reference-scaled criterion 
      
(     )  (  
    
 ) 
  
      , for   
    
    (2.7.5.1) 
Constant-scaled criterion 
     
(     )  (  
    
 ) 
  
      , for   
    
    (2.7.5.2) 
where; 
    Population bioequivalence limit, 
    Mean of the test treatment formulation, 
    Mean of the reference treatment formulation, 
  
   The total variance of the test treatment formulation, 
  
   The total variance of the reference treatment formulation, 
  
   Specified threshold value of the total variance. 
The reference-scaled criterion is to be applied when the total variance,   
  is 
greater than an FDA (2001) specified threshold value,   
  0.04. Otherwise, the 
constant-scaled criterion is used. Population bioequivalence is concluded if it can 
be demonstrated that         where the recommended value for    1.7448, 
found as follows: 
    
                                               
               
 
  
   (    )  (  
    
  ) 
  
  
  
   (    )      
    
 
 1.7448 
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The FDA (2001) guidance document uses the notation    
    
  and    
    
  
for the total variances of the respective formulations. The hypothesis tested is: 
  
   :        versus   
   :       .    (2.7.5.3) 
PBE is concluded if   
    is rejected. 
2.7.6 Individual Bioequivalence 
Chen (2007) states that the FDA started investigations as from 1992 to find out 
whether average bioequivalence is adequate for the assessment of comparisons 
between test and reference treatment formulations. In 1999 the question of 
whether average bioequivalence is sufficient or not, was posed to the generic 
drugs Advisory Committee Meeting to deliberate on the issue, check whether 
average bioequivalence has limitations and motivate the need for assessing 
individual bioequivalence as prerequisite for approval of generic drugs. 
Subsequently groups were formed through the Centre for Drug Evaluation and 
Research of the FDA from the academics, industry and regulatory authority to 
explore the issue of individual bioequivalence. The underlying questions to 
address this issue were asked: 
 Is there a need to change the basis of bioequivalence criteria from average 
bioequivalence to individual bioequivalence? 
 What are the desirable properties of bioequivalence criteria if we are not 
satisfied with the current criteria based on average bioequivalence? 
 What are the general approaches in developing the criteria of individual 
bioequivalence if this concept is chosen for bioequivalence assessment? 
(FDA, 1999). 
Switchability is the main thrust of individual bioequivalence. It looks at the 
possibility of safely and effectively switching a patient from the original marketed 
formulation to another. Individual bioequivalence evaluates three components: 
 comparison of means, 
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 compares subject by formulation interaction, 
 compares within subject variances. 
The key issues involved in the formulation of the criteria for individual 
bioequivalence are the individual therapeutic window and intra subject variability. 
An individual therapeutic window can be viewed as the distance between the 
minimum effective exposure and the maximum tolerable exposure of a drug, 
whereas the intra subject variability can be viewed as the distribution of the 
individual’s responses to the drug. In theory, if a drug product given is both 
efficacious and safe to a patient, the distribution of his or her responses should fall 
within his or her own therapeutic window. When a test product is introduced that 
is interchangeable with the reference product, the distribution of this patient’s 
responses from the test product must also fall within his or her therapeutic 
window (Chen, 2007). 
Therapeutic window is defined as an interval of bioavailability metric or 
pharmacokinetic response such as        in which the drug is efficacious and 
safe (Chow and Liu, 2000). The lower and upper limits of a therapeutic window 
are known as: the minimally effective level (MEL) and the maximally tolerated 
level (MTL) respectively. If the difference between the MTL and MEL is large, 
the therapeutic window is wide while if the difference is small, the therapeutic 
window is narrow. 
The individual bioequivalence criterion (IBE) is: 
  
      
      
             
 (         )
  2(1  )           (2.7.6.1) 
Reference-scaled criterion 
          
(     )    
  (   
 
    
 ) 
   
      , for    
     
  (2.7.6.2) 
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Constant-scaled criterion 
          
(     )    
  (   
 
    
 ) 
   
      , for    
     
  (2.7.6.3) 
Here    
  is a constant (pre-set value), of which the FDA (2001) recommended 
value for    
  0.04 
IBE is concluded if        . Currently, the FDA (2001) recommended value for 
    2.2448 when   
  0.02 and    2.4948 when   
  0.03. 
    
                                         
               
 
  
   (    )    
  (    
     
 )   
   
  
  
   (    )           
    
 
 2.2448. 
  
  or    
 the pre-specified threshold value for both PBE and IBE is 0.04. 
where; 
   Individual bioequivalence limit, 
   Mean of the test treatment formulation, 
   Mean of the reference treatment formulation, 
  
  Subject by formulation interaction component of the variance, 
(   
     
 ) are between subject variances of the test and reference formulations 
respectively, 
   
  Within subject variance of the test treatment formulation, 
   
  Within subject variance of the reference treatment formulation. 
The denominator of    
  provides a scaling factor FDA (2001) suggested that the 
reference scaled individual bioequivalence be applied when the estimated 
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magnitude of    
  exceeds a pre-set value of the variance (   
 ) :(   
 ˃   
 ), 
otherwise, a constant-scaled criterion is used. 
The hypothesis tested is: 
  
   :        versus   
   :           (2.7.6.4) 
IBE is concluded if   
    is rejected. 
2.8 Comparison of Average Bioequivalence, Population Bioequivalence and 
Individual Bioequivalence 
Endrenyi, Amidon, Midha and Skelly (1998) observe that it is not easy to use the 
models for individual bioequivalence, they are more complicated and have more 
parameters than those applied for average bioequivalence. More questions arose 
as well investigating whether individual bioequivalence is really necessary or not: 
 Has average bioequivalence failed, that is, have there been documented 
problems observed following the substitution of bioequivalence? 
 Is there evidence that subject by formulation interactions are important? 
 What populations, for example, healthy volunteers or patients, are 
appropriate for the evaluation of IBE and, in particular, for the study of the 
subject by formulation interaction? 
 Are comparisons of within (intra) subject and intra formulation variations 
relevant? (Endrenyi et al, 1998). 
All these questions were dealt with by groups formed at the Centre for Drug 
Evaluation and Research. One such group comprises of Chen, Patnaik, Hauck, 
Schuirmann, Hyslop, and William (2000) who worked on individual 
bioequivalence as well as developing the statistical methods to assess 
bioavailability measures. Individual bioequivalence has an advantage over 
average and population bioequivalence because it allows assessment of subjects 
by formulation interaction and compares population averages as well as variances 
between the test and reference treatment drugs. Population bioequivalence 
38 
accounts for average bioequivalence only, variances are not considered, hence as a 
result, there is need for individual bioequivalence to complement population 
bioequivalence. The need for individual bioequivalence is further enhanced by 
that pharmacokinetic responses for test and reference products differ among 
individuals. Meredith (2003) is among such researchers who are argued that 
population bioequivalence should go hand in hand with individual bioequivalence. 
He states that bioequivalence is achieved by certifying two treatment drugs as 
ABE, but, there are concerns on the use of ABE only since it does not effectively 
evaluate treatment formulations with a narrow or wide therapeutic interval or high 
intra subject or inter subject variability. To alleviate the fears observed using 
ABE, the use of IBE is suggested. 
Drug interchangeability, which can be classified as either drug prescribability or 
drug switchability differentiates between population and individual 
bioequivalence. The treatment formulation a physician chooses to prescribe to a 
patient compared to the other available drugs is known as drug prescribability. 
Drug switchability is a case where a patient is switched from one treatment 
formulation to another, ensuring that the concentration of the drug has been toned 
to a steady, efficacious and safe level as compared to the first one. Switchability, 
an attribute obtained through individual bioequivalence, is synonymous to a 
guarantee that once drug products have been certified as bioequivalent, they can 
then be used interchangeably in the target population, hence the seriousness by all 
stakeholders currently in pursuing the blending of population and individual 
bioequivalence. Prescribability is assured by population bioequivalence through 
comparing the population means and variance components between the test and 
the reference treatments. The concept of individual bioequivalence is really 
important because it ensures that, for a certain period, as deemed sufficient by 
regulatory authorities (Chen et al, 2000). The bioavailability or bioequivalence 
measure for an individual remains unchanged in order to ascertain safety and 
efficacy of that individual (FDA, 2001). 
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Average bioequivalence is compared and contrasted with individual 
bioequivalence, of which the observations are: 
 Average bioequivalence is used by the FDA to approve the marketing of 
thousands of generic drugs; 
 For a few other drugs, in vivo studies are waived and market access is 
granted based on in vitro studies; 
 Large amount of empirical evidence suggests that generic drugs are used 
regularly without problems of safety or efficacy. 
However, on the other hand, the realisations were that individual bioequivalence: 
 Has been proposed by the FDA (2001) as an improvement on the study 
design, in formativeness and method of analysis of bioequivalence studies; 
 Controversial topic with many debates and public discussion; 
 Has not been universally accepted (Chen and Lesko, 2001). 
The other drawback of IBE is that it allows patients to be switched from a 
reference treatment formulation to its corresponding test treatment. However, it 
falls short regarding switching a patient from one test treatment to another generic 
drug formulation, a trend happening in practice (Patterson, 2010). 
To show that test and reference formulations are average bioequivalent it is only 
necessary to show that the ratio of the means AUC and      for test and reference 
treatment formulations are within the accepted bioequivalence interval as per a 
regulatory authority specifications. It is possible for one drug to be much more 
variable than the other, yet similar in terms of the means, therefore, ABE has 
some limitation since it does not consider the variability. Population 
bioequivalence is a measure which combines the mean and variance of the drug 
products. Individual bioequivalence has more information to enable the approval 
of generic drugs as bioequivalent though there are also challenges on using IBE 
models. The way forward which seem to be a general consensus among 
researchers on bioequivalence, is that the concepts involved in population 
bioequivalence need to be integrated with individual bioequivalence so as to be 
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thorough on ascertaining generic drugs as being bioequivalent (McCarthy and 
Guo, 2008). 
The next chapter looks at the criteria used for selecting study subjects for a 
bioequivalence study, assuming human beings are used. The crossover design is 
discussed and implemented using data obtained from the study subjects (sheep). 
Data from sheep dosed using the RT and TR was assessed for ABE and PBE 
using various statistical techniques. 
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Chapter 3 
Methodology 
3.1 Introduction 
This chapter focusses on the methods of how the test treatment and reference 
treatment formulations will be compared in terms of their bioavailability. Methods 
include in vitro studies, comparative clinical studies, pharmacodynamics studies 
and pharmacokinetic studies. Pharmacokinetic studies are preferred as compared 
to the other methods of assessing bioequivalence and justification is given as to 
why they are chosen in a bioequivalence study. 
Bioequivalence regulatory authorities prescribe standard requirements for 
candidates to be used in the study, tables with such requirements are available in 
this chapter. A 2 2 crossover design is used once study subjects have been 
identified and enrolled to find pharmacokinetic parameters. Some study subjects, 
with very low or extremely high bioavailability, known as outliers are discussed 
in this chapter, including the various methods for detecting them. Methods of 
statistical analysis are classified into parametric and nonparametric, where the 
former method is applied on the pharmacokinetic parameters:       ,        
and      but      utilizes the latter method. This chapter also discusses the 
power of a test, bootstrapping and effect sizes. 
According to the FDA (2003) and Mastan et al. (2011), bioequivalence between a 
test drug and reference drug can be assessed through mainly four ways, namely: 
 in vitro studies, 
 comparative clinical studies, 
 pharmacodynamic studies, 
 pharmacokinetic studies. 
The methods of assessing bioequivalence, mentioned above, are applied 
depending on the type of treatment formulation or method of administering the 
drug(s). They can be used in isolation or as combinations. Bioequivalence is well 
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established through pharmacokinetic studies. Pharmacodynamics studies are not 
recommended where pharmacokinetic methods can be used. Clinical studies can 
be utilized for situations where other methods for assessing bioequivalence cannot 
be used (Wang and Bakhai, 2006). In vitro studies are more appropriate for 
immediate release (IR) solid oral dosage forms (Polli, 2008). The FDA (2003) 
guidance for bioequivalence has a clause, 21 CFR 320.24, which clearly indicates 
that clinical studies need to be avoided if possible. These guidelines also indicate 
that bioequivalence can be tested by in vitro or in vivo studies given immediate 
release solid oral dosage forms approved after 1962 and for bio-problem treatment 
formulations approved before 1962. Pharmacokinetic studies are usually used or 
preferred in assessing bioequivalence because the parameters obtained enable the 
researchers to measure bioavailability. The measurements taken should indicate 
the concentration of the drug in the body, that is, the amount of the treatment drug 
in a given volume of blood. If for some reasons, measurements of the drug cannot 
be extracted through the blood, then measurements can be achieved through 
urinary excretion. 
3.2 Study Subjects for a Bioequivalence Study 
Study subjects which are preferred for a bioequivalence study should possess 
attributes like: 
 The study subjects for population bioequivalence are chosen in such a 
manner that there is maximum variability among them but differences 
between pharmaceutical products should be noticeable without much 
difficulty; 
 Healthy volunteers of either sex, in the range 18 to 55 years old are 
normally preferred to be in the study; 
 Women who still have a potential of giving birth are screened on an 
individual basis; 
 The weight of study subjects is also considered before enrolling into the 
bioequivalence study, the recommended weight should be proportional to 
the body mass index. Non-smokers, who have never consumed alcohol, 
are preferred; 
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 Candidates for study are thoroughly screened and undergo a medical 
examination before they can be enrolled (FDA, 2003). 
Below are Tables 3.1, 3.2 and 3.3, showing regulatory requirements (human 
beings) for demographics, sample size and whether study subjects need to be fed 
or fast for different regulatory bodies from Tamboli, Todkar and Sayyad (2010) 
contrasted with FDA (2003) and MCC (2003) bioequivalence requirements. 
Regulatory requirements in tables below were included in this research report to 
discuss what is needed if human beings were to be used in a bioequivalence study. 
Table 3.1 Regulatory Requirements for Demographics  
Regulatory 
Authority 
Age Gender BMI (kg/m²) 
India Greater than or equal to 
18 years, but if the 
treatment formulation is 
for use by the elderly, the 
majority of the study 
subjects should be 60 
years of age or older. 
Gender 
selection 
should be 
consistent 
and depend 
on usage and 
the safety 
criteria. 
Not specified. 
USA 18 years or older. Male or 
female. 
Not specified.  
Europe 18 years or older. Male or 
female. 
18,5 to 30kg/m² 
Canada 18 to 55 years. Males or 
female. 
Ratio of height/weight 
should be within 15% 
of the normal interval 
of healthy volunteers. 
ASEAN 18 to 55 years. Male or 
female. 
 
18 to 25kg/m² 
South 
Africa 
18 to 55 years. Male or 
female. 
Recommended BMI or 
within 15% of the 
normal body mass. 
Brazil 
(ANVISA) 
18 to 50 years. Male or 
female. 
Within 15% of the 
accepted interval. 
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Table 3.2 Regulatory Requirements for Sample Size 
Regulatory 
Authority 
Minimum Sample size specifications 
India 16 years or more. The number of subjects required for a 
study should be statistically significant 
and should be large enough to allow for 
possible drop outs from the study. 
USA 12 years The total number of subjects in the 
study should provide sufficient power 
to conclude bioequivalence. 
Europe 12 years or more. The sample size calculation method 
determines the sample size. 
Brazil 12 years or more. The number of subjects required is 
determined by: 
 The error variance linked with the 
main characteristic to be studied as 
estimated from a pilot experiment 
obtained from previous studies or 
from published data. 
 The desired level of significance. 
 The expected deviation from the 
reference treatment formulation 
compatible with bioequivalence. 
 The required power. 
South 
Africa 
12 years or more 
subjects for immediate 
release and 20 subjects 
for modified release 
oral dosage forms 
The number of subjects should be 
justified on the basis of providing at 
least 80% power of achieving the 
acceptance criteria or appropriate 
equations should be used to calculate 
the sample size. 
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Table 3.3 Fasting and FED Study Requirements 
Regulatory 
Authority 
Fasting requirements 
India Should fast for 10 hours or more at night followed by 4 
hours of fasting after taking a treatment formulation. If 
dosing is done many times at night, fasting should be 2 
hours before and 2 hours after dosing. 
Europe and Brazil Greater than or equal to 8 hours before and greater than 
or equal to 4 hours after dosing. 
USA and Canada Should be greater than or equal to 10 hours and continued 
for at least 4 hours after dosing. 
ASEAN Greater than or equal to 8 hours before taking the 
treatment formulation. 
South Africa The same time period of fasting should be maintained 
before and after dosing. 
 
All of these criteria above were relevant if the data that were used for 
bioequivalence analyses were for human trials, but they were from an animal trial. 
Animals used in bioequivalence studies must be healthy and from a homogeneous 
group (age, breed, sex, weight, hormonal and nutritional status, level of 
production among other aspects). When it is difficult to conserve homogeneity of 
all animals within a study (for example, sheep), it would be acceptable to use non-
homogeneous stock provided that animals in each treatment group were carefully 
matched for characteristics including age, weight and sex. Selected animals must 
be representative of the target population for which the product is intended. Group 
size: for ethical and economic reasons, the appropriate number of animals should 
be carefully estimated; it depends on several factors including variance of the 
response, differences in the two treatment formulations and level of rejection of 
the hypothesis (The European Agency for the Evaluation of Medicinal Products, 
2001). 
3.3 Crossover Design 
The two sequences, two periods, crossover study design is recommended by many 
researchers on assessing bioequivalence using pharmacokinetics parameters. In 
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this research report, generic and brand name products are administered to study 
subjects (experimental units) with the objective of trying to establish differences 
(if any) due to availability of generic and brand name products on different study 
subjects. A crossover study seeks to investigate the response of individual study 
subjects to two different treatments (Jones and Kenward, 2003). 
Sequence Period 1 Washout Period 2 
1 R  T 
2 T  R 
Figure 3.1 2 2 Crossover Design 
A crossover design is a design used when collecting blood samples from study 
subjects such that pharmacokinetic parameters can be obtained. In a crossover 
model, study subjects are randomized into two groups then given a sequence of 
treatments at uniform intervals of time (periods). In the first sequence, each study 
subject receives, say, a test treatment in period 1, then a reference treatment in 
period 2 and this arrangement is reversed in the second sequence, reference 
treatment is given followed by the test treatment. 
Wang and Bakhai (2006) illustrated the 2 2 crossover design diagrammatically as 
shown below: 
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A model for the 2 2 crossover design from Chow and Liu (2000) is given as: 
    = +   +  + (   )+ (     )+          (3.3.1) 
where; 
     represents the response, for example, AUC of the  
   subject in the     
sequence at the     period, 
  The overall mean of the model, 
    The random effect of the  
   subject in the     sequence where i 1,2,…,g, 
   The fixed effect of the  
   period, where j 1,…,p and ∑ Pj 0, 
 (   )  The direct fixed effect of the formulation in the  
   sequence which is 
administered at the     period and ∑ (   )  0, 
 (     )  The fixed first order carryover effect of the formulation in the  
   
sequence which is administered at the (   )   period where  (   )  0 
and ∑ (     )  0, 
     The random error in observing      . 
It is assumed that     are independently and identically distributed (iid) with mean 
0 and variance   
 , and      are independently distributed with mean 0 and 
variance   
 , where t = 1,2,…,L (the number of formulations to be compared).     
and      are assumed to be mutually independent. The estimate of   
  is usually 
used to explain the inter-subject variability, and the estimates of   
  are used to 
assess the intra subject variabilities for the     formulation. 
3.3.1 Advantages of a Crossover Design 
The crossover designs are preferred as compared to other experimental designs 
because they are not influenced much by physiological variables. Greenblatt et al. 
(1998) states that physiological variables such as age, gender, body height, 
ethnicity, hepatic and renal disease might affect drug disposition. Using crossover 
designs, therefore, enables the researcher(s) to find the difference between the 
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drug concentrations of a generic and a brand name drug due to formulations of the 
drug.  
The crossover design is viewed favourably because of its advantages: 
 Each subject receives both treatment formulations hence a comparison can 
be made within subjects; 
 It eliminates the inter subject variability from comparison between 
formulations; 
 With a proper randomization of subjects to the sequences of treatment 
formulations, the crossover design provides the best unbiased estimates for 
the differences (or ratios) of the means (Jones and Kenward, 2003; FDA, 
1992 and Chow and Liu, 2000). 
Each trial subject acts as his own control since both drug formulations are 
administered per study subject. The crossover design is thus very useful because 
both treatments, generic and brand name, are given to the same subject. Drug 
concentration measurements are taken from each study subjects for both treatment 
formulations such that bioequivalence can be assessed (Galpin, 2007). 
3.3.2 Disadvantage of a Crossover Design 
The crossover design is a powerful study design where comparison is made within 
study subjects though it has a disadvantage of that it is not suitable for treatment 
formulations with long half-life and the effect of a treatment given in one period, 
called a carryover effect, might still be present at the start of the following period. 
3.4 Carryover Effect 
There are cases where it is not possible to totally eliminate the effect of a previous 
treatment resulting in a carryover effect. A carryover effect is a situation where 
some amount of a treatment (drug) from one period will still be available when 
blood samples are taken on the next period. Senn (2001) indicates that a carryover 
effect arises if a treatment (drug) administered in one period continue to affect the 
study subject in subsequent period(s). He goes on to state that a carryover effect 
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introduces bias to estimates of the amounts of a particular drug in blood samples 
(generic or brand name), because the assumption will be that the effect of one 
treatment is being observed yet two or more drugs will be still within the study 
subject(s).  
The carryover effect arises due to a short interval of time allowed to pass before 
administering the next drug formulation to a study subject. Other causes of a 
carryover effect could be as a result of: 
 Drugs which have a long half-life, though with an inadequate washout 
period; 
 Trial subjects with poor metabolism rates, hence taking a long time to 
eliminate the drug in the body; 
 Random occurrence (Patterson, 2010). 
In bioequivalence studies a long washout period is allowed between dosing 
periods such that the carryover effect is eliminated. The washout period is the 
interval between dosing periods. In a crossover design, the washout period should 
be long enough such that the effect of one treatment formulation administered at 
one period is not available at the next period of dosing (Chow and Liu, 2000). 
Jones and Kenward (2003) indicated that a washout period, between dosing 
periods, should be at least five half-lives so as to ensure that the carryover effects 
are eliminated completely. As a consequence of having a long washout period, 
there is no need to test for a differential carryover effect (FDA, 2001). 
The 2 2 crossover model without the carryover effect becomes: 
               (   )            (3.4.1) 
where the components of this model are defined in equation 3.3.1. 
 
The crossover design, Figure 3.2, was used at the University of Pretoria at the 
Directorate of Veterinary Pharmacology where sheep were randomized then dosed 
with the reference treatment formulation (an antibiotic) followed by the test 
treatment formulation after an adequate washout period was allowed before the 
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next dosing period to obtain the bioequivalence data. The model 3.3.1 was used in 
this study when assessing ABE and PBE. 
3.5 Pharmacokinetic Parameters 
The pharmacokinetic parameters obtained after collecting the blood samples from 
study subjects are     : the rate (but also extent) of absorption. Estimated 
directly from the data, where      max(  ,  ,  ,…  ). 
    : is the corresponding time point estimate at which      occurs. 
Chow and Liu (2000) and Wang and Bakhai (2006) explained how to calculate 
the AUC: the extent of drug absorption, obtained as follows: 
       ∑ (
       
 
 
   )(        )      (3.5.1) 
                     
        
     
 
       (3.5.2) 
λ = Slope *  2.303        (3.5.3) 
Slope is obtained from the plots of ln(Concentration) in Appendix 4, at the time 
points where the elimination of the drugs become approximately linear. 
Calculations for finding the AUC in this study were done from Appendix 1 to 
Appendix 5. 
 
3.6 Parametric versus Nonparametric Tests 
Parametric and nonparametric tests will be used in this research study to analyse 
the figures obtained after collecting blood samples from the study subjects in 
order to determine the pharmacokinetics parameters. Given a data set, a researcher 
needs to make a choice as to whether use parametric or nonparametric tests so that 
reasonable decisions based on the data obtained can be taken. The selection of the 
tests to use is guided by the nature of the data, as indicated earlier. If the data 
follows a normal distribution or approximately so, the parametric tests are 
recommended in order to get best results but if the data does not follow a normal 
distribution, nonparametric tests are appropriate. There are quite a number of 
ways which can be used to determine whether the data set is normal or not, 
common approaches of checking normality include: plotting a histogram, finding 
the coefficient of skewness or kurtosis. Kurtosis is a measure which indicates 
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whether the data is peaked or flat relative to a normal distribution. It is easy to 
visualize whether the data follows a normal distribution or is skewed if a 
histogram is plotted. When determining normality by skewness, the coefficient of 
skewness is used. The coefficient of skewness for a normal distribution is equal to 
zero. Data sets with a coefficient of skewness greater or less than zero need to be 
transformed to try and reduce skewness: The transformations which can be 
applied on data include the log transformation, square root, square, inverse, 
bucketing and many more. However, in this report, the choice of tests was as per 
the FDA (2001) recommendations since most of the research done on 
bioequivalence is per criteria established by the FDA. 
3.6.1 Parametric Tests 
Concordet (2004) points out that a statistical property of the distribution of data is 
that all data can be completely described by a finite number of parameters. 
Guassian (Normal) distribution, N(    ), is an example of a parametric 
distribution. Parametric distributions assumptions are: 
 homoscedasticity, 
 independence, 
 normality. 
Homoscedasticity refers to a situation where the variance of the dependent 
variable is constant, that is, it does not vary with independent variables which are: 
the drug formulation, study subject and period. 
Independence is a situation whereby the random variables which feature in the 
bioequivalence analysis are independent. 
Normality in a distribution is achieved if the pharmacokinetic parameters used in 
the bioequivalence analysis are normally distributed. 
For bioequivalence studies the pharmacokinetic parameters which usually utilise 
the parametric tests are the AUC and     . 
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ABE and PBE were used to test for bioequivalence between the two drugs for the 
sheep, on the pharmacokinetic parameters. 
3.6.2 Nonparametric Tests 
Nonparametric tests are applied for situations where the distribution of data is not 
defined by a finite number of parameters. It can only be defined by its shape, 
number of modes, regularity and other features. It should be noted that for 
nonparametric distributions, the number of parameters used to estimate the 
distribution with n data increases with n. A known statistical distribution cannot 
be linked to nonparametric tests, that is, we cannot say that this distribution of 
data follows a Normal, Exponential, Binomial, Poisson, Geometric or some other 
of the common statistical distributions. The nonparametric tests are usually less 
powerful, since it is more difficult to show bioequivalence even for cases where 
there is bioequivalence, as compared to their parametric counterparts but 
nonetheless there are situations which require nonparametric methods (where the 
distribution is not normal, as pointed out earlier). For bioequivalence studies, 
    , is analysed by using nonparametric methods (FDA, 2001). 
Nonparametric tests are a branch of statistical inference (decision making) 
whereby the estimation or hypothesis tested is not necessarily about a population 
or sample statistic and distribution assumptions are not used as compared to the 
parametric tests. According to Galpin (2007) nonparametric tests are appropriate 
for a data set which is severely skewed whereby even transforming the data to 
approximate normality is a futile exercise, hence normality of the data cannot be 
assumed and there is no indication as to which distribution the data can follow. 
When a data set is normally distributed, the mean is equal to the median and we 
use the mean as our measure of centre. However, if the data set is skewed, then 
the median is a much better measure of centre. Therefore, just like the Z (normal 
distribution), t (Student test) and F (Analysis of Variance) tests made inferences 
about the mean(s) on parametric tests, nonparametric tests make inferences about 
the population median(s). 
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Parametric tests were used in this study when assessing ABE and PBE for the 
pharmacokinetic parameters AUC and      because the histogram for the data, 
Appendix 7, Figure 1 and Appendix 8, Figure 1, exhibits a distribution which is 
almost normal. Non-parametric test, Wilcoxon Mann-Whitney test statistics were 
used in this study to evaluate ABE and PBE for the parameter      because the 
data is not normally distributed. 
3.7 Outliers 
In a bioequivalence study there are observations obtained from the drug 
concentration time profiles which are extremely high or low as compared to the 
rest, such observations are called outliers. Outliers are probable as a result of an 
error in typing data or a data value(s) obtained mistakenly from a study subject(s) 
which is/are not supposed to be included in the research for a variety of reasons. 
Outliers are defined by Patterson (2010) in terms of the residuals in the model, 
whereby a data value that is too large or small cannot be fitted into the model, 
hence becomes an outlier. There are four different types of outliers: 
 Observations which arise unexpectedly in concentration time profiles; 
 Observations which are very huge or minute in one of the treatment 
formulations; 
 A large significant difference, extremely large or small, in bioavailability 
when the generic drug is contrasted to the reference formulation; 
 Observations which exhibit an unusually high or low concentration of drug 
in a study subject in both treatment formulations (Chow and Liu, 2000). 
Causes of outliers are varied, though basically common according to many 
authors on bioequivalence. Frequent changes in laboratory tests may result in 
some observations becoming too high or low, hence becoming outliers. Human 
error on measuring the concentration of blood can also cause an outlier (Karasoy 
and Daghan, 2012). 
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Other causes of outliers may be attributed to: 
 Defects in a drug, treatment formulation may be broken (though coated) or 
having a wrong dosage; 
 Sudden changes in a study subject, probable someone starts vomiting or 
develops diarrhoea; 
 Laboratory error, say, a wrong drug is prescribed; 
 A study subject can have an unusual reaction to a treatment formulation or 
both drugs resulting in a subject by formulation interaction which was not 
expected (Schall, Ring and Endrenyi, 2010). 
There are tests which can be used to detect outlying subjects. Chow and Liu 
(2000), Ramsoy and Elkum (2004) and Karasoy and Daghan (2012) discussed 
methods of identifying outliers: 
3.7.1 Likelihood Distance Test (LD) 
The LD was developed on the basis that the period and treatment formulation 
effects do not exist on the 2 2 crossover model 3.4.1. The model 3.4.1 with the 
period and treatment formulation equal to zero reduces to: 
                                          (3.7.1.1) 
The parameters of interest in model 3.7.1.1 are:  ,   
  and   
 . Let   
(        )
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L( ) 
   
 
log2  
 
 
log(    
   
) 
 
   
∑ ∑ (      )
 
   
  
     
 
 
(
 
  
 
 
  
)∑ ( ̅    )
 
   
 
     (3.7.1.2) 
The maximum likelihood estimators (MLEs) of the parameters   ,    and    
derived by maximizing L( ) given that   =   are: 
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The LD statistic becomes: 
   ( ̂)    [ ( ̂)   ( ̂( ))]      (3.7.1.6) 
where  ̂( ) is the MLE of   after deleting the  
   subject. It can be shown that as n 
approaches infinity    ( ̂) is asymptotically distributed as a chi-square with three 
degrees of freedom. The     subject is considered to be an outlier if     ( ̂)  
    
  ( ) where    
  ( ) is the     upper percentile of a central chi-square 
distribution with three degrees of freedom. 
3.7.2 Estimates Distance Test (ED) 
ED is a method of detecting outliers and was developed based on the difference of 
the parameter estimates obtained after deleting the     subject, slightly different 
from the LD which is based on the difference in the log-likelihood function after 
deleting the     subject. 
   ( ̂)    
  ( ̂   ̂  )
 ∑̂  ( ̂   ̂  )    (3.7.2.1) 
Equation 3.7.2.1 is the ED statistic where ∑̂   is the MLE of the variance matrix 
below  
∑ [
      
    
  (   )  
     
 
]     (3.7.2.2)) 
The    ( ̂) statistic was shown to be asymptotically distributed as a chi-square 
with three degrees of freedom by Chow and Tse (1990). The     subject is 
identified as an outlier by the ED test if    ( ̂)      
  ( ). 
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3.7.3 Hotelling    Test (HT) 
This is an outlier detection procedure based upon the order statistics of the two-
sample Hotelling    statistic. This procedure was proposed by Liu and Weng 
(1991) according to Ramsoy and Elkum (2004). HT is based on the assumption 
that there are no period effects and the compound symmetry covariance structure 
for f responses observed on the     subject is relaxed such that it becomes 
spherical. These assumptions enable HT to identify only one outlier. In practice, 
pharmacokinetic parameters can have more than one outlier. To detect outlying 
subjects, let    (       )
  be the vector of the response variables observed on 
the     subject. Define 
  
  (      ̅)
      (      ̅)     (3.7.3.1) 
where   ̅and   are the sample mean and the matrix of the sums of squares and 
cross-products computed from          The HT statistic for the  
   subject is: 
  
   
(   )  
 
(
   
 
   
 )
       (3.7.3.2) 
To detect whether subject i is an outlier or not, we compare the value obtained 
from equation 3.7.3.2 to the critical value. The     subject is identified to be an 
outlier if at   0.05 level of significance: 
  
          (  
 )    ( )
       (3.7.3.3) 
3.7.4 Mean-Shift Test (MS) 
The mean-shift test was developed by Wang and Chow (2003) based on the 
likelihood function. The mean shift for the     subject’s response on the     
treatment formulation is: 
                              (3.7.4.1) 
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Two quantities developed from the model 3.7.4.1 are: 
     
(    ̅  ) (    ̅   )
∑ (    ̅  ) (    ̅   )
      (3.7.4.2) 
and 
     
 ̅ 
 
∑  ̅ 
  .        (3.7.4.3) 
where in equations 3.7.4.2 and 3.7.4.3,    is the vector of residuals for the  
   
subject,  ̅  stands for the mean of    and    is a vector whose members are 1. 
Combining equations 3.7.4.2 and 3.7.4.3 the MS statistic is: 
                    (3.7.4.4) 
The statistic    is used to test whether the  
   subject is an outlier or not and is 
distributed as the sum of two independent beta random variables: 
        ,  ⁄  (   )  ⁄ -      ,  ⁄  (   )  ⁄ -  (3.7.4.5) 
The     subject is detected as an outlier if    is greater than the  
  order statistic 
at   0.05 level of significance for a given sample size. 
3.7.5 Residuals Test 
The residuals test utilizes the means of treatment formulations to detect outlying 
subjects. Given     the  
   treatment formulation mean, the resulting studentized 
residuals,     where i 1,2,…,n and j = 1,2,…,f. The test compares the maximum 
values of the residuals with the critical values. The     subject is identified to be 
an outlier if the maximum residual:        ( ). 
The Cook’s distance, likelihood distance test (LD), Figure 4.1 and Figure 4.2 in 
Chapter 4 is used to detect the outlying observations for the pharmacokinetic 
parameters        and      respectively. The likelihood distance test could be 
obtained using the model 3.7.1.1, and equations 3.7.1.2 and 3.7.1.6 though in this 
study the model in equation 3.4.1 is applied to get LD, where the pharmacokinetic 
parameters        and      for both untransformed and transformed data are 
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subjected to ANOVA in which the variance is partitioned into components due to 
animals (sheep), periods, sequence and treatment effects. 
3.8 Outliers simulation 
Karasoy and Daghan (2012) conducted a simulation bioequivalence study using 
twenty three study subjects to detect outlying observations. The same 
observations were identified to be outliers by the LD, ED, HT MS tests. 
Confidence intervals obtained for the pharmacokinetic parameter AUC including 
the outlier and without the outlier were both totally included in the C.I. acceptance 
range, 0.8 to 1.25. The outlier changed the ratio of means but equivalence limits 
were not affected much, Table 3.4. 
Table 3.4 Outliers Ratio of Means and Confidence Intervals 
AUC 90% C.I. with outliers 90% C.I. without outliers 
Ratio of 
means 
Lower limit Upper limit Lower limit Upper limit 
0.9581 0.9989 0.9815 0.9975 
Ratio of 
means 
0.979 0.990 
Ramsoy and Elkum (2004) also conducted a simulation study to identify outliers 
using LD, ED, HT and MS. The same outlying subjects were detected by all the 
methods, similar to the study done by Karasoy and Daghan (2012). Ramsoy and 
Elkum (2004) further contrasted the tests checking if any was better. They 
observed that all tests performed well, though ED outperformed other methods 
where there is only one outlier. 
3.9 Power of a Test 
Statistical power analysis is performed at the planning stage of a bioequivalence 
study since it assists in improving the chances of achieving efficient results when 
assessing average bioequivalence. Appropriate sample size for a study is 
determined by power analysis as well as the research objective, design, data 
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analysis method, type 1 error, variability and effect size. In a bioequivalence 
study, sample size, refers to the number of subjects or volunteers participating in 
the study. Chow and Liu (2000) point out that appropriate sample size for a study 
is chosen depending on a power function of the statistic for the hypothesis of 
equality between treatment formulation effects. 
The statistical power of a test is defined, in general, as the probability of rejecting 
the null (research) hypothesis when it is actually false. (reject    when    is 
false). Ahmad and Yahya (2015) states that in terms of efficacy for a drug, power 
of a test refers to the probability of correctly concluding that a drug is effective 
when in fact it is. With reference to a 2 2 crossover design used in 
bioequivalence studies, power implies not mistakenly concluding that the two 
treatment formulations are bioequivalent when there are not. Important aspects to 
be known about the power of a test: 
 As the sample size increase, the power of the test also increases. That is, 
by taking larger samples, we improve our ability to find a difference in 
means of the treatment formulations, if they really exist; 
 As the population variances decrease, the power of the test increases. It 
should, however, be noted that the researcher has no control over the 
variances; 
 As the difference in the means:       increases, the power also 
increases. The difference in the means of the two treatment formulations 
can also not be controlled by the researcher (Elsayir, 2012). 
Factors that affect the power of a test are mainly, the sample size, significance test 
and effect size: 
 If the sample size is large, the power of a test increases; 
 If the level of significance is high, the power of a test also becomes high 
because the acceptance region is reduced; 
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 If there is a large difference between the true value of the mean of the 
treatment formulations and the hypothesized value of the mean, the power 
of a test becomes high (Chow and Liu, 2000). 
The power of a test is determined from the outcomes of a hypothesis test. When a 
hypothesis test is performed, there are four possible outcomes. Two of the four 
outcomes are correct while the other two are wrong. The conclusions which are 
not correct are known as the type 1 and type 2 errors, also sometimes referred to 
as consumer’s risk and producer’s risk respectively. Four conclusions on 
hypothesis testing are: 
   is true and your test leads you fail to reject   : correct decision; 
   is true but your test leads you to reject   : wrong decision (Type 1 error); 
   is false but your test leads you to fail to reject   : wrong decision (Type 2 
error); 
   is false and your test leads you to reject   : correct decision (Crawshaw and 
Chambers, 2001). 
The four conclusions for a hypothesis test can be depicted on a table, Table 3.5: 
Table 3.5 Classical Type 1 and Type 2 errors 
  Test decision 
Fail to reject    Reject    
Actual situation 
   is true Correct decision Type 1 error 
   is false Type 2 error Correct decision 
 
The power of a test is defined as the probability of correctly rejecting    when    
is false. The choice of the null hypothesis is based on the seriousness of the errors 
which can be committed. Chow and Liu (2000) illustrate the relationship between 
type 1 and type 2 errors for a bioequivalence trial as in Table 3.6: 
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Table 3.6 Bioequivalence Type 1 and Type 2 errors 
Decision True State    
Bioinequivalent Bioequivalent 
Bioinequivalent  
(fail to reject    ) 
Right decision Type 2 error 
Bioequivalent (reject    ) Type 1 error Right decision 
A type 1 error, also referred to as the consumer’s risk in bioequivalence terms, is 
more serious contrasted to a type 2 error, the producer’s risk. Hence to control 
both, that is, having the errors remaining as minimal as possible, the significance 
level is controlled at an acceptable level, while there should be a way to try to 
minimize the type 2 error, usually done by choosing an appropriate sample size 
(Chow and Liu, 2000). 
3.10 Simulation of Power 
The TOST procedure is normally preferred for power simulation in 
bioequivalence studies. It is difficult to calculate the exact power for TOST since 
the relevant formulae require some complex numerical integration. Simulation is 
used as an alternative to computations given that an algebraic approach cannot be 
found. The intention is to find a sample size which will achieve a certain desired 
power. Power should generally be at least 80%. Simulating power empirically 
yields an approximate power estimate which is nearly accurate because a large 
number of data sets are generated as per specifications of the distribution used for 
the power analysis. 
A bioequivalence study was conducted with the objective of finding a sample size 
necessary to achieve at least 95% power. Two different treatment formulations 
were used with a geometric mean ratio of 1.1 and variance 0.1003. Hypothesis 
tested is: 
  :      ln(0.8) or       ln(1.25) versus 
  :ln(0.8)        ln(1.25)     (3.10.1) 
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Table 3.7 Power and sample size SAS 9.4 output 
Fixed Scenario Elements 
Distribution Normal 
Method Exact 
Lower Equivalence Bound -0.22314 
Upper Equivalence Bound 0.223144 
Alpha 0.05 
Mean Difference 0.09531 
Standard Deviation 0.223942 
Nominal Power 0.95 
 
Computed N per Group 
Actual Power N per Group 
0.952 68 
The SAS 9.4 output, Table 3.7, indicates that 68 study subjects will be required to 
obtain an actual power of 95.2% (Sun, 2010). 
3.11 Power curve 
Table 3.8 Power curve and sample size SAS 9.4 output  
Fixed Scenario Elements 
Distribution Normal 
Method Exact 
Null Difference 0 
Alpha 0.05 
Mean Difference 4 
Standard Deviation 3 
Number of Sides 2 
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Computed N per Group 
Index Nominal Power Actual Power N per Group 
1 0.80 0.805 10 
2 0.90 0.903 13 
3 0.95 0.954 16 
The three groups in Table 3.8 results in different power values per given sample 
size. As the sample size increase in a particular group, the power also increases. 
Sample group size 10, power 80.5%, sample group size 13, power increases to 
90.3% and a further power increase to 95.2% is achieved when the sample group 
size is 16. The power curve, Figure 3.3 illustrates visually the increase in power as 
the sample group size increases (Plets and Strominger, 2013). 
This study had two groups of 7 sheep in sequence 1 and the other 7 were in 
sequence 2. Comparing the sample size of the groups in this study and the groups 
in the simulation study, Figure 3.3, it was observed that more sheep were needed 
in this study to obtain a power of at least 80%. 
Figure 3.3 Power curve and sample sizes  
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3.12 Bootstrapping 
Bootstrapping is a technique which enables researchers to do statistical inference 
without checking any model assumptions and without any sampling distribution. 
Bootstrapping is a nonparametric method which refers to sampling with 
replacement from the original data. It depends solely on the original data, thus 
avoiding as many assumptions compared to parametric methods (Moony and 
Duval, 2012; Schmidheiny, 2012 and Rochowicz, 2011). Bootstrapping is also 
defined as a resampling method which is effectively performed using a computer 
for estimating sample statistics such as the measures of spread, confidence 
intervals, hypothesis testing and other statistical properties. The number of 
bootstrap samples depends on what you like to do. If bootstrapping to estimate the 
standard error, twenty five to two hundred resamples should be sufficient but for 
all other applications, bootstrap samples should be more than one thousand. For a 
situation where there is a small number of data values in a given sample, 
bootstrapping technique can be used to increase the sample size. Population 
parameter estimates can then be obtained from this large sample which could have 
been formed through bootstrapping. As a result, aspects of the population such as 
skewness, kurtosis and percentiles can be checked (Efron and Tibshirani, 1993). 
Boostrapping is a powerful statistical technique and a very useful tool used when 
the distribution of a statistic is unknown, very complex or when the sample size is 
small and asymptotic distribution assumptions such as normality may not be 
appropriate. The bootstrap method in short is: 
 Resample a given data set with replacement a specified number of times, 
where each, bootstrap sample has the same number of data points as the 
number in the original sample though some of the values of the original 
sample might not appear, some might appear once, twice or thrice; 
 Calculate a statistic of interest for each of the bootstrap samples; 
 The distribution of the statistic from the bootstrap samples can then be 
used to obtain estimated standard errors, create confidence intervals, and 
to perform hypothesis testing with the statistic (Rice and Thornotn, 2013). 
65 
Bootstrapping statistics actually enables a researcher to analyse any distribution 
and make inferences. Bootstrapping liberates researchers from being limited to 
doing statistical analysis using known sampling distributions only by using 
computers. Bootstrapping as a computer intensive method, can be easily 
performed nowadays because modern computers have fast processors and are 
within the reach of researchers (Chernick, 2008). Besides bootstrapping as a 
resampling method, there are other techniques available in literature, which 
include the jacknife, cross–validation, random subsampling and permutation 
procedures. Permutation tests unlike, bootstrap, are procedures whereby 
resampling is done though not randomly, instead, it considers all possible 
permutations (arrangements) of the sample (Moony and Duval, 2012). 
Bootstrapping has pros and cons: 
Advantages  
 Checking assumptions of a distribution is not required. 
 Can be used for cases where permutation tests fail because bootstrap 
requires very minimum assumptions. 
 A large sample size is obtained. 
Disadvantages 
 Efficient computers in terms of speed are needed. 
 Randomness when sampling with replacement should be understood. 
 Bootstrap is not exact. 
 Large sample sizes must be generated though for large samples, 
permutation tests perform better than bootstrap (Moony and Duval, 2012). 
Bootstrapping was done in this study, Appendix 9, to illustrate the fact that as the 
sample size is increased statistical inference can be made without checking any 
model assumptions. 
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3.13 Assessing Average, Population and Individual Bioequivalence 
3.13.1 Average Bioequivalence 
The 90% confidence interval for the ratio of means of the parameter      and 
AUC should lie within the interval 0.80 to 1.25, the bioequivalence acceptance 
range. The acceptance interval may need to be changed especially in cases where 
the drugs have a narrow therapeutic range. In such cases a wide acceptance range 
of 0.90 to 1.111 should be applied (Schall and Endrenyi, 2010). 
Quite a number of regulatory authorities use the above interval to certify a generic 
formulation as average bioequivalent compared to a reference formulation. Below 
is a table, Table 3.9 showing different regulatory authorities accepted intervals for 
the pharmacokinetic parameters AUC and     . 
It should be noted that in South Africa the average bioequivalence acceptance 
interval for the pharmacokinetic parameter      of 0.75 to 1.33 differs with most 
regulatory authorities. However for formulations which have a narrow therapeutic 
range, the average bioequivalence acceptance range is the same as the regulatory 
authorities on Table 3.9, for most regulatory authorities (countries), that is, the 
interval from 0.8 to 1.25 (Galgate, Jamdade, Aute, Chaudhari, 2013). 
Table 3.9 Regulatory Acceptance Criteria for Bioequivalence (Tamboli et al, 
pp.91). 
Regulatory 
Authority 
90% confidence interval on log transformed data 
                     
India 80-125  80-125  80-125  
USA 80-125  80-125  80-125  
Europe and 
Australia 
80-125  80-125  Not applicable 
South Africa 75-133 and 80-
125 (for narrow 
therapeutic range) 
80-125  Not applicable 
ASEAN 80-125  80-125  80-125  
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Decision rules based on confidence intervals and the acceptance range on 
certifying drug formulations as average bioequivalent or not: 
 C.I. entirely outside the acceptance range. Average bioinequivalence 
proven; 
 C.I. overlaps the acceptance range. Average bioequivalence not proven; 
 C.I. lies entirely within the acceptance range. Average bioequivalence 
proven (Schutz, 2013). 
3.13.2 Population Bioequivalence 
To establish population bioequivalence, unbiased estimators obtained using the 
method-of-moments (MM) are used on logarithmic transformed values of      
and AUC. Population bioequivalence is achieved if the 90% upper confidence 
bound calculated after finding unbiased estimators is less than or equal to the 
population bioequivalence limit,    1.7448, as recommended by the FDA 
(2001). 
3.13.3 Individual Bioequivalence 
Individual Bioequivalence focuses on estimation of the mean difference between 
test and reference formulation, the subject by formulation interaction variance and 
the within subject variance for each of the formulations. To estimate the 
components of IBE the FDA (2001) recommends the method-of-moments 
approach by Chinchilli and Esinhart (1996). It is also indicated that the restricted 
maximum likelihood (REML) method is useful to estimate mean difference and 
variances when subjects with missing data are included in the statistical analysis. 
A 90% upper confidence bound for individual bioequivalence is calculated and 
then compared to the individual bioequivalence limit. The FDA (2001) 
recommended value for    2.2448 when   
  0.02 and    2.4948 when 
  
  0.03.   
  represents the subject by formulation variance component when 
calculating   . Individual bioequivalence is achieved if the 90% upper confidence 
bound is less than or equal to the bioequivalence limit. 
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Individual bioequivalence is necessary in bioequivalence studies since it takes into 
account between subject variation, within subject variability and subject by 
formulation interaction, hence having the property of switchability, whereby 
patients can be changed from one drug formulation to the other, a property not 
found when assessing bioequivalence using ABE and PBE. However, in this 
research report, IBE cannot be calculated since the data used is a from a standard 
2 2 crossover design which is not appropriate for assessing IBE (FDA, 1999; 
2001; Chow and Liu, 2000 and Jones and Kenward, 2003). The FDA (1999) 
guidance for industry and FDA (2001) guidance on statistical approaches 
recommends the higher order designs such as: [RTR, TRT] or [RTRT, TRTR] for 
the evaluation of IBE. Examples of higher order designs are illustrated in Table 
3.10 In higher order designs, each study subject receives each treatment 
formulation more than one time in a sequence or period hence such designs are 
called replicate crossover designs. The more sophisticated the design becomes, the 
more information for assessing bioequivalence can be extracted. 
Table 3.10 Examples of 2 3 and 2 4 Crossover Designs 
Three period crossover design 
 
 Period 
1 2 3 
Sequence 
1 T R T 
2 R T R 
 
Four period crossover design 
 
 
 
 
To estimate the within and between subject variances, components which are 
necessary when finding IBE, the appropriate design is the replicate design. 
Pharmaceutical companies and bioequivalence regulatory bodies around the globe 
prefer using the 2 2 crossover design for assessing ABE, however, this design is 
 Period 
1 2 3 4 
Sequence 
1 T R T R 
2 R T R T 
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not adequate to estimate the subject by formulation interaction (Jones and 
Kenward, 2003). IBE is discussed in this research report but cannot be evaluated 
since some necessary components for assessing IBE cannot be obtained from a 
standard 2 2 crossover design. 
3.14 Effect Sizes 
When presenting the results of a statistical research (or study), in addition to null 
hypothesis significance tests, researchers are encouraged to also report effect sizes 
(ES) as well as their corresponding confidence intervals. Kelley and Preacher 
(2012) is for the above view, that is, of including effect sizes and confidence 
intervals when reporting research results as emphasized by methodologists, 
journal editors, reviewers and professional organizations. Elsayir (2012) states 
that effect sizes have been available for decades, though not reported by 
statisticians when presenting results of their findings from research studies. He 
also indicated that the concept of effect sizes is actually from meta-analysis. Meta-
analysis refers to a branch in social sciences and statistics where results or 
information from past research are used to motivate future studies (Nandy, 2012). 
Becker (2000) defines meta-analysis as a summary of previous research findings 
that uses quantitative methods to compare outcomes from different studies. Coe 
(2012) also indicated that effect sizes have been available for at least sixty years, 
though most of the literature on statistics does not cover effect sizes, with the 
exception of the books or material on meta-analysis. ES are rarely taught in 
introductory courses on statistics. Effect sizes are useful because: 
 They enable researchers to report the magnitude of the difference of the 
means between two treatment effects by a unit less measure. It becomes 
easy for researchers to explain whether the results are practically viable or 
not basing their opinion on the actual size of the unit less ES, instead of 
only reporting the statistical significance; 
 Effect sizes enable researchers to make comments on meta-analysis 
findings by comparing standard effect sizes from different bioequivalence 
studies; 
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 Effect sizes from past studies can be used in the planning stages of another 
study; 
 Effect sizes help in sample size calculations for any study (Coe, 2012 and 
Nandy, 2012). 
A statistical hypothesis is an assumption about the actual value of a population 
parameter, whereby there is the null hypothesis, H0 (a claim) and the alternative 
hypothesis, Hα (used to ascertain as to whether the claim is valid or not). 
Hypothesis testing refers to the formal procedure used by statisticians or 
researchers in related fields to reject or fail to reject the null hypothesis (claim). 
Results which indicate that H0 is reject (statistical significant) imply there is a 
difference, say, between means of two different groups (claim not valid). 
However, the magnitude or size of the difference is not known, hence, there is a 
need then to quantify the difference which leads to the calculation of effect sizes 
and their corresponding confidence intervals (Kelly and Preacher, 2012; Becker, 
2000; Nandy, 2012 and Elsayir, 2012). 
Researchers define effect sizes in a similar way however, there are variations in 
some of the definitions. The definition of effect size is split into the terms effect 
and size, then combined later as: Effect is a change or state of change caused by 
somebody or something while size refers to the degree of how huge or small a 
quantity is. Combining the two, effect size refers to expressing the difference of 
treatment means in terms of a specific value (Nandy, 2012). Effect size is a family 
of metrics that measure the magnitude of the difference between the treatment 
effects. ES differ from significance tests in the sense that they are independent of 
sample size (Becker, 2000 and Elsayir, 2012). Effect sizes are a family of indices 
that assign a number to the size of the difference between treatment effects and 
are used to address a question of interest (Kelly and Preacher, 2012). 
The definitions of ES by Nandy (2012), Becker (2000) and Elsayir (2012) are 
basically the same, however, the one by Kelly and Preacher (2012) is broad since 
it links effect size with the question of interest. Effect sizes determine the practical 
importance of a study. Effect size analysis actually compares the mean of the test 
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treatment group with the mean of the reference treatment group. Statistical 
significance does not indicate the magnitude of the effect hence silent on the 
practical significance of a study (Steyn, 1999). Elsayir (2012) also talks of effect 
sizes being a useful method used when presenting findings from a research study 
and interpreting how the study is effective. ES has many advantages when 
compared to tests of statistical significance. They actually propel researchers to 
report results moving beyond the null hypothesis tests. 
Confidence intervals give an indication as to whether two treatment means from 
different groups are the same or not, just like the hypotheses tests but the 
difference between an effect size and confidence interval is that an ES is an index 
that measures the magnitude of the difference of the means between treatments 
given as a range while confidence interval reflects the degree of confidence for 
having the magnitude of the difference of means in the interval. That is, effect size 
is a value, of which guidelines are then available, according to the various indices, 
on how to interpret them whereas given a confidence interval, one can indicate, 
with confidence, that a percentage of a particular statistic would lie in that interval 
(Steyn, 1999). 
Effect sizes have the following facets, where facet relates to some characteristics 
of the effect size that relates to the manner by which the term is used. Facets of ES 
include: 
 dimension, 
 measure or index, 
 value (Kelly and Preacher, 2012). 
Dimension reflects to the type of information of interest so as to identify the 
appropriate units to be used. In real life there are a variety of dimensions, for 
example in Physics, dimensions include distance, weight, density, force and many 
more, of which all of them have different units. Variance is an example of an ES 
in statistics. Variance and other related measures of dispersion (spread) are unit 
less, hence effect size dimension gives a roadmap on how a research question will 
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be addressed in terms of the difference in magnitude (generally mean values) 
(Elsayir, 2012 and Kelly and Preacher, 2012). 
Effect size measure, also known as effect size index, gives the formula that is 
suitable to calculate ES for a given situation (Lakens, 2013). 
Effect size value is the number obtained when formulae has been used on 
bioequivalence data to obtain some statistics of interest. It is the magnitude of the 
effect size which is then used when reporting research findings (Becker, 2000). 
Effect sizes are measured using a variety of formula depending on the situation 
(or study) since they vary from study to study. The two main ways of measuring 
effect sizes are: 
 By calculating the difference between the means; 
 By finding the relationship between the independent variable and the 
respective measurements of the dependent variable (Kelley and Preacher, 
2012). 
In essence, effect sizes are either reported as the magnitude of an effect or 
correlation coefficient, that is, the strength of the relationship between variables. 
The necessary characteristics of ES are that: 
 Computed numerical values need to be compared from different 
bioequivalence studies; 
 Ability to calculate the standard error; 
 Should not be directly linked to sample size (Nandy, 2012). 
The fact that ES is not affected by sample size is also shared by Becker (2000) 
and Elsayir (2012). 
Mathematically, the effect size is the magnitude of the difference between the 
actual of the statistic and the value specified in the null hypothesis. In other 
words, it is the difference between two means, generally, mean of the generic drug 
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minus the mean of the reference drug divided by the standard deviation of the two 
types of drugs. The division by the standard deviation is necessary since it enables 
researchers to compare effect sizes across experiments. It should be noted that 
means on their own simply gives the differences, on average, but does not say 
anything about the dispersion (spread) of the difference between the means. Types 
of effect sizes are discussed by researchers such as Nandy (2012), Becker (2000), 
Elsayir (2012), Warmbrod (2001), Lakens (2013) and Coe (2002). 
3.14.1 Mean Differences Between Group Effect Sizes 
3.14.1.1 Cohen’s, d 
Cohen’s d is calculated by t-tests if given two independent samples. These effect 
sizes fall in the interval from    to   and their interpretation is based on the 
number of standard deviations. 
d 
 ̅   ̅ 
       
 where         √
(    )  
  (    )  
 
     
   (3.14.1.1.1) 
3.14.1.2 Hedge’s, g 
Compute ES using Hedge’s, g if the sample size is small. Hedge’s compares the 
means of two groups where the mean differences have been standardized. Some 
authors on ES state that the Cohen’s, d is also known as the Hedge’s g effect sizes 
(Warmbrod, 2001; Coe, 2002 and Elsayir, 2012). While others such as Becker 
(2000), Nandy (2012) and Lakens (2013) view these two types effect sizes as 
different. The slight difference between the Cohen’s, d and the Hedge’s g effect 
sizes is the minus two on the denominator of the pooled standard deviation. 
g 
 ̅   ̅ 
       
 where         √
(    )  
  (    )  
 
       
   (3.14.1.2.1) 
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3.14.1.3 Glass’s,   
Effect sizes are calculated by the Glass’s,   if the sample has unequal variances 
for given groups. The sample standard deviation of the reference group only is 
used so that effect size would be within accepted limits (Becker, 2000). 
  
 ̅   ̅ 
  
        (3.14.1.3.1) 
General guidelines for interpretation of effect sizes: 
 Less than or equal to 0.20 is a small effect size, where the variance 
explained is 1%; 
 The magnitude of a moderate effect size is 0.50, with the variance 
explained being 10%; 
 Greater than or equal to 0.80 is a large effect accounting for 25% 
variance explained (Cohen, 1992). 
Cohen (1992) interpreted effect sizes as either being: small, medium and large 
depending on the assumption that both the reference and test groups are 
approximately normally distributed. 
3.14.2 Correlation or Regression Effect Sizes 
3.14.2.1 Pearson’s Correlation Coefficient 
Pearson’s, r 
    
∑(   ̅)(   ̅)
√∑ (      ̅)
  
   √∑ (     ̅)
  
 
 where  1     1   (3.14.2.1.1) 
Pearson’s, r is ES is used to indicate the strength of the relationship between two 
variables. 
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Pearson’s,    
Pearson’s    is known as the coefficient of determination gives the amount 
variation, in percentages, accounted for by the linear regression model.    gives 
an indication as to how the model fits data (Nandy, 2012). 
3.14.2.2 Cohen’s,    
   
  
    
 
  
    
       (3.14.2.2.1) 
is used in multiple linear regression where      . The standardized ES is the 
amount of variation explained by the model over the amount not explained. 
Cohen’s    is a biased estimate and tend to overestimate the ES for ANOVA. The 
unbiased estimate is called Omega-squared (Elsayir, 2012). 
3.14.3 Contigency Tables Effect Sizes 
Table 3.11 2 2 Table showing Smokers, Non-Smokers and their Disease Status 
Risk 
Disease Status 
Present Absent 
Smokers a b 
Non-smokers c d 
3.14.3.1 Odds Ratio (OR) 
OR 
  
  
        (3.14.3.1.1) 
Odds Ratio is used in situations where there are binary or categorical outcomes. 
OR values ranges from zero to infinity. If OR is greater than one, there is an 
increase in the odds relative to the reference group and a decrease in odds is 
attained if OR is less than one (Wilson, 2011). 
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3.14.3.2 Relative Risk (RR) 
RR 
 
(   )⁄
 
(   )⁄
        (3.14.3.2.1) 
RR is a measure of risk relative to the independent variable. Relative risk is 
approximately equal to OR for small probabilities. Given as: 
 
(   )⁄
 
(   )⁄
 
  
  
        (3.14.3.2.2) 
The risk of disease X among smokers in Table 3.11 is equal to the relative risk 
times the risk of disease X among non-smokers if RR is greater than one (Wilson, 
2011). 
3.14.4 ANOVA or GLM Effect Sizes 
3.14.4.1 Eta-Squared,    and Partial Eta-Squared,   
  
Both are measures that estimate the association between variables of given 
samples. 
    
           
       
 ;   
  
           
               
 where 0    1 (3.14.4.1.1) 
these ES standardizes the amount of variance shared by the continuous and 
categorical outcomes. Partial Eta-Squared accounts for the percentage of the 
variance in the dependent variable explained by the variance in the independent 
variable. The interpretation of these effect sizes is synonymous to that of    
(coefficient of determination) in linear regression. Eta-squared is biased and 
generally overestimates the variance explained in the population. However, as the 
sample size increases, Eta-squared decrease (Lakens, 2013). 
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3.14.4.2 Omega-Squared,   
 ̂  
                               
               
     (3.14.4.2.1) 
Omega-squared estimate the amount of variance in the population that is 
explained by the treatment. Omega-squared is always smaller than    or   
  since 
Omega relates to the population and Eta measures the sample variance 
(Warmbrod, 2001). 
3.14.4.3 Intraclass Correlation Coefficient 
Intra correlation coefficient (ICC) is used for finding inter-rater reliability for two 
or more raters, though can also assess test-retest reliability. The ratio between 
group variance to the total variance is also a measure of ICC. 
ICC  
                   
            (   )       
     (3.14.4.3.1) 
ICC is interpreted in a similar way as Omega-squared (Warmbrod, 2001). 
3.14.5 Chi-Square Tests Effect Sizes 
3.14.5.1 Phi, Φ 
Φ √
  
 
        (3.14.5.1.1) 
used when there are crosstabs or chi-square tests specifically to test for the 
equality of proportions or tests of independence between two binary variables. Phi 
effect sizes are similar to correlation and Cohen’s, d since they all measure the 
relationship between variables. The interpretation of the phi effect sizes is like 
that for Pearson’s, r and    (Nandy, 2012). 
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3.14.5.2 Cramer’s, Φ or V 
Cramer’s phi can be used with categorical variables with more than two categories 
given contingency tables. 
   √
  
 (   )
 k min(R;C)    (3.14.5.2.1) 
measures the inter-correlation of the variables, but is biased since it increases with 
the number of cells. An increase in the number of rows and columns is an 
indication of a strong correlation between variables (Nandy, 2012). 
Table 3.12 Magnitude of Effect Sizes (Nandy, 2012, pp 28) 
Effect Size Small Medium Large 
r 0.10 0.30 0.50 
r
2
 0.01 0.09 0.25 
   0.01 0.06 0.14 
R
2
 0.01 0.06 0.14 
Cohen’s, d 0.20 0.50 0.80 
Cramer’s, V 0.10 0.30 0.50 
Cohen’s, f2 0.02 0.15 0.30 
OR 1.44 2.47 4.25 
 
The following is relevant regarding the choice of effect size preferred in a given 
study: 
 If all studies in the analysis are based on the same kind of data (means, 
binary or correlational), the researcher should select an effect size based 
on that kind of data; 
 When some studies use means, other studies use binary data and some 
studies use correlational data, formulae to convert among effect sizes can 
then be applied; 
79 
 Studies that use different measures may differ from each other in 
substantive ways hence there is a need to consider this possibility when 
deciding if it makes sense to include the various studies in the same 
analysis (Kelly and Preacher, 2012). 
When conversions are done to different ES measures, certain assumptions need to 
be made about the nature of the underlying effects. It should be noted that even if 
these assumptions do not hold exactly, the decision to use conversions is often 
better than the alternative, which is simply to omit the studies that happened to 
use a different metric since this would involve loss of information and possibly 
resulting in a biased sample of studies. Conversions were illustrated by Nandy 
(2012) moving from correlation, chi-square and odds ratio effect sizes to Cohen’s, 
d effect sizes, the formulae are given in Table 3.13. 
Table 3.13 Effect Size Conversions 
Effect Size Converted to Cohen’s (d) 
Correlation 
   
  
√    
 
Chi-Square 
         df 1 
         df > 1 
  √
   
    
 
√
   
 
 
Odds Ratio 
  
   (  )
    
 
 
It should be noted that while it is a noble idea to report effect sizes when 
presenting findings of a research study as suggested in this section, there are, 
however limitations: 
 A problem may arise when interpreting standardized effect sizes if there is 
a limit on the sample size; 
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 Where the ES is not calculated using data which follows a normal 
distribution; 
 When the ES is derived from a measure with an unknown reliability; 
 There can also be issues related to variance estimate, notably if the 
methods of calculating effect sizes may have an influence on the estimate 
of the variance, for example, if the difference between the means is 
computed from dichotomous data or if the numerator of the differences is 
adjusted for baseline or other covariates or the study data involves clusters 
(Coe, 2012). 
ES were calculated in this study on results found on ABE by using the C.I. 
approach, TOST, Wilcoxon Mann-Whitney test statistics and PBE. ES were 
also calculated on results obtained after bootstrapping. 
Results obtained after assessing ABE and PBE between the test and reference 
treatment formulations are outlined and analysed in the next chapter of this 
study. Outliers were checked and the sample size required to achieve the 
required power is also discussed. Effect sizes were used to quantify the 
difference between the ratios of means of the two treatment formulations. 
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Chapter 4 
Results and Analysis 
4.1 Introduction 
Pharmacokinetic parameters     ,     ,        and        obtained from 
sheep 1 to 14 are in Tables 4.1, 4.2, 4.3 and 4.4. Steps used for calculating 
       are in Appendices 1, 2, 3, 4 and 5. Data sets in tables mentioned above 
were used to compare the bioavailability between the test treatment and reference 
treatment formulations in this research report. 
Outliers are identified using the Cook’s likelihood distance test, though will not 
be deleted from the data set as recommended by the FDA (1992) and Patterson 
(2010). If the power of a test is at least 80%, the bioequivalence study can be done 
efficiently, saving on time and resources since the appropriate number of study 
subjects will be found prior to the commencement of the study. Section 4.3 
contains SAS 9.4 outputs illustrating the effect of sample size in determining the 
power of a test. By achieving the relevant sample size to obtain desired power of a 
test, of at least 80%, pharmacokinetic parameters for the test treatment and 
reference treatment formulations are then tested for bioequivalence. ABE is 
assessed through the classic confidence interval approach and the interval 
hypothesis testing approach using Schuirmann’s TOST procedures. Results for the 
parameter      are obtained using the nonparametric test, Wilcoxon Mann-
Whitney two one-sided test statistics. In this chapter, the test treatment and 
reference treatment formulations are shown to be population bioequivalent (PBE) 
by using the relevant criteria. Bootstrapping, a resampling method which 
increases the sample size is done and pharmacokinetic parameters        and 
     are shown to be average bioequivalent by the classic confidence interval 
approach. Effect sizes are covered in Section 4.7. 
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Table 4.1 Values of      and      in Sequence 1 
 
Animal 
   
Test 5 2 7.3284 1.991757 
 
6 2 9.4104 2.241815 
 
9 9 21 3.044522 
 
10 2.02 13.5789 2.608517 
 
11 2 9.5904 2.260763 
 
12 1 8.4611 2.135479 
 
14 1 11.4642 2.439229 
Reference 5 2 11.9468 2.480463 
 
6 1 16.2239 2.786485 
 
9 2 10.3462 2.336619 
 
10 2 12.8158 2.550679 
 
11 1 8.0715 2.088339 
 
12 0.5 14.7725 2.692767 
 
14 0.5 15.699 2.753597 
Table 4.2 Values of      and      in Sequence 2 
 
Animal 
   
Reference 1 2 17.303 2.85088 
 
2 2 8.5327 2.143906 
 
3 2 11.0619 2.403507 
 
4 2 10.7164 2.371775 
 
7 2 9.7471 2.27697 
 
8 2 11.4669 2.439465 
 
13 1 10.2324 2.325559 
Test 1 2 11.5974 2.450781 
 
2 2 9.3668 2.237172 
 
3 4 11.1924 2.415235 
 
4 2 12.6993 2.541547 
 
7 2 11.2346 2.418998 
 
8 2 12.7964 2.549164 
 
13 2 12.8171 2.55078 
The crossover design, Figure 3.2, was used at the University of Pretoria at 
Onderstepoort within the Directorate of Veterinary Pharmacology where 
randomization was done such that some sheep ended up in sequence 1 while 
others in sequence 2. Table 4.1 shows values of      and      from the 
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bioequivalence data obtained, courtesy of the University of Pretoria after dosing 
sheep 5, 6, 9, 10, 11, 12 and 14 in sequence 1 with the test treatment formulation 
in period 1, an adequate washout period was allowed to pass, then sheep were 
dosed with the reference treatment formulation in period 2. Table 4.2 indicates 
values of      and      for sheep 1, 2, 3, 4, 7, 8 and 13 in sequence 2 after 
dosing with the reference treatment formulation in period 1, a long enough 
washout period was taken then sheep were dosed with the test treatment 
formulation in period 2. 
Table 4.3 Calculating        for the sheep in Sequence 1 
Sequence 1 
     
 
Animal 
  
ʎ 
  
Test 5 132.0207 0.0195 0.192945 132.1218 4.883724 
 
6 170.1138 0.2103 0.130879 171.7206 5.145869 
 
9 222.0024 0.209 0.07494 224.7913 5.415172 
 
10 173.6732 0.0075 0.222355 173.7069 5.15737 
 
11 119.2981 0.1943 0.084889 121.587 4.80063 
 
12 138.9857 0.0972 0.095022 140.0086 4.941704 
 
14 190.5718 0.0664 0.160888 190.9845 5.252192 
Reference 5 170.5818 0.0597 0.10755 171.1369 5.142464 
 
6 196.4537 0.0066 0.242045 196.481 5.280566 
 
9 207.0228 0.1126 0.145411 207.7972 5.336562 
 
10 159.9659 0.0845 0.179335 160.4371 5.077902 
 
11 119.1357 0.0376 0.162292 119.3674 4.782206 
 
12 153.0361 0.1695 0.154854 154.1307 5.037801 
 
14 220.8329 0.1949 0.151353 222.1206 5.403221 
AUC was calculated using formulae 3.5.1 and 3.5.2, the procedure for the 
calculations are outlined in Appendices 1, 2, 3, 4 and 5. Table 4.3 shows values of 
       after sheep 5, 6, 9, 10, 11, 12 and 14 were dosed with the test treatment 
formulation in period 1 followed by the reference treatment formulation in period 
2. Table 4.4 is for values of        for sheep 1, 2, 3, 4, 7, 8 and 13 in sequence 2 
dosed with the reference treatment formulation in period 1 then the test treatment 
formulation in period 2. 
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Table 4.4 Calculating        for the sheep in Sequence 2 
Sequence 2 
     
 
Animal 
  
ʎ 
  
Reference1 1 167.1385 0.0336 0.19534 167.3105 5.119851 
 
2 166.5281 0.1206 0.146724 167.3501 5.120088 
 
3 181.6076 0.0852 0.166944 182.118 5.204655 
 
4 152.5701 0.1561 0.148981 153.6179 5.034468 
 
7 174.1533 0.0079 0.256715 174.1841 5.160113 
 
8 152.1165 0.0507 0.192024 152.3805 5.026381 
 
13 195.1567 0.0985 0.117522 195.9948 5.278088 
Test 1 170.3735 0.1173 0.162799 171.094 5.142213 
 
2 164.6649 0.0885 0.119894 165.4031 5.108385 
 
3 187.0004 0.1407 0.15338 187.9177 5.236004 
 
4 184.3159 0.0517 0.192347 184.5847 5.218108 
 
7 201.7071 0.1005 0.123786 202.519 5.310834 
 
8 183.1658 0.0099 0.22369 183.2101 5.210633 
 
13 214.0738 0.0992 0.172126 214.6501 5.369009 
 
4.2 Outliers 
4.2.1 Outliers for AUC from time zero to infinity 
 
Figure 4.1 Outliers for the Parameter        
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Observations 5 and 12 are outliers for the pharmacokinetic parameter       , 
transformed data, shown in Figure 4.1. Considering        for the 
untransformed data, Appendix 7, Figure 2 there are also two outliers. The same 
number of outliers for the transformed and untransformed data identified could be 
attributed to the fact that untransformed data was nearly symmetric, hence 
transforming did not change the data structure much. The histogram in Appendix 
7, Figure 1 is almost symmetric, confirming that the original data was almost 
symmetric. 
Observation 3 is the only outlier for the pharmacokinetic parameter      detected 
in Figure 4.2. Comparing the outlier outputs for the transformed and 
untransformed data, Figure 2, Appendix 8 exhibits three outlying observations 
whereas for the transformed data there is only one outlier. The histogram in 
Figure 1, Appendix 8 is skewed to the right which explains the need to transform 
the data and the difference of the number of outliers identified using transformed 
and original data. 
4.2.2 Outliers for      
 
Figure 4.2 Outliers for the Parameter      
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The Cook’s likelihood distance test was used in this research report because it 
clearly identifies the outliers, indicating the exact number of the observation 
which is an outlier graphically. Suppose other methods for detecting outliers were 
used, ED, HT or MS, the same outliers could have been identified for the 
parameters        and      though in a different format, not as figures 
obtained using the LD. 
Outliers can be detected from a dataset but cannot be removed for the evaluation 
of bioequivalence (FDA, 1992 and Patterson, 2010). An outlier detection test can 
be done but this is not necessarily an expectation of the medicine agencies. 
Deleting an outlier is unacceptable since outliers do not usually affect the overall 
results on bioequivalence because the individual observations form a negligible 
portion of the overall average results, for example, when calculating the parameter 
AUC the contribution of say one or two observations does not affect the AUC 
value that much. The inference on bioequivalence done by various regulatory 
authorities is based on the complete data set. The implication for not removing 
outlying observations when doing data analysis and evaluation is that in practice 
outliers do not exist in a bioequivalence data set. It is recommended that 
statisticians need to check for the normality assumptions in their bioequivalence 
models, though, they are advised not to spend too much time since outliers do not 
contribute much on bioequivalence results. The opinion of other authors on 
bioequivalence is that the decision of deleting outlying observations in a data set 
depends on the discretion of different bioequivalence regulatory bodies (Patterson, 
2010). 
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4.3 Power 
Table 4.5 Power        
Mu1 Mu2 StDev1 StDev2 Corr N 
5.1432 5.1566 0.04412 0.04412 0.69172 
28 
42 
56 
 
Alpha StDevDiff NCP Critical Value Power 
0.05 0.034644 
4.18906 4.21001 0.50552 
6.28360 4.07855 0.68712 
8.37813 4.01620 0.81156 
 
Table 4.6 Power      
Mu1 Mu2 StDev1 StDev2 Corr N 
2.4644 2.4204 0.0665 0.0665 -0.11476 
28 
42 
56 
 
Alpha StDevDiff NCP Critical Value Power 
0.05 0.099295 
5.49805 4.21001 0.61826 
8.24708 4.07855 0.80065 
10.9961 4.01620 0.90279 
In Tables 4.5 and 4.6, Mu1 and Mu2 are the least squares mean for the test and 
reference treatments respectively while StDev1 and StDev2 are the respective 
standard deviations for the test and reference treatment formulations. For the 
parameter AUC the power of the test increases from 0.50552 to 0.68712 and 
eventually to 0.81156 shown in Table 4.5 as the sample size increases from 28, 42 
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and 56 respectively. Considering the parameter      as the sample sizes increase 
from 28 to 42 and to 56, the respective power increases from 0.61826 to 0.80065 
and finally to 0.90279 in Table 4.6. 
This confirms the discussion in Section 3.9 stating that as the sample size 
increases, the power of a test also increases. This strategy of increasing the power 
is used if the power is low. Increasing the power of a test by taking a larger 
sample size improves the ability to find the difference in means of the treatment 
formulations when they indeed exist. As the population variance gets smaller, the 
power of a test improves by increasing and vice versa and as differences in means 
increases the power increases, but the researcher has no control over the 
population variances or difference in means. The feasible way for the researcher 
to improve the power of a test if it is low, is to increase the sample size (Elsayir, 
2012). 
4.4 Average Bioequivalence 
4.4.1 Confidence Intervals Approach 
4.4.1.1 Classic Confidence Interval of the Difference 
The ANOVA Table 4.7 is used to find the variance (mean square error) which is 
half of 0.00565711 obtained from model 3.4.1 and needed when calculating 
confidence intervals (C.I.) using formula 2.7.2.1.1. The variance for a 2 2 
crossover design is multiplied by 0.5, however, if a parallel design is used the 
MSE in Table 4.7 is captured as it is for purposes of calculating C.I. (Concordet, 
2004). Multiplying the MSE by 0.5 is done in all cases where the ANOVA using 
GLM procedure is done, that is, in Tables 4.10 and 4.13.  
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Table 4.7 ANOVA for        using the GLM Procedure in SAS 9.4 
Source DF Sum of Squares Mean Square F Value Pr > F 
Model 15 0.66681567 0.04445438 7.86 0.0005 
Error 12 0.06788537 0.00565711     
Corrected Total 27 0.73470104       
 
R-Square Coeff Var Root MSE           
0.907601 1.461718 0.075214 5.145576 
 
Source DF Type I SS Mean Square F Value Pr > F 
Treatment 1 0.00092452 0.00092452 0.16 0.6931 
Period 1 0.04656188 0.04656188 8.23 0.0141 
Seq 1 0.02983240 0.02983240 5.27 0.0405 
Animal 12 0.58949687 0.04912474 8.68 0.0004 
 
Table 4.8 ANOVA for        using Mixed Procedure in SAS 9.4 
Least Squares Means 
Treatment Estimate S.E. DF t Value Pr > |t| Alpha 
Lower 
Bound 
Upper 
Bound 
R 5.1398 0.04423 12 116.20 <.0001 0.1 5.0610 5.2187 
T 5.1513 0.04423 12 116.46 <.0001 0.1 5.0725 5.2302 
 
ANOVA Table 4.8 provides the mean for the reference treatment, 5.1398 and the 
mean for the test treatment, 5.1513. 
  
90 
Table 4.9 Confidence Intervals (C.I.) for AUC from time zero to time t 
 Standard 
error 
Lower 
Bound 
Lower 90% 
Confidence 
Limit 
Upper 90% 
Confidence 
Limit 
Upper 
Bound 
C.I. for 
difference 
of means 
0.02843 
 0.2231  0.03917 0.06217 0.2231 
C.I. for 
ratio of 
means 
0.8 0.96159 1.06414 1.25 
 
Average bioequivalence of the two treatment drug formulations has been achieved 
at 5% significance level using classic C.I. of the difference of the means as well as 
the classic C.I. of the ratio of the means since for the C.I. of the differences, the 
limits  0.03917 and 0.06217 in Table 4.9 lie entirely in the acceptance range, 
 0.2231 to 0.2231. For the C.I. on the ratios, 0.96159 and 1.06414 in Table 4.9 
lie entirely in the acceptance interval of 0.8 to 1.25. 
Therefore the test treatment and reference treatment formulations are average 
bioequivalent using the pharmacokinetic parameter AUC from time zero to time t 
by the classic confidence interval approach. 
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Table 4.10 ANOVA for        using GLM Procedure in SAS 9.4 
Source DF Sum of Squares Mean Square F Value Pr > F 
Model 15 0.65811748 0.04387450 7.58 0.0006 
Error 12 0.06941768 0.00578481     
Corrected 
Total 27 0.72753516       
 
R-Square Coeff Var Root MSE           
0.904585 1.476892 0.076058 5.149865 
 
Source DF Type I SS Mean Square F Value Pr > F 
Treatment 1 0.00125533 0.00125533 0.22 0.6497 
Period 1 0.04444893 0.04444893 7.68 0.0169 
Seq 1 0.02774817 0.02774817 4.80 0.0490 
Animal 12 0.58466505 0.04872209 8.42 0.0004 
The MSE for the parameter AUC to infinity is half of 0.00578481 in Table 4.10 
obtained using model 3.4.1. 
Table 4.11 ANOVA for        using Mixed Procedure in SAS 9.4 
Least Squares Means 
Treatment Estimate S.E. DF t Value Pr > |t| Alpha L.B. U.B. 
R 5.1432 0.04412 12 116.57 <.0001 0.1 5.0645 5.2218 
T 5.1566 0.04412 12 116.87 <.0001 0.1 5.0779 5.2352 
The mean for the reference treatment drug is 5.1432 while the one for the test 
treatment formulation is 5.1566, both in Table 4.11.  
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Table 4.12 Confidence Intervals for AUC from time zero to infinity 
 Standard 
error 
Lower 
Bound 
Lower 90% 
Confidence 
Limit 
Upper 90% 
Confidence 
Limit 
Upper 
Bound 
C.I. for 
difference 
of means 
0.02875 
 0.2231  0.03784 0.06464 0.2231 
C.I. for 
ratio of 
means 
0.8 0.96287 1.06677 1.25 
The lower confidence limits and upper confidence limits for the mean differences 
of the parameter AUC from time zero to infinity,   .03784 and 0.06464 in Table 
4.12 for the two treatment formulations are totally included within the average 
bioequivalence bounds  0.2231 and 0.2231. 
Similarly, for the confidence intervals for the ratio of the means, 0.96287 and 
1.06677 in Table 4.12 lies entirely within the average bioequivalence range, 0.8 to 
1. 25. 
Average bioequivalence of the two treatment formulations, test and reference 
formulations, is therefore concluded for the parameter AUC from time zero to 
infinity using the classic confidence interval approach. 
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Table 4.13 ANOVA for      using GLM Procedure in SAS 9.4 
Source DF Sum of Squares Mean Square F Value Pr > F 
Model 15 0.76395940 0.05093063 0.76 0.6965 
Error 12 0.80427853 0.06702321     
Corrected 
Total 27 1.56823793       
 
R-Square Coeff Var Root MSE            
0.487145 10.59982 0.258888 2.442385 
 
Source DF Type I SS Mean Square F Value Pr > F 
Treatment 1 0.01351912 0.01351912 0.20 0.6613 
Period 1 0.06208561 0.06208561 0.93 0.3548 
Seq 1 0.00676723 0.00676723 0.10 0.7561 
Animal 12 0.68158744 0.05679895 0.85 0.6105 
 
The MSE for the parameter      is half of 0.06702321 in Table 4.13 found using 
the model 3.4.1. 
Table 4.14 ANOVA for      using Mixed Procedure in SAS 9.4 
Least Squares Means 
Treatment Estimate S.E. DF t Value Pr > |t| Alpha L.B. U.B. 
R 2.4644 0.06650 12 37.06 <.0001 0.1 2.3458 2.5829 
T 2.4204 0.06650 12 36.40 <.0001 0.1 2.3019 2.5389 
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From Table 4.14, the least mean squares 2.4644 and 2.4204 for the reference 
treatment and test treatment, respectively, are obtained. 
Table 4.15 Confidence Intervals for      
 Standard 
error 
Lower 
Bound 
Lower 90% 
Confidence 
Limit 
Upper 90% 
Confidence 
Limit 
Upper 
Bound 
C.I. for 
difference 
of means 
0.09785 
 0.2231  0.21860 0.13040 0.2231 
C.I. for 
ratio of 
means 
0.8 0.80364 1.13928 1.25 
Average bioequivalence of the two treatments has been achieved using the classic 
confidence interval approach for the difference of means of parameter      
because both confidence limits  0.21840 and 0.13040 in Table 4.15 are totally 
included in the acceptance range of  0.2231 to 0.2231.  
Considering the C.I. for the ratio of means, average bioequivalence is also 
concluded since the confidence limits 0.80364 and 1.13928, Table 4.15, lies 
entirely in the acceptance range of 0.8 to 1.25. 
The test treatment and reference treatment formulations have been shown to be 
average bioequivalent using the classic confidence interval approach. 
4.4.2 Interval Hypothesis Testing Approach 
4.4.2.1 Schuirmann’s Two One-Sided tests procedure 
The generally accepted method of testing for ABE according to Jones and 
Kenward (2003) and Chow and Liu (2000) is the TOST procedure proposed by 
Schuirmann (1987). 
The Schuirmann’s two one-sided tests lower and upper limits, 0.9908 and 1.0153, 
calculated by using 2.7.3.1.4 are obtained from Table 4.16. The geometric mean is 
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applied hence the confidence limits are for the ratio of means. The lower and 
upper limits (above) lie entirely in the confidence acceptance range 0.8 to 1.25, 
which implies that average bioequivalence is achieved. 
Using the hypotheses approach, average bioequivalence is achieved if    is 
rejected on both sets, in favour of the alternative hypothesis. C.I. limits in Table 
4.16 indicate that the null hypothesis of 2.7.3.1.2 is rejected on both sides of the 
test, therefore, average bioequivalence is concluded using the Schuirmann’s two 
one-sided tests procedure at 5% significance level for the parameter AUC from 
time zero to infinity. 
Table 4.16 TOST for        
N 
Geometric 
Mean Coefficient of Variation Minimum Maximum 
14 1.0030 0.0258 0.9491 1.0363 
 
Geometric 
Mean 95% CL Mean Coefficient of Variation 95% CL CV 
1.0030 0.9881 1.0180 0.0258 0.0187 0.0415 1.0030 
 
Geometric 
Mean 
Lower 
Bound   90% CL Mean   
Upper 
Bound Assessment 
1.0030 0.8 < 0.9908 1.0153 < 1.25 Equivalent 
 
Test Null DF t Value P-Value 
Lower 0.8 13 32.82 <.0001 
Upper 1.25 13 -31.96 <.0001 
Overall       <.0001 
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Table 4.17 TOST for      
N Geometric Mean Coefficient of Variation Minimum Maximum 
14 0.9815 0.1474 0.7930 1.3030 
 
Geometric 
Mean 95% CL Mean Coefficient of Variation 95% CL CV 
0.9815 0.9018 1.0682 0.1474 0.1066 0.2396 
 
Geometric 
Mean 
Lower 
Bound   90% CL Mean   
Upper 
Bound Assessment 
0.9815 0.8 < 0.9157 1.0520 < 1.25 Equivalent 
 
Test Null DF t Value P-Value 
Lower 0.8 13 5.22 <.0001 
Upper 1.25 13 -6.17 <.0001 
Overall       <.0001 
Average bioequivalence is concluded using      as in Table 4.17, 0.9157 to 
1.052 is totally included in the average bioequivalence interval, 0.8 to 1.25. 
Considering hypotheses 2.7.3.1.2, both sets rejects the null hypothesis, which 
implies that average bioequivalence is found between the two treatment 
formulations at 5% level of significance using the Schuirmann’s two one-sided 
tests procedures. 
4.4.3 Wilcoxon Mann-Whitney Two One-Sided test statistics 
For the pharmacokinetic parameter      the Wilcoxon Mann-Whitney test 
statistics are shown in Appendix 6 and the ±20 rule is used since the data is 
untransformed.      is sampled from discrete values, thus a nonparametric 
method is applied to assess ABE. RL calculated using equation 2.7.4.10 and    
are the sum of ranks of the response for sheep in sequence 1 and sum of ranks for 
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sheep in sequence 2 respectively. WL and    the Wilcoxon Mann-Whitney test 
statistics for the null and alternative hypothesis respectively are calculated using 
equations 2.7.4.11 and 2.7.4.13 respectively. 
Table 4.18 Wilcoxon Mann-Whitney Two One-Sided test statistics 
RL 77    57 
WL  49    29 
W0.95 37 W7;7;0.05 40 
Recall the hypothesis is as follows: 
      
                  
    and       
                 
    
Of which the decision rule says: 
                       (   ) and we reject     if     ( ), whereby 
average bioequivalence is achieved if both sets of hypotheses are rejected at 5% 
significance level. 
The Wilcoxon Mann-Whitney two one-sided test statistics indicate that indeed 
    is rejected at 5% level of significance and     is also rejected. Average 
bioequivalence of the two treatments, the test and reference drug formulations is 
concluded since   =49 is greater than  (   )=37 and   =29 is less than 
 ( )=40. 
4.5 Population Bioequivalence 
Kenward and Jones (2003) suggested that PBE can be calculated using data either 
from the 2 2 crossover design or from a replicate design, as long as an 
appropriate mixed model is fitted. The same view is shared by the FDA (1999, 
2001), whereby they state that the standard 2   crossover design may be used for 
PBE. 
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ANOVA Tables 4.19, 4.20 and 4.21 on covariance parameter estimates       , 
      and      indicates FA(1,1) and FA(2,2) the total variance for the 
reference treatment formulation and total variance for the total variance of the test 
treatment formulation respectively. Least square means, reference and test 
treatment formulations for       ,        and      are obtained from Tables 
4.8, 4.11 and 4.14 respectively. The values of FA(1,1) and FA(2,2) are substituted 
in equation 2.7.5.1, the reference-scaled moment based criterion for finding the 
population bioequivalence value to be compared to   =1.7448, the population 
bioequivalence limit FDA (2001). The reference-scaled criterion is applied in all 
the three cases since   
      
 , that is, the total variance for the reference drug 
formulation is greater than 0.04, the pre-specified constant total variance. If the 
specified constant total variance was less than the total variance for the reference 
treatment drug then the constant-scaled criterion 2.7.5.2 could have been used. 
Table 4.19 ANOVA for Covariance Parameter Estimates for AUC from time zero 
to time t 
Covariance Parameter Estimates 
Cov Parm Subject Group Estimate 
FA(1,1) Animal   0.1610 
FA(2,1) Animal   0.1350 
FA(2,2) Animal   0.09814 
Residual Animal Treatment R 0.000486 
Residual Animal Treatment T 0.000518 
 
Type 3 Tests of Fixed Effects 
Effect Num DF Den DF F Value Pr > F 
Seq 1 12 0.61 0.4509 
Period 1 12 8.23 0.0141 
Treatment 1 12 0.16 0.6931 
 
Estimates 
Label Estimate S.E. DF t value Pr > |t| Alpha L.B. U.B. 
test-ref 0.0114 0.0284 12 0.40 0.6931 0.1 -0.0391 0.0621 
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Table 4.20 ANOVA for Covariance Parameter Estimates for AUC from time zero 
to infinity 
Covariance Parameter Estimates 
Cov Parm Subject Group Estimate 
FA(1,1) Animal   0.1612 
FA(2,1) Animal   0.1311 
FA(2,2) Animal   0.1001 
Residual Animal Treatment R 0.000530 
Residual Animal Treatment T 0.000537 
 
Type 3 Tests of Fixed Effects 
Effect Num DF Den DF F Value Pr > F 
Seq 1 12 0.52 0.4837 
Period 1 12 6.97 0.0216 
Treatment 1 12 0.29 0.5991 
 
Estimates 
Label Estimate S.E DF t value Pr > |t| Alpha L.B. U.B. 
test-ref 0.0158 0.0292 12 0.54 0.5991 0.1 -0.0363 0.0679 
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Table 4.21 ANOVA for Covariance Parameter Estimates for      
Covariance Parameter Estimates 
Cov Parm Subject Group Estimate 
FA(1,1) Animal   0.2312 
FA(2,1) Animal   -0.02211 
FA(2,2) Animal   0.2594 
Residual Animal Treatment R 0.002344 
Residual Animal Treatment T 0.000233 
 
Type 3 Tests of Fixed Effects 
Effect Num DF Den DF F Value Pr > F 
Seq 1 12 0.12 0.7359 
Period 1 12 0.93 0.3548 
Treatment 1 12 0.20 0.6613 
 
Estimates 
Label Estimate S.E. DF t value Pr > |t| Alpha L.B. U.B. 
test-ref -0.0439 0.0978 12 -0.45 0.6613 0.1 -0.2183 0.1305 
Table 4.22 compares population bioequivalence values (    ) for the 
pharmacokinetic parameters        ,        and     . All the      values are 
less than 1.7448 (population bioequivalent limit) FDA (2001). Therefore 
population bioequivalence of the two treatment formulations, reference and test, 
has been achieved using the moment-based criterion 2.7.5.1.  
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Table 4.22 Evaluation of Population Bioequivalence 
         Results Conclusion 
       0.904515 
1.7448 
Reject    
Population 
Bioequivalent 
       0.906715 Reject    
Population 
Bioequivalent 
     1.070594 Reject    
Population 
Bioequivalent 
The hypotheses criterion for assessing population bioequivalence equivalent to 
criterion 2.7.5.1 and 2.7.5.2 is: 
  
   :        versus   
   :        
Population bioequivalence is concluded if   
    is rejected. 
In Table 4.22, the null hypothesis is rejected in favour of the alternative 
hypothesis therefore population bioequivalence is concluded for       ,        
and for     . 
4.6 Bootstrapping 
Bootstrapping resamples are on Appendix 9. These bootstrap samples were 
obtained using the INDEX function on Excel. The function is: INDEX((range of 
cells), ROWS(range of cells)*RAND()+1, COLUMNS(range of 
cells)*RAND()+1) (Rochowicz, 2011).  
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4.6.1 Bootstrapping        
Table 4.23 ANOVA for the Bootstrap Samples of        using the GLM 
Procedure in SAS 9.4 
Source DF Sum of Squares Mean Square F Value Pr > F 
Model 15 0.13972056 0.00931470 0.42 0.9701 
Error 96 2.13268671 0.02221549     
Corrected 
Total 111 2.27240727       
 
R-Square Coeff Var Root MSE           
0.061486 2.887142 0.149049 5.162497 
 
Source DF Type I SS Mean Square F Value Pr > F 
Treatment 1 0.00020412 0.00020412 0.01 0.9238 
Period 1 0.02811500 0.02811500 1.27 0.2634 
Seq 1 0.02184208 0.02184208 0.98 0.3239 
Animal 12 0.08955937 0.00746328 0.34 0.9805 
 
Table 4.24 ANOVA for the Bootstrap Samples of        using the Mixed 
Procedure in SAS 9.4 
Least Squares Means 
Treatment Estimate S.E. DF t value Pr > |t| Alpha L.B. U.B. 
R 5.1638 0.01917 96 269.39 <.0001 0.1 5.1320 5.1957 
T 5.1611 0.01917 96 269.25 <.0001 0.1 5.1293 5.1930 
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The MSE is half of 0.02221549 in Table 4.23 the least mean squares for the test 
and reference formulation are 5.1611 and 5.1638 respectively from Table 4.24. 
The calculated C.I for bootstrap samples is for the ratio of means. When 
calculating the bootstrap C.I. the critical values used are from the Normal 
distribution since the sample size is large, n=112. For a large sample the t-
distribution approximates the Normal distribution. Table 4.25 indicates that the 
bootstrap C.I. for AUC from time zero to infinity is 0.98281 to 1.02119 which lies 
entirely in the confidence acceptance region 0.8 to 1.25. ABE is therefore 
concluded for the bootstrap samples by using the classic C.I. approach. 
Table 4.25 Bootstrap C.I. for        
 Standard 
error 
Lower 
Bound 
Lower 90% 
Confidence 
Limit 
Upper 90% 
Confidence 
Limit 
Upper 
Bound 
C.I. for 
ratio of 
means 
0.02817 0.8 0.98281 1.02119 1.25 
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4.6.2 Bootstrapping      
Table 4.26 ANOVA for the Bootstrap Samples of      using the GLM 
Procedure in SAS 9.4 
Source DF Sum of Squares Mean Square F Value Pr > F 
Model 15 1.11089103 0.07405940 1.49 0.1228 
Error 96 4.75928937 0.04957593     
Corrected 
Total 111 5.87018040       
 
R-Square Coeff Var Root MSE            
0.189243 9.183376 0.222657 2.424561 
 
Source DF Type I SS Mean Square F Value Pr > F 
Treatment 1 0.09528051 0.09528051 1.92 0.1689 
Period 1 0.00001635 0.00001635 0.00 0.9855 
Seq 1 0.59020016 0.59020016 11.90 0.0008 
Animal 12 0.42539402 0.03544950 0.72 0.7334 
The MSE is 0.5 0.04957593 obtained in Table 4.26 while the least squares mean 
for the test treatment is 2.4537 and that of the reference treatment is 2.3954 in 
Table 4.27. The calculated C.I. for the ratio of means for the pharmacokinetic 
parameter      is 1.0371 to 1.09818 in Table 4.28. This confidence interval is 
totally included in the ABE acceptance region 0.8 to 1.25. Bootstrap samples of 
     have been proved to be average bioequivalent by the classic C.I. approach. 
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Table 4.27 ANOVA for the Bootstrap Samples of      the Mixed Procedure in 
SAS 9.4 
Least Squares Means 
Treatment Estimate S.E. DF t value Pr > |t| Alpha L.B. U.B. 
R 2.3954 0.02928 96 81.81 <.0001 0.1 2.3468 2.4440 
T 2.4537 0.02928 96 83.81 <.0001 0.1 2.4051 2.5024 
Table 4.28 Bootstrap C.I. for      
 Standard 
error 
Lower 
Bound 
Lower 90% 
Confidence 
Limit 
Upper 90% 
Confidence 
Limit 
Upper 
Bound 
C.I. for 
ratio of 
means 
0.04208 0.8 1.03710 1.09818 1.25 
 
4.7 Effect Sizes 
Table 4.29 Effect Sizes Values for Different Types of ES 
Effect size             
Cohen’s d 2.316 0.656 
Pearson’s, r 0.692 0.115 
Eta-Squared,    0.002 0.018 
Pearson’s, r and Eta-Squared,    ES are calculated using equations 3.14.2.1.1 and 
3.14.4.1.1 of which, according to Cohen (1992), both ES are interpreted as small. 
This implies that there is an insignificant difference of bioavailability between the 
two treatment formulations. Eta’s squared for        effect size, 0.002, is also a 
small ES. However, the parameter exhibits a        medium ES, 0.692, using 
Pearson’s and a large ES, 2.316, using Cohen’s, d.      also has a medium ES 
when calculated using Cohen’s, d. Ideally, all ES should be small since for two 
treatment formulations to be bioequivalent, the magnitude of the difference of the 
means should be minimal. 
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A summary of the results discussed in this chapter follows in the next chapter. We 
consider all statistical tests carried out and then conclude as whether the aims and 
objectives of the study were achieved or not. Limitations of the study and possible 
improvements which can be done are also covered in the next chapter. 
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Chapter 5 
Conclusion on Results and Recommendations 
5.1 Introduction 
The aims and objectives of this research report have been achieved since it has 
been established by statistical techniques that the test and reference treatment 
formulations are ABE and PBE. Generic drugs (test), which cost less as compared 
to the brand name drugs (reference) can be taken without much fear because it can 
be shown that two treatment formulations are bioequivalent hence reducing the 
cost of healthcare. The model used, 2 2 crossover design, is however inadequate 
for assessing IBE which gives room for the use of a higher order model. 
5.2 Summary 
Average bioequivalence between the test and reference drugs used in this research 
report is achieved for the pharmacokinetic parameters AUC and      by using the 
classical (shortest) confidence intervals, Schuirmann’s two one-sided tests and 
interval hypotheses. ABE is also concluded from the bootstrap samples of 
       and      by using the classic C.I. approach. For the parameter      
evaluated by the nonparametric test, Wilcoxon Mann-Whitney two one-sided test 
statistics, we also conclusively arrive at the decision of average bioequivalence 
between the generic and brand name drug since both sides of the test suggests that 
the formulations are bioequivalent. Using the Wilcoxon Mann-Whitney two one-
sided test statistics, both sides of the test should be average bioequivalent but if 
one is not, then bioequivalence is not wholly achieved. 
Pharmacokinetic parameters,       ,        and      proved to be population 
bioequivalent because      is less than 1.7448 (population bioequivalence limit). 
Using hypothesis 2.7.5.3,   
    is rejected, confirming that the two treatment 
formulations are bioequivalent. Outliers could not have had too much effect on 
the results as discussed in the analysis Section 4.2. Individual bioequivalence 
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could not be assessed due to the inadequacy of the model design used for dosing, 
that is, the 2 2 crossover model, discussed in Section 3.13.3. 
Based on the results obtained for average bioequivalence and population 
bioequivalence, it can be indicated that bioequivalence studies can go a long way 
if applied by regulatory authorities in various countries on certifying drug 
formulations as bioequivalent or not, hence reducing healthcare costs. Generic 
drugs should be as safe and effective as brand name drugs, of which, to guarantee 
safety and effectiveness of generic drugs bioequivalence studies play a crucial 
role. It should be stressed that the quality of generic drugs should not be 
compromised, but should be similar to that of brand name drugs. 
5.3 Conclusion 
Many physicians and pharmacists have done research on average bioequivalence 
and the majority of them concur that there are limitations if drugs are certified as 
bioequivalent by assessing average bioequivalence only. They agree that it is not 
enough to show that drugs are average bioequivalent instead there is a need to 
investigate population and individual bioequivalence. As discussed above, 
population and individual bioequivalence have components which are not 
possessed by average bioequivalence which are important if drugs are to be 
certified as bioequivalent. ABE looks at only the comparison of means between 
the generic and brand name drug, while, PBE compare the means and variances of 
the test and reference formulation and has a property of prescribability. IBE 
compares means, within subject variances and subject by formulation interaction, 
hence has a property of switchability, where a patient can be safely and effectively 
transferred from one drug formulation to the other. PBE and IBE offer more 
components which are important when certifying drugs as being bioequivalent. 
But, there are challenges faced, especially when implementing IBE. Individual 
bioequivalence requires higher order designs and is expensive to carry out. 
Bioequivalence studies are worthwhile in certifying drugs as bioequivalent, 
leading to people buying generic drugs at a lower cost as compared to brand name 
drugs, hence reducing healthcare costs. However, there are issues which make 
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people not to be completely satisfied when purchasing generic drugs. For 
example, bioequivalence procedures were not properly followed in the US in the 
late 1980s on certifying drugs as bioequivalent which led the public to develop 
lack of confidence on generic drugs. Other issues include: 
 The development of generic drugs does not require large and extensive 
trials to be conducted on study subjects hence, generic drugs are still 
viewed as inferior compared to the brand name drugs; 
 The use of the same acceptance limit(s) for all drugs by most regulatory 
authorities is questionable since some treatment formulations have a 
narrow or wide therapeutic range; 
 Use of normal and healthy subjects, generally between 18 and 55 years is 
of concern since this sample age group cannot be representative of the 
whole population in various countries. Infants and elderly, say, above 70 
years are likely to react differently when they take the same drugs with 
people who are in the interval 18 to 55 years; 
 Packaging of the generic drugs (different from the brand name) can also be 
an issue to be concerned about, especially to the elderly (Meredith, 2003). 
5.4 Recommendations 
The use of generic drugs has generally gained momentum worldwide. As a result, 
bioequivalence studies still need to be improved so as to overcome some of the 
issues noted above, which lead some people to view generic drugs as inferior 
compared to brand name drugs. Issues which need to be addressed so as to 
improve bioequivalence include: 
 Higher order crossover designs should be used because there are the ones 
needed to evaluate IBE. Drugs with high intra subject (within) or inter 
subject (between) variability which are not covered by ABE but are dealt 
with under IBE; 
 Additional simulation assessment must be considered when evaluating the 
value of data collection period for PBE and IBE; 
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 The sensitivity of subject by formulation interaction to sample size and 
inherent variability of the compounds should be further explored through 
simulation studies. 
The use of generic drugs all over the world will continue because generic drugs 
are cheaper, hence, reduces the cost of healthcare. Though generic drugs are 
cheaper, caution must always be taken when using them especially with regard to 
certain drug classes and patient populations. 
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Appendices 
 
Appendix 1 Concentration Time Profiles for Subject (Sheep) and 
Period after dosing with Reference and Test Formulations. 
 
Figure 1: Fit Plot for Concentration Time Profile for Sheep 1, 
Sequence 2, Test Treatment in Period 2 
 
Figure 3: Fit Plot for Concentration Time Profile for Sheep 2, 
Sequence 2, Reference Treatment in Period 1 
 
 
 
 
 
 
Figure 2: Fit Plot for Concentration Time Profile for Sheep 1, 
Sequence 2, Reference Treatment in Period 1 
  
Figure 4: Fit Plot for Concentration Time Profile for Sheep 2, 
Sequence 2, Test Treatment in Period 2 
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Figure 5: Fit Plot for Concentration Time Profile for Sheep 3, 
Sequence 2, Test Treatment in Period 2 
 
 
 
Figure 7: Fit Plot for Concentration Time Profile for Sheep 4, 
Sequence 2, Reference Treatment in Period 1 
 
Figure 6: Fit Plot for Concentration Time Profile for Sheep 3, 
Sequence 2, Reference Treatment in Period 1 
 
 
  
Figure 8: Fit Plot for Concentration Time Profile for Sheep 4, 
Sequence 2, Test Treatment in Period 2 
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Figure 9: Fit Plot for Concentration Time Profile for Sheep 5, 
Sequence 1, Reference Treatment in Period 2 
 
 
 
Figure 11: Fit Plot for Concentration Time Profile for Sheep 6, 
Sequence 1, Test Treatment in Period 1 
  
Figure 10: Fit Plot for Concentration Time Profile for Sheep 5, 
Sequence 1, Test Treatment in Period 1 
 
 
  
Figure 12: Fit Plot for Concentration Time Profile for Sheep 6, 
Sequence 1, Reference Treatment in Period 2 
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Figure 13: Fit Plot for Concentration Time Profile for Sheep 7, 
Sequence 2, Test Treatment in Period 1 
 
 
 
Figure 15: Fit Plot for Concentration Time Profile for Sheep 8, 
Sequence 2, Reference Treatment in Period 1 
  
Figure 14: Fit Plot for Concentration Time Profile for Sheep 7, 
Sequence 2, Test Treatment in Period 1 
 
 
  
Figure 16: Fit Plot for Concentration Time Profile for Sheep 8, 
Sequence 2, Test Treatment in Period 2 
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Figure 17: Fit Plot for Concentration Time Profile for Sheep 9, 
Sequence 1, Reference Treatment in Period 2 
 
 
 
Figure 19: Fit Plot for Concentration Time Profile for Sheep 10, 
Sequence 1, Test Treatment in Period 1 
  
Figure 18: Fit Plot for Concentration Time Profile for Sheep 9, 
Sequence 1, Test Treatment in Period 1 
 
 
  
Figure 20: Fit Plot for Concentration Time Profile for Sheep 10, 
Sequence 1, Reference Treatment in Period 2 
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Figure 21: Fit Plot for Concentration Time Profile for Sheep 11, 
Sequence 1, Test Treatment in Period 1 
 
 
 
Figure 23: Fit Plot for Concentration Time Profile for Sheep 12, 
Sequence 1, Test Treatment in Period 1 
  
Figure 22: Fit Plot for Concentration Time Profile for Sheep 11, 
Sequence 1, Reference Treatment in Period 2 
 
 
  
Figure 24: Fit Plot for Concentration Time Profile for Sheep 12, 
Sequence 1, Reference Treatment in Period 2 
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Figure 25: Fit Plot for Concentration Time Profile for Sheep 13, 
Sequence 2, Test Treatment in Period 2 
 
 
 
Figure 27: Fit Plot for Concentration Time Profile for Sheep 14, 
Sequence 1, Test Treatment in Period 1 
  
Figure 26: Fit Plot for Concentration Time Profile for Sheep 13, 
Sequence 2, Reference Treatment in Period 1 
 
 
 
Figure 28: Fit Plot for Concentration Time Profile for Sheep 14, 
Sequence 1, Reference Treatment in Period 2 
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Appendix 2 Calculating AUC from time zero to time t. 
 
 Actual 
time Animal Conc Treatment  
 
 
 
 
 
 
Actual 
Time Animal Conc Treatment 
 
 
 
 
 
 
0.00 1 0 T NA NA NA 0.00 1 0 R NA NA NA 
0.50 1 8.3332 T 4.1666 0.50 2.0833 0.50 1 10.1554 R 5.0777 0.50 2.53885 
1.00 1 10.4159 T 9.37455 0.50 4.687275 1.00 1 12.5728 R 11.3641 0.50 5.68205 
2.00 1 11.5974 T 11.00665 1.00 11.00665 2.00 1 17.303 R 14.9379 1.00 14.9379 
4.05 1 11.1884 T 11.3929 2.05 23.35545 4.00 1 9.9144 R 13.6087 2.00 27.2174 
6.07 1 8.204 T 9.6962 2.02 19.554 6.00 1 8.5193 R 9.21685 2.00 18.4337 
9.00 1 7.1336 T 7.6688 2.93 22.49515 9.03 1 6.1342 R 7.32675 3.03 22.22448 
12.00 1 5.1534 T 6.1435 3.00 18.4305 12.00 1 4.4043 R 5.26925 2.97 15.63211 
24.00 1 1.7674 T 3.4604 12.00 41.5248 24.00 1 1.8197 R 3.112 12.00 37.344 
36.00 1 0.7566 T 1.262 12.00 15.144 36.00 1 0.687 R 1.25335 12.00 15.0402 
48.00 1 0.2632 T 0.5099 12.00 6.1188 48.03 1 0.1749 R 0.43095 12.03 5.185765 
72.00 1 0.1173 T 0.19025 24.00 4.566 72.00 1 0.0336 R 0.10425 23.97 2.498525 
96.00 1 0 T 0.05865 24.00 1.4076 96.02 1 0 R 0.0168 24.02 0.40348 
      
170.3735 
      
167.1385 
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Actual 
Time Animal Conc Treatment 
 
 
 
 
 
 
 
Actual 
Time Animal Conc Treatment 
 
 
 
 
 
 
0.00 2 0 R NA NA NA 0.00 2 0 T NA NA NA 
0.50 2 6.0324 R 3.0162 0.50 1.5081 0.50 2 7.7087 T 3.85435 0.50 1.927175 
1.00 2 8.3025 R 7.16745 0.50 3.583725 1.00 2 8.9049 T 8.3068 0.50 4.1534 
2.00 2 8.5327 R 8.4176 1.00 8.4176 2.00 2 9.3668 T 9.13585 1.00 9.13585 
4.00 2 7.8854 R 8.20905 2.00 16.4181 4.00 2 8.2435 T 8.80515 2.00 17.6103 
6.00 2 7.6404 R 7.7629 2.00 15.5258 6.00 2 6.3296 T 7.28655 2.00 14.5731 
9.00 2 6.7815 R 7.21095 3.00 21.63285 9.00 2 5.3302 T 5.8299 3.00 17.4897 
12.00 2 4.9191 R 5.8503 3.00 17.5509 12.00 2 3.9859 T 4.65805 3.00 13.97415 
24.00 2 2.4476 R 3.68335 12.00 44.2002 24.00 2 3.113 T 3.54945 12.00 42.5934 
36.00 2 0.9889 R 1.71825 12.00 20.619 36.00 2 1.0224 T 2.0677 12.00 24.8124 
48.00 2 0.458 R 0.72345 12.00 8.6814 48.00 2 0.3971 T 0.70975 12.00 8.517 
72.00 2 0.1206 R 0.2893 24.00 6.9432 72.00 2 0.1688 T 0.28295 24.00 6.7908 
96.00 2 0 R 0.0603 24.00 1.4472 96.00 2 0.0885 T 0.12865 24.00 3.0876 
      
166.5281 
      
164.6649 
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Actual 
Time Animal Conc Treatment 
 
 
 
 
 
 
 
Actual 
Time Animal Conc Treatment 
 
 
 
 
 
 
0.00 3 0 T NA NA NA 0.00 3 0 R NA NA NA 
0.50 3 6.3276 T 3.1638 0.50 1.5819 0.50 3 9.5422 R 4.7711 0.50 2.38555 
1.00 3 9.0636 T 7.6956 0.50 3.8478 1.03 3 10.5317 R 10.03695 0.53 5.35304 
2.00 3 11.0009 T 10.03225 1.00 10.03225 2.00 3 11.0619 R 10.7968 0.97 10.43691 
4.00 3 11.1924 T 11.09665 2.00 22.1933 4.00 3 10.7004 R 10.88115 2.00 21.7623 
6.00 3 10.0088 T 10.6006 2.00 21.2012 6.00 3 9.3407 R 10.02055 2.00 20.0411 
9.00 3 8.2297 T 9.11925 3.00 27.35775 9.00 3 7.2836 R 8.31215 3.00 24.93645 
12.00 3 6.4307 T 7.3302 3.00 21.9906 12.00 3 5.5551 R 6.41935 3.00 19.25805 
24.00 3 1.248 T 3.83935 12.00 46.0722 24.00 3 2.1309 R 3.843 12.00 46.116 
36.00 3 1.1917 T 1.21985 12.00 14.6382 36.00 3 0.8436 R 1.48725 12.00 17.847 
48.00 3 0.4199 T 0.8058 12.00 9.6696 48.00 3 0.3536 R 0.5986 12.00 7.1832 
72.00 3 0.1407 T 0.2803 24.00 6.7272 72.00 3 0.0852 R 0.2194 24.00 5.2656 
96.00 3 0 T 0.07035 24.00 1.6884 96.00 3 0 R 0.0426 24.00 1.0224 
      
187.0004 
      
181.6076 
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Actual 
Time Animal Conc Treatment 
 
 
 
 
 
 
 
Actual 
Time Animal Conc Treatment 
 
 
 
 
 
 
0.00 4 0 R NA NA NA 0.00 4 0 T NA NA NA 
0.52 4 5.6722 R 2.8361 0.52 1.465318 0.50 4 8.84 T 4.42 0.50 2.21 
1.02 4 8.761 R 7.2166 0.50 3.6083 1.00 4 10.7492 T 9.7946 0.50 4.8973 
2.00 4 10.7164 R 9.7387 0.98 9.576388 2.00 4 12.6993 T 11.72425 1.00 11.72425 
4.00 4 9.3046 R 10.0105 2.00 20.021 4.00 4 12.5011 T 12.6002 2.00 25.2004 
6.00 4 8.0849 R 8.69475 2.00 17.3895 6.00 4 10.8577 T 11.6794 2.00 23.3588 
9.00 4 6.7065 R 7.3957 3.00 22.1871 9.00 4 8.3821 T 9.6199 3.00 28.8597 
12.00 4 3.9893 R 5.3479 3.00 16.0437 12.00 4 6.1864 T 7.28425 3.00 21.85275 
24.00 4 1.5077 R 2.7485 12.00 32.982 24.00 4 1.4588 T 3.8226 12.00 45.8712 
36.00 4 0.9594 R 1.23355 12.00 14.8026 36.00 4 0.4553 T 0.95705 12.00 11.4846 
48.00 4 0.2773 R 0.61835 12.00 7.4202 48.00 4 0.2713 T 0.3633 12.00 4.3596 
72.00 4 0.1561 R 0.2167 24.00 5.2008 72.00 4 0.0517 T 0.1615 24.00 3.876 
96.00 4 0 R 0.07805 24.00 1.8732 96.03 4 0 T 0.02585 24.03 0.621262 
      
152.5701 
      
184.3159 
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Actual 
Time Animal Conc Treatment 
 
 
 
 
 
 
 
Actual 
Time Animal Conc Treatment 
 
 
 
 
 
 
0.00 5 0 R NA NA NA 0.00 5 0 T NA NA NA 
0.50 5 8.3506 R 4.1753 0.50 2.08765 0.50 5 3.9791 T 1.98955 0.50 0.994775 
1.00 5 9.7089 R 9.02975 0.50 4.514875 1.00 5 4.8763 T 4.4277 0.50 2.21385 
2.00 5 11.9468 R 10.82785 1.00 10.82785 2.00 5 7.3284 T 6.10235 1.00 6.10235 
4.00 5 11.3999 R 11.67335 2.00 23.3467 4.00 5 6.9689 T 7.14865 2.00 14.2973 
6.00 5 8.5153 R 9.9576 2.00 19.9152 6.00 5 6.5418 T 6.75535 2.00 13.5107 
9.00 5 6.4408 R 7.47805 3.00 22.43415 9.00 5 5.0062 T 5.774 3.00 17.322 
12.00 5 4.486 R 5.4634 3.00 16.3902 12.00 5 3.7108 T 4.3585 3.00 13.0755 
24.00 5 1.5305 R 3.00825 12.00 36.099 24.00 5 2.1651 T 2.93795 12.00 35.2554 
36.00 5 1.0458 R 1.28815 12.00 15.4578 36.00 5 0.9521 T 1.5586 12.00 18.7032 
48.00 5 0.4962 R 0.771 12.00 9.252 48.00 5 0.2425 T 0.5973 12.00 7.1676 
72.00 5 0.1494 R 0.3228 24.00 7.7472 72.00 5 0.0195 T 0.131 24.00 3.144 
96.00 5 0.0597 R 0.10455 24.00 2.5092 96.00 5 0 T 0.00975 24.00 0.234 
      
170.5818 
      
132.0207 
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Actual 
Time Animal Conc Treatment 
 
 
 
 
 
 
 
Actual 
Time Animal Conc Treatment 
 
 
 
 
 
 
0.00 6 0 T NA NA NA 0.00 6 0 R NA NA NA 
0.50 6 6.9937 T 3.49685 0.50 1.748425 0.50 6 13.105 R 6.5525 0.50 3.27625 
1.00 6 8.9846 T 7.98915 0.50 3.994575 1.00 6 16.2239 R 14.66445 0.50 7.332225 
2.00 6 9.4104 T 9.1975 1.00 9.1975 2.02 6 15.0403 R 15.6321 1.02 15.89264 
4.00 6 9.0616 T 9.236 2.00 18.472 4.00 6 12.9108 R 13.97555 1.98 27.71817 
6.00 6 7.9323 T 8.49695 2.00 16.9939 6.00 6 11.1877 R 12.04925 2.00 24.0985 
9.00 6 6.341 T 7.13665 3.00 21.40995 9.00 6 7.6651 R 9.4264 3.00 28.2792 
12.00 6 4.7806 T 5.5608 3.00 16.6824 12.00 6 5.213 R 6.43905 3.00 19.31715 
24.00 6 2.0218 T 3.4012 12.00 40.8144 24.00 6 2.1001 R 3.65655 12.00 43.8786 
36.00 6 1.1188 T 1.5703 12.00 18.8436 36.00 6 0.845 R 1.47255 12.00 17.6706 
48.00 6 0.5665 T 0.84265 12.00 10.1118 48.00 6 0.209 R 0.527 12.00 6.324 
72.00 6 0.2103 T 0.3884 24.00 9.3216 72.00 6 0.0066 R 0.1078 24.00 2.5872 
96.00 6 0 T 0.10515 24.00 2.5236 96.00 6 0 R 0.0033 24.00 0.0792 
      
170.1138 
      
196.4537 
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Actual 
Time Animal Conc Treatment 
 
 
 
 
 
 
 
Actual 
Time Animal Conc Treatment 
 
 
 
 
 
 
0.00 7 0 T NA NA NA 0.00 7 0 R NA NA NA 
0.50 7 5.6495 T 2.82475 0.50 1.412375 0.50 7 6.5191 R 3.25955 0.50 1.629775 
1.00 7 9.2156 T 7.43255 0.50 3.716275 1.00 7 7.7943 R 7.1567 0.50 3.57835 
2.00 7 11.2346 T 10.2251 1.00 10.2251 2.00 7 9.7471 R 8.7707 1.00 8.7707 
4.00 7 10.0604 T 10.6475 2.00 21.295 4.00 7 9.6688 R 9.70795 2.00 19.4159 
6.00 7 9.0281 T 9.54425 2.00 19.0885 6.00 7 9.4525 R 9.56065 2.00 19.1213 
9.00 7 7.9102 T 8.46915 3.00 25.40745 9.00 7 8.0507 R 8.7516 3.00 26.2548 
12.00 7 6.1167 T 7.01345 3.00 21.04035 12.00 7 6.1368 R 7.09375 3.00 21.28125 
24.00 7 2.3893 T 4.253 12.00 51.036 24.00 7 2.155 R 4.1459 12.00 49.7508 
36.00 7 1.5392 T 1.96425 12.00 23.571 36.00 7 0.6776 R 1.4163 12.00 16.9956 
48.00 7 0.5665 T 1.05285 12.00 12.6342 48.00 7 0.1722 R 0.4249 12.00 5.0988 
72.00 7 0.1782 T 0.37235 24.00 8.9364 72.00 7 0.0079 R 0.09005 24.00 2.1612 
96.00 7 0.1005 T 0.13935 24.00 3.3444 96.00 7 0 R 0.00395 24.00 0.0948 
      
201.7071 
      
174.1533 
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Actual 
Time Animal Conc Treatment 
 
 
 
 
 
 
 
Actual 
Time Animal Conc Treatment 
 
 
 
 
 
 
0.00 8 0 R NA NA NA 0.00 8 0 T NA NA NA 
0.50 8 10.3496 R 5.1748 0.50 2.5874 0.50 8 11.7661 T 5.88305 0.50 2.941525 
1.00 8 11.3571 R 10.85335 0.50 5.426675 1.00 8 11.6697 T 11.7179 0.50 5.85895 
2.00 8 11.4669 R 11.412 1.00 11.412 2.00 8 12.7964 T 12.23305 1.00 12.23305 
4.00 8 9.798 R 10.63245 2.00 21.2649 4.00 8 11.8217 T 12.30905 2.00 24.6181 
6.00 8 8.3814 R 9.0897 2.00 18.1794 6.00 8 10.5832 T 11.20245 2.00 22.4049 
9.00 8 6.2741 R 7.32775 3.00 21.98325 9.00 8 8.5582 T 9.5707 3.00 28.7121 
12.00 8 4.4873 R 5.3807 3.00 16.1421 12.00 8 5.0771 T 6.81765 3.00 20.45295 
24.00 8 1.3102 R 2.89875 12.00 34.785 24.00 8 1.6423 T 3.3597 12.00 40.3164 
36.00 8 0.7934 R 1.0518 12.00 12.6216 36.00 8 0.7412 T 1.19175 12.00 14.301 
48.00 8 0.0965 R 0.44495 12.00 5.3394 48.00 8 0.369 T 0.5551 12.00 6.6612 
72.00 8 0.0507 R 0.0736 24.00 1.7664 72.00 8 0.0099 T 0.18945 24.00 4.5468 
96.00 8 0 R 0.02535 24.00 0.6084 96.00 8 0 T 0.00495 24.00 0.1188 
      
152.1165 
      
183.1658 
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Actual 
Time Animal Conc Treatment 
 
 
 
 
 
 
 
Actual 
Time Animal Conc Treatment 
 
 
 
 
 
 
0.00 9 0 R NA NA NA 0.00 9 0 T NA NA NA 
0.50 9 8.9297 R 4.46485 0.50 2.232425 0.50 9 5.4319 T 2.71595 0.50 1.357975 
1.00 9 8.8112 R 8.87045 0.50 4.435225 1.00 9 6.0926 T 5.76225 0.50 2.881125 
2.00 9 10.3462 R 9.5787 1.00 9.5787 2.00 9 7.797 T 6.9448 1.00 6.9448 
4.02 9 9.0897 R 9.71795 2.02 19.59787 4.03 9 7.9162 T 7.8566 2.03 15.97509 
6.02 9 9.0147 R 9.0522 2.00 18.1044 6.00 9 7.8071 T 7.86165 1.97 15.46125 
9.00 9 7.8452 R 8.42995 2.98 25.14935 9.00 9 21 T 14.40355 3.00 43.21065 
12.00 9 6.7688 R 7.307 3.00 21.921 12.00 9 4.9914 T 12.9957 3.00 38.9871 
24.00 9 2.2146 R 4.4917 12.00 53.9004 24.02 9 2.3927 T 3.69205 12.02 44.36613 
36.00 9 1.9167 R 2.06565 12.00 24.7878 36.00 9 1.3136 T 1.85315 11.98 22.20691 
48.00 9 0.7285 R 1.3226 12.00 15.8712 48.00 9 0.6073 T 0.96045 12.00 11.5254 
72.00 9 0.1126 R 0.42055 24.00 10.0932 72.00 9 0.3871 T 0.4972 24.00 11.9328 
96.00 9 0 R 0.0563 24.00 1.3512 96.00 9 0.209 T 0.29805 24.00 7.1532 
      
207.0228 
      
222.0024 
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Actual 
Time Animal Conc Treatment 
 
 
 
 
 
 
 
Actual 
Time Animal Conc Treatment 
 
 
 
 
 
 
0.00 10 0 T NA NA NA 0.00 10 0 R NA NA NA 
0.50 10 10.2244 T 5.1122 0.50 2.5561 0.50 10 12.3016 R 6.1508 0.50 3.0754 
1.02 10 12.6899 T 11.45715 0.52 5.919528 1.00 10 12.0091 R 12.15535 0.50 6.077675 
2.02 10 13.5789 T 13.1344 1.00 13.1344 2.00 10 12.8158 R 12.41245 1.00 12.41245 
4.00 10 11.8779 T 12.7284 1.98 25.24466 4.00 10 11.009 R 11.9124 2.00 23.8248 
6.00 10 9.5904 T 10.73415 2.00 21.4683 6.00 10 7.0098 R 9.0094 2.00 18.0188 
9.00 10 6.5224 T 8.0564 3.00 24.1692 9.00 10 5.1347 R 6.07225 3.00 18.21675 
12.00 10 4.4539 T 5.48815 3.00 16.46445 12.00 10 4.166 R 4.65035 3.00 13.95105 
24.00 10 1.5653 T 3.0096 12.00 36.1152 24.00 10 2.4456 R 3.3058 12.00 39.6696 
36.00 10 0.7419 T 1.1536 12.00 13.8432 36.00 10 0.4982 R 1.4719 12.00 17.6628 
48.00 10 0.5626 T 0.65225 12.00 7.827 48.00 10 0.1133 R 0.30575 12.00 3.669 
72.00 10 0.0075 T 0.28505 24.00 6.8412 72.00 10 0.0845 R 0.0989 24.00 2.3736 
96.00 10 0 T 0.00375 24.00 0.09 96.00 10 0 R 0.04225 24.00 1.014 
      
173.6732 
      
159.9659 
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Actual 
Time Animal Conc Treatment 
 
 
 
 
 
 
 
Actual 
Time Animal Conc Treatment 
 
 
 
 
 
 
0.00 11 0 T NA NA NA 0.00 11 0 R NA NA NA 
0.50 11 3.3788 T 1.6894 0.50 0.8447 0.50 11 6.902 R 3.451 0.50 1.7255 
1.00 11 8.0922 T 5.7355 0.50 2.86775 1.00 11 8.0715 R 7.48675 0.50 3.743375 
2.00 11 9.5904 T 8.8413 1.00 8.8413 2.00 11 7.5862 R 7.82885 1.00 7.82885 
4.00 11 7.941 T 8.7657 2.00 17.5314 4.00 11 6.3671 R 6.97665 2.00 13.9533 
6.00 11 6.3055 T 7.12325 2.00 14.2465 6.00 11 5.1882 R 5.77765 2.00 11.5553 
9.00 11 4.075 T 5.19025 3.00 15.57075 9.00 11 3.5803 R 4.38425 3.00 13.15275 
12.00 11 2.6357 T 3.35535 3.00 10.06605 12.00 11 2.5373 R 3.0588 3.00 9.1764 
24.00 11 1.1382 T 1.88695 12.00 22.6434 24.00 11 2.1088 R 2.32305 12.00 27.8766 
36.00 11 0.6876 T 0.9129 12.00 10.9548 36.00 11 0.8041 R 1.45645 12.00 17.4774 
48.00 11 0.3857 T 0.53665 12.00 6.4398 48.00 11 0.3844 R 0.59425 12.00 7.131 
72.00 11 0.1943 T 0.29 24.00 6.96 72.00 11 0.0376 R 0.211 24.00 5.064 
96.00 11 0 T 0.09715 24.00 2.3316 96.00 11 0 R 0.0188 24.00 0.4512 
      
119.2981 
      
119.1357 
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Actual 
Time Animal Conc Treatment 
 
  
 
 
Actual 
Time Animal Conc Treatment 
 
 
 
 
 
 
0.00 12 0 T NA NA NA 0.00 12 0 R NA NA NA 
0.50 12 7.8037 T 3.90185 0.50 1.950925 0.50 12 14.7725 R 7.38625 0.50 3.693125 
1.00 12 8.4611 T 8.1324 0.50 4.0662 1.00 12 13.0554 R 13.91395 0.50 6.956975 
2.00 12 7.9048 T 8.18295 1.00 8.18295 2.00 12 11.8779 R 12.46665 1.00 12.46665 
4.00 12 7.779 T 7.8419 2.00 15.6838 4.00 12 9.5409 R 10.7094 2.00 21.4188 
6.00 12 6.3584 T 7.0687 2.00 14.1374 6.00 12 7.8499 R 8.6954 2.00 17.3908 
9.00 12 4.6266 T 5.4925 3.00 16.4775 9.00 12 4.7223 R 6.2861 3.00 18.8583 
12.00 12 3.2415 T 3.93405 3.00 11.80215 12.00 12 3.6077 R 4.165 3.00 12.495 
24.00 12 1.4207 T 2.3311 12.00 27.9732 24.00 12 1.5017 R 2.5547 12.00 30.6564 
36.00 12 1.2319 T 1.3263 12.00 15.9156 36.00 12 1.0317 R 1.2667 12.00 15.2004 
48.00 12 0.5042 T 0.86805 12.00 10.4166 48.00 12 0.2023 R 0.617 12.00 7.404 
72.00 12 0.215 T 0.3596 24.00 8.6304 72.00 12 0.1695 R 0.1859 24.00 4.4616 
96.02 12 0.0972 T 0.1561 24.02 3.749002 96.00 12 0 R 0.08475 24.00 2.034 
      
138.9857 
      
153.0361 
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Actual 
Time Animal Conc Treatment 
 
 
 
 
 
 
 
Actual 
Time Animal Conc Treatment  
 
 
 
 
 
0.00 13 0 T NA NA NA 0.00 13 0 R NA NA NA 
0.50 13 11.5164 T 5.7582 0.50 2.8791 0.50 13 8.6753 R 4.33765 0.50 2.168825 
1.00 13 12.5293 T 12.02285 0.50 6.011425 1.00 13 10.2324 R 9.45385 0.50 4.726925 
2.00 13 12.8171 T 12.6732 1.00 12.6732 2.00 13 9.9372 R 10.0848 1.00 10.0848 
4.00 13 12.6859 T 12.7515 2.00 25.503 4.00 13 9.806 R 9.8716 2.00 19.7432 
6.00 13 11.1342 T 11.91005 2.00 23.8201 6.00 13 8.2917 R 9.04885 2.00 18.0977 
9.00 13 9.0335 T 10.08385 3.00 30.25155 9.00 13 7.1497 R 7.7207 3.00 23.1621 
12.00 13 7.864 T 8.44875 3.00 25.34625 12.00 13 5.3897 R 6.2697 3.00 18.8091 
24.00 13 1.6182 T 4.7411 12.00 56.8932 24.00 13 2.5165 R 3.9531 12.00 47.4372 
36.00 13 1.1014 T 1.3598 12.00 16.3176 36.00 13 1.2794 R 1.89795 12.00 22.7754 
48.00 13 0.2994 T 0.7004 12.00 8.4048 48.00 13 0.7405 R 1.00995 12.00 12.1194 
72.00 13 0.0992 T 0.1993 24.00 4.7832 72.00 13 0.2485 R 0.4945 24.00 11.868 
96.00 13 0 T 0.0496 24.00 1.1904 96.00 13 0.0985 R 0.1735 24.00 4.164 
      
214.0738 
      
195.1567 
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Actual 
Time Animal Conc Treatment  
 
 
 
 
 
 
Actual 
Time Animal Conc Treatment  
 
 
 
 
 
0.00 14 0 T NA NA NA 0.00 14 0 R NA NA NA 
0.50 14 7.1283 T 3.56415 0.50 1.782075 0.50 14 15.699 R 7.8495 0.50 3.92475 
1.00 14 11.4642 T 9.29625 0.50 4.648125 1.00 14 15.6876 R 15.6933 0.50 7.84665 
2.00 14 10.381 T 10.9226 1.00 10.9226 2.00 14 15.0303 R 15.35895 1.00 15.35895 
4.00 14 10.1862 T 10.2836 2.00 20.5672 4.00 14 13.3239 R 14.1771 2.00 28.3542 
6.00 14 8.6332 T 9.4097 2.00 18.8194 6.00 14 9.0957 R 11.2098 2.00 22.4196 
8.98 14 6.6623 T 7.64775 2.98 22.81579 9.00 14 7.7843 R 8.44 3.00 25.32 
12.00 14 5.286 T 5.97415 3.02 18.02202 12.00 14 6.4883 R 7.1363 3.00 21.4089 
24.00 14 2.7502 T 4.0181 12.00 48.2172 24.00 14 2.6646 R 4.57645 12.00 54.9174 
36.00 14 1.4059 T 2.07805 12.00 24.9366 36.00 14 1.0833 R 1.87395 12.00 22.4874 
48.00 14 0.5451 T 0.9755 12.00 11.706 48.00 14 0.4232 R 0.75325 12.00 9.039 
72.00 14 0.0664 T 0.30575 24.00 7.338 72.00 14 0.1949 R 0.30905 24.00 7.4172 
96.00 14 0 T 0.0332 24.00 0.7968 96.00 14 0 R 0.09745 24.00 2.3388 
      
190.5718 
      
220.8329 
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Appendix 3 Slope and Intercept (vertical axis) of figures in Appendix 4 
Figure Intercept (vertical intercept) Slope 
1 2.49478 -0.07069 
2 2.59006 -0.08482 
3 2.37959 -0.06371 
4 2.13646 -0.05206 
5 2.54009 -0.06666 
6 2.58152 -0.07249 
7 2.33197 -0.06469 
8 2.72571 -0.08352 
9 1.58798 -0.04670 
10 2.47347 -0.08378 
11 2.30245 -0.05683 
12 3.08311 -0.10510 
13 2.41261 -0.05375 
14 3.39896 -0.11147 
15 2.51812 -0.08338 
16 2.93585 -0.09713 
17 2.56782 -0.06314 
18 1.42249 -0.03254 
19 2.45498 -0.07787 
20 2.88456 -0.09655 
21 0.94957 -0.03686 
22 2.11897 -0.07047 
23 1.51104 -0.04126 
24 2.39776 -0.06724 
25 2.74958 -0.07474 
26 2.33186 -0.05103 
27 2.57993 -0.06986 
28 2.68121 -0.06572 
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Appendix 4 Finding   on Calculating        
 
   = 0.1173 
  = (-0.07069)*(-2.303) 
= 0.162799 
Figure 1: Fit Plot for In(Conc) for Sheep 1, 
 Test Treatment in Period 2 
 
 
 
 
 
 
 
 
 
 
 
   = 0.0336 
  = (-0.08482)*(-2.303) 
= 0.19534 
Figure 2: Fit Plot for In(Conc) for Sheep 1, 
 Reference Treatment in Period 1 
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   = 0.1206 
  = (-0.06371)*(-2.303) 
= 0.146724 
Figure 3: Fit Plot for In(Conc) for Sheep 2, 
 Reference Treatment in Period 1 
 
   = 0.0885 
  = (-0.05206)*(-2.303) 
= 0.119894 
Figure 4: Fit Plot for In(Conc) for Sheep 2, 
 Test Treatment in Period 2 
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   = 0.1407 
  = (-0.06666)*(-2.303) 
= 0.15338 
Figure 5: Fit Plot for In(Conc) for Sheep 3, 
 Test Treatment in Period 2 
 
 
  =0.0852 
  =(-0.07249)*(-2.0303) 
= 0.166944 
Figure 6: Fit Plot for In(Conc) for Sheep 3, 
 Reference Treatment in Period 1 
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   = 0.1561 
  = (-0.06469)*(-2.303) 
= 0.148981 
Figure 7: Fit Plot for In(Conc) for Sheep 4, 
 Reference Treatment in Period 1 
 
 
   = 0.0517 
  = (-0.08352)*(-2.303) 
= 0.192347 
Figure 8: Fit Plot for In(Conc) for Sheep 4, 
 Test Treatment in Period 2 
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   = 0.0597 
  = (-0.04670)*(-2.303) 
= 0.10755 
Figure 9: Fit Plot for In(Conc) for Sheep 5, 
 Reference Treatment in Period 2 
 
 
   = 0.0195 
  = (-0.08378)*(-2.303) 
= 0.192945 
Figure 10: Fit Plot for In(Conc) for Sheep 5, 
 Test Treatment in Period 1 
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   = 0.2103 
  = (-0.05683)*(-2.303) 
= 0.130879 
Figure 11: Fit Plot for In(Conc) for Sheep 6, 
 Test Treatment in Period 1 
 
 
   = 0.0066 
  = (-0.1051)*(-2.303) 
= 0.242045 
Figure 12: Fit Plot for In(Conc) for Sheep 6, 
 Reference Treatment in Period 2 
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   = 0.1005 
  = (-0.05375)*(-2.303) 
= 0.123786 
Figure 13: Fit Plot for In(Conc) for Sheep 7, 
 Test Period in Period 2 
 
 
   = 0.0079 
  = (-0.11147)*(-2.303) 
= 0.256715 
Figure 14: Fit Plot for In(Conc) for Sheep 7, 
 Reference Treatment in Period 1 
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   = 0.0507 
  = (-0.08338)*(-2.303) 
= 0.192024 
Figure 15: Fit Plot for In(Conc) for Sheep 8, 
 Reference Treatment in Period 1 
 
 
   = 0.0099 
  = (-0.09713)*(-2.303) 
= 0.22369 
Figure 16: Fit Plot for In(Conc) for Sheep 8, 
 Test Treatment in Period 2 
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   = 0.1126 
  = (-0.06314)*(-2.303) 
= 0.145411 
Figure 17: Fit Plot for In(Conc) for Sheep 9, 
 Reference Treatment in Period 2 
 
 
   = 0.209 
  = (-0.03254)*(-2.303) 
=0.07494  
Figure 18: Fit Plot for In(Conc) for Sheep 9, 
 Test Treatment in Period 1 
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   = 0.0845 
  = (-0.07787)*(-2.303) 
= 0.179335 
Figure 19: Fit Plot for In(Conc) for Sheep 10, 
 Reference Treatment in Period 2 
 
 
   = 0.0075 
  = (-0.09655)*(-2.303) 
= 0.222355 
Figure 20: Fit Plot for In(Conc) for Sheep 10, 
 Test Treatment in Period 1 
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   = 0.1943 
  = (-0.03686)*(-2.303) 
= 0.084889 
Figure 21: Fit Plot for In(Conc) for Sheep 11, 
 Test Treatment in Period 1 
 
 
   = 0.0376 
  = (-0.07047)*(-2.303) 
= 0.162292 
Figure 22: Fit Plot for In(Conc) for Sheep 11, 
 Reference Treatment in Period 2 
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   = 0.0972 
  = (-0.04126)*(-2.303) 
= 0.095022 
Figure 23: Fit Plot for In(Conc) for Sheep 12, 
 Test Treatment in Period 1 
 
 
   = 0.1695 
  = (-0.06724)*(-2.303) 
= 0.154854 
Figure 24: Fit Plot for In(Conc) for Sheep 12, 
 Reference Treatment in Period 2 
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   = 0.0992 
  = (-0.07474)*(-2.303) 
= 0.172126 
Figure 25: Fit Plot for In(Conc) for Sheep 13, 
 Test Treatment in Period 2 
 
 
   = 0.0985 
  = (-0.05103)*(-2.303) 
= 0.117522 
Figure 26: Fit Plot for In(Conc) for Sheep 13, 
 Reference Treatment in Period 1 
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   = 0.0664 
  = (-0.06986)*(-2.303) 
= 0.160888 
Figure 27: Fit Plot for In(Conc) for Sheep 14, 
 Test Treatment in Period 1 
 
 
   = 0.1949 
  = (-0.06572)*(-2.303) 
 = 0.151353 
Figure 28: Fit Plot for In(Conc) for Sheep 14, 
 Reference Treatment in Period 2 
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Appendix 5 Calculating AUC from time zero to infinity 
 
Sequence 1 
       
 
Animal 
  
Slope Constant ʎ 
  
Test 5 132.0207 0.0195 -0.08378 -2.303 0.192945 132.1218 4.883724 
 
6 170.1138 0.2103 -0.05683 -2.303 0.130879 171.7206 5.145869 
 
9 222.0024 0.209 -0.03254 -2.303 0.07494 224.7913 5.415172 
 
10 173.6732 0.0075 -0.09655 -2.303 0.222355 173.7069 5.15737 
 
11 119.2981 0.1943 -0.03686 -2.303 0.084889 121.587 4.80063 
 
12 138.9857 0.0972 -0.04126 -2.303 0.095022 140.0086 4.941704 
 
14 190.5718 0.0664 -0.06986 -2.303 0.160888 190.9845 5.252192 
Reference 5 170.5818 0.0597 -0.0467 -2.303 0.10755 171.1369 5.142464 
 
6 196.4537 0.0066 -0.1051 -2.303 0.242045 196.481 5.280566 
 
9 207.0228 0.1126 -0.06314 -2.303 0.145411 207.7972 5.336562 
 
10 159.9659 0.0845 -0.07787 -2.303 0.179335 160.4371 5.077902 
 
11 119.1357 0.0376 -0.07047 -2.303 0.162292 119.3674 4.782206 
 
12 153.0361 0.1695 -0.06724 -2.303 0.154854 154.1307 5.037801 
 
14 220.8329 0.1949 -0.06572 -2.303 0.151353 222.1206 5.403221 
         Sequence 2 
       
 
Animal 
  
Slope Constant ʎ 
 
 
Reference1 1 167.1385 0.0336 -0.08482 -2.303 0.19534 167.3105 5.119851 
 
2 166.5281 0.1206 -0.06371 -2.303 0.146724 167.3501 5.120088 
 
3 181.6076 0.0852 -0.07249 -2.303 0.166944 182.1179 5.204655 
 
4 152.5701 0.1561 -0.06469 -2.303 0.148981 153.6179 5.034468 
 
7 174.1533 0.0079 -0.11147 -2.303 0.256715 174.1841 5.160113 
 
8 152.1165 0.0507 -0.08338 -2.303 0.192024 152.3805 5.026381 
 
13 195.1567 0.0985 -0.05103 -2.303 0.117522 195.9948 5.278088 
Test 1 170.3735 0.1173 -0.07069 -2.303 0.162799 171.094 5.142213 
 
2 164.6649 0.0885 -0.05206 -2.303 0.119894 165.4031 5.108385 
 
3 187.0004 0.1407 -0.0666 -2.303 0.15338 187.9177 5.236004 
 
4 184.3159 0.0517 -0.08352 -2.303 0.192347 184.5847 5.218108 
 
7 201.7071 0.1005 -0.05375 -2.303 0.123786 202.519 5.310834 
 
8 183.1658 0.0099 -0.09713 -2.303 0.22369 183.2101 5.210633 
 
13 214.0738 0.0992 -0.07474 -2.303 0.172126 214.6501 5.369009 
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Appendix 6 Wilcoxon Mann-Whitney Two One-Sided Tests Calculations 
 
Sequence Subject Period 
 
Diff L Ranks L U Ranks U 
1 Number 1 2 
     RT 5 2 2 0 0.314 8 -0.314 3 
RT 6 1 2 0.5 0.814 12.5 0.186 12.5 
RT 9 2 9 3.5 3.814 14 3.186 14 
RT 10 2 2.02 0.01 0.324 9 -0.304 4 
RT 11 1 2 0.5 0.814 12.5 0.186 12.5 
RT 12 0.5 1 0.25 0.564 10.5 -0.064 5.5 
RT 14 0.5 1 0.25 0.564 10.5 -0.064 5.5 
2 
        TR 1 2 2 0 0 3.5 0 7.5 
TR 2 2 2 0 0 3.5 0 7.5 
TR 3 4 2 -1 -1 1 -1 1 
TR 4 2 2 0 0 3.5 0 7.5 
TR 7 2 2 0 0 3.5 0 7.5 
TR 8 2 2 0 0 3.5 0 7.5 
TR 13 2 1 -0.5 -0.5 2 -0.5 2 
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Appendix 7 Outliers Plot and Histogram for        untransformed data. 
 
Figure 1 Fit Histogram for Residuals of        untransformed data 
Appendix 8 Outliers Plot and Histogram for      untransformed data. 
 
Figure 1 Fit Histogram for Residuals of      untransformed data 
 
 
Figure 2 Fit Outliers Plot for        untransformed data 
 
 
Figure 2 Fit Outliers Plot for      untransformed data 
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Appendix 9 Bootstrap Samples of        and      
 
Bootstrap 
Samples of 
       ln       
 Bootstrap 
Samples of 
     ln     
160.4371 5.077902 11.4669 2.439465 
171.7206 5.145869 12.8158 2.550679 
187.9177 5.236004 10.3462 2.336619 
154.1307 5.037801 9.7471 2.27697 
171.094 5.142213 11.4642 2.439229 
202.519 5.310834 11.9468 2.480463 
174.1841 5.160113 10.3462 2.336619 
184.5847 5.218108 10.7164 2.371775 
171.1369 5.142464 8.5327 2.143906 
154.1307 5.037801 12.6993 2.541547 
207.7972 5.336562 9.7471 2.27697 
174.1841 5.160113 9.4104 2.241815 
171.7206 5.145869 10.3462 2.336619 
222.1206 5.403221 10.2324 2.325559 
202.519 5.310834 10.7164 2.371775 
171.094 5.142213 11.2346 2.418998 
195.9948 5.278088 11.0619 2.403507 
153.6179 5.034468 9.4104 2.241815 
190.9845 5.252192 15.699 2.753597 
184.5847 5.218108 7.3284 1.991757 
171.1369 5.142464 11.4669 2.439465 
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Bootstrap 
Samples of 
       ln       
 Bootstrap 
Samples of 
     ln     
207.7972 5.336562 10.2324 2.325559 
173.7069 5.15737 17.303 2.85088 
171.1369 5.142464 10.2324 2.325559 
182.118 5.204655 21 3.044522 
132.1218 4.883724 11.2346 2.418998 
190.9845 5.252192 12.8171 2.55078 
183.2101 5.210633 15.699 2.753597 
202.519 5.310834 11.2346 2.418998 
174.1841 5.160113 17.303 2.85088 
152.3805 5.026381 9.7471 2.27697 
167.3501 5.120088 11.2346 2.418998 
190.9845 5.252192 8.4611 2.135479 
182.118 5.204655 12.8171 2.55078 
196.481 5.280566 9.4104 2.241815 
187.9177 5.236004 10.7164 2.371775 
152.3805 5.026381 8.0715 2.088339 
132.1218 4.883724 8.0715 2.088339 
140.0086 4.941704 12.7964 2.549164 
160.4371 5.077902 11.4669 2.439465 
160.4371 5.077902 8.0715 2.088339 
207.7972 5.336562 12.7964 2.549164 
119.3674 4.782206 10.7164 2.371775 
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Bootstrap 
Samples of 
       ln       
 Bootstrap 
Samples of 
     ln     
152.3805 5.026381 11.0619 2.403507 
167.3501 5.120088 8.0715 2.088339 
195.9948 5.278088 11.4642 2.439229 
165.4031 5.108385 10.7164 2.371775 
171.094 5.142213 21 3.044522 
160.4371 5.077902 12.8171 2.55078 
184.5847 5.218108 12.8158 2.550679 
202.519 5.310834 11.0619 2.403507 
195.9948 5.278088 12.8158 2.550679 
153.6179 5.034468 11.1924 2.415235 
182.118 5.204655 11.9468 2.480463 
196.481 5.280566 11.1924 2.415235 
173.7069 5.15737 9.5904 2.260763 
184.5847 5.218108 10.2324 2.325559 
196.481 5.280566 17.303 2.85088 
171.1369 5.142464 11.0619 2.403507 
165.4031 5.108385 15.699 2.753597 
174.1841 5.160113 12.7964 2.549164 
171.094 5.142213 7.3284 1.991757 
132.1218 4.883724 11.9468 2.480463 
184.5847 5.218108 11.0619 2.403507 
195.9948 5.278088 11.0619 2.403507 
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Bootstrap 
Samples of 
       ln       
 Bootstrap 
Samples of 
     ln     
160.4371 5.077902 10.2324 2.325559 
224.7913 5.415172 9.3668 2.237172 
132.1218 4.883724 12.6993 2.541547 
196.481 5.280566 8.5327 2.143906 
174.1841 5.160113 9.4104 2.241815 
153.6179 5.034468 10.7164 2.371775 
165.4031 5.108385 9.7471 2.27697 
222.1206 5.403221 15.699 2.753597 
160.4371 5.077902 16.2239 2.786485 
222.1206 5.403221 11.5974 2.450781 
214.6501 5.369009 17.303 2.85088 
214.6501 5.369009 10.7164 2.371775 
187.9177 5.236004 21 3.044522 
214.6501 5.369009 14.7725 2.692767 
171.7206 5.145869 12.8171 2.55078 
132.1218 4.883724 11.2346 2.418998 
222.1206 5.403221 11.4669 2.439465 
165.4031 5.108385 9.3668 2.237172 
140.0086 4.941704 16.2239 2.786485 
153.6179 5.034468 8.5327 2.143906 
207.7972 5.336562 7.3284 1.991757 
167.3105 5.119851 8.4611 2.135479 
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Bootstrap 
Samples of 
       ln       
 Bootstrap 
Samples of 
     ln     
140.0086 4.941704 11.5974 2.450781 
167.3105 5.119851 8.4611 2.135479 
140.0086 4.941704 9.7471 2.27697 
119.3674 4.782206 11.4642 2.439229 
153.6179 5.034468 10.3462 2.336619 
187.9177 5.236004 15.699 2.753597 
222.1206 5.403221 8.0715 2.088339 
167.3105 5.119851 11.5974 2.450781 
167.3105 5.119851 7.3284 1.991757 
196.481 5.280566 8.0715 2.088339 
165.4031 5.108385 13.5789 2.608517 
202.519 5.310834 11.5974 2.450781 
173.7069 5.15737 12.7964 2.549164 
154.1307 5.037801 11.4669 2.439465 
184.5847 5.218108 11.5974 2.450781 
132.1218 4.883724 7.3284 1.991757 
154.1307 5.037801 16.2239 2.786485 
183.2101 5.210633 14.7725 2.692767 
171.7206 5.145869 12.6993 2.541547 
222.1206 5.403221 13.5789 2.608517 
167.3105 5.119851 12.8158 2.550679 
207.7972 5.336562 9.5904 2.260763 
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Bootstrap 
Samples of 
       ln       
 Bootstrap 
Samples of 
     ln     
153.6179 5.034468 10.2324 2.325559 
183.2101 5.210633 10.7164 2.371775 
207.7972 5.336562 12.8171 2.55078 
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Appendix 10 SAS codes 
Power AUC 
data pairedauc; 
Mu1=5.1432; Mu2=5.1566; StDev1=0.04412;StDev2=0.04412; Corr=0.691717; 
N=28;Alpha=0.05; 
StDevDiff = sqrt(StDev1**2 +StDev2**2 -2*Corr*StDev1*StDev2); 
NCP = (Mu2-Mu1)**2 /(StDevDiff**2/N); 
CriticalValue = FINV(1-Alpha, 1,N-1, 0); 
Power = SDF('f', CriticalValue,1, N-1, NCP); 
proc print data=pairedauc; 
run; 
 
Power calculation 
proc power; 
twosamplemeans test=equiv_diff alpha=0.05 
lower=&log_pt_8 upper=&log_1_pt_25 std=&std_derived 
meandiff=&log_true_gmr 
npergroup=. 
power =0.95; 
run; 
 
Power curve 
proc power;  
twosamplemeans test=diff  
nulldiff= 0  
meandiff= 4  
stddev= 3  
power= 0.8 0.9 0.95  
alpha = 0.05  
npergroup = .;  
plot y=power yopts=(ref=0.8 0.9 0.95);  
run; 
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ANOVA 
lnAUC 
proc glm data=lnAUC; 
   class Treatment Period Seq Animal; 
   model lnAUC=Treatment Period Seq Animal; 
   random Animal/ test; 
run; 
 
Mixed Procedure: ANOVA 
lnAUC 
proc mixed data=lnAUC; 
      class Seq Period Treatment Animal;  
      model lnAUC=Seq Period Treatment;  
      random Animal(Seq);  
      lsmeans Treatment/pdiff cl alpha=0.1;  
      estimate 'T/R' Treatment 1 2 / cl alpha=0.1;  
     * make 'LSMEANS' out=lsmean; *used in old SAS versions;  
     * make 'estimate' out=est; *used in old SAS versions;  
run; 
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ANOVA code for covariances 
lnAUC 
 
proc mixed data=covauc; 
classes Seq Animal Period Treatment; 
model lnAUC= Seq Period Treatment / ddfm=satterth; 
random Treatment/type=FA0(2) sub=Animal G; 
repeated/grp=Treatment sub=Animal; 
estimate 'test-ref' Treatment -1 1/ CL alpha=0.10; 
run; 
 
TOST 
lnAUC 
ods graphics on; 
proc ttest data=TOSTFL dist=lognormal tost(0.8, 1.25); 
paired TestlnAUC*ReflnAUC; 
run; 
ods graphics off; 
 
 
